{"id": 0, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 27. 根据国家药品监督管理局，公安部，国家卫⽣健康委员会的有关规定，⼜服固体制剂每剂量单位含羟考酮碱不超过5毫克，且不含其他⿇醉药品，精神药品或者药品类易制毒化学品的复⽅制剂列⼊（）。\nOptions: A. 含⿇醉药品复⽅制剂的管理\nB. 第⼆类精神药品管理\nC. 第⼀类精神药品管理\nD. 医疗⽤毒性药品管理\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question and determine the correct answer, let's apply the three reasoning methods and assess the consistency of the conclusions.\n\n### Reasoning Method 1: Direct Deduction\n- **Key Terms:** Oral solid dosage, oxycodone base not exceeding 5 mg per dose unit, no other narcotics, psychotropic substances, or precursor chemicals.\n- **Analysis:** The key information indicates that the preparation contains oxycodone, a known narcotic, but it's in a low dose and does not include other restricted substances. According to Chinese regulations, such formulations are often subjected to lesser stringent controls compared to those with higher concentrations or additional controlled substances.\n- **Preliminary Conclusion:** The formulation could likely be managed under a specific category that allows for low-dose narcotics without stronger narcotics or psychotropics.\n\n### Reasoning Method 2: Systematic Elimination\n- **Eliminate A:** This option would apply if the preparation were specifically a compound containing multiple narcotic substances, which it is not, as there are no other narcotic or psychotropic add-ons.\n- **Eliminate C:** Schedule I psychotropic substances include those with a higher risk of abuse and addiction potential, which is not consistent with low-dose formulations like the one described.\n- **Eliminate D:** Toxic medicinal substances typically imply items that require stringent control due to their high harm potential, not aligning with a low-dose formulation like the one described.\n- **Remaining Options:** B (Second class psychotropic management)\n- **Preliminary Conclusion:** Option B seems suitable given the context of lesser restriction for low-dose formulations with only one controlled substance.\n\n### Reasoning Method 3: Comparative Analysis\n- **Comparison of similar options:** A and C both involve strict control due to high abuse potential. Options B and D pertain to less strict management or different substance types.\n- **Key differences identification:** The primary distinction is the control category based on the substance type and dose. Since the dose is low and controlled substances are not compounded, stricter categories like those in A and C seem excessive.\n- **Option that best fits the question:** Option B aligns with the description as it concerns psychotropic management but under lesser restrictive conditions due to the low dose.\n- **Preliminary Conclusion:** Option B\n\n### Consistency Assessment\n- **Method 1 Conclusion:** B - Confidence: Medium\n- **Method 2 Conclusion:** B - Confidence: High\n- **Method 3 Conclusion:** B - Confidence: Medium\n- **Consistency Analysis:** All methods consistently point to option B as the most suitable answer for the described preparation under the given Chinese regulations.\n\n**Final Determination:** Correct answer: B - Reason: Consistent conclusions across all methods, supported by strong reasoning in Method 2.", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 1, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 112. 患者，男，70岁，因抑郁症长期服⽤舍曲林。新诊断为帕⾦森病，宜选⽤的药物有（）。\nOptions: A. 司来吉兰\nB. 普拉克索\nC. ⾦刚烷胺\nD. 吡贝地尔\nE. 恩他卡朋\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze this question, let's apply the three reasoning methods and assess consistency.\n\n### Reasoning Method 1: Direct Deduction\n- **Analysis**: The patient, who is 70 years old, is being treated for depression with sertraline (a selective serotonin reuptake inhibitor) and has now been diagnosed with Parkinson's disease (PD). The treatment of Parkinson's requires medications that can enhance dopaminergic function or manage symptoms effectively. \n  - Selegiline (司来吉兰) is an MAO-B inhibitor used for Parkinson’s, potentially providing mild symptomatic relief and possibly neuroprotective effects.\n  - Pramipexole (普拉克索) is a dopamine agonist used to treat Parkinson's symptoms.\n  - Amantadine (⾦刚烷胺) is used for symptom management, particularly tremor and dyskinesia.\n  - Piribedil (吡贝地尔) is another dopamine agonist.\n  - Entacapone (恩他卡朋) is a COMT inhibitor used to extend the effect of levodopa.\n- **Preliminary conclusion**: A, B, possibly C\n\n### Reasoning Method 2: Systematic Elimination\n- **Eliminate A**: Selegiline can be used, so not eliminated.\n- **Eliminate B**: Pramipexole is a suitable choice, so not eliminated.\n- **Eliminate C**: Amantadine can be beneficial for certain symptoms, so not eliminated.\n- **Eliminate D**: Piribedil is similar to pramipexole (also a dopamine agonist), not unique enough to warrant elimination solely on its pharmacology.\n- **Eliminate E**: Entacapone is usually used with levodopa; if no levodopa is mentioned, it may not be the initial choice.\n- **Remaining options**: A, B, C, possibly D\n- **Preliminary conclusion**: A, B, C\n\n### Reasoning Method 3: Comparative Analysis\n- **Comparison of similar options**: Options A and B are both used as first-line or adjunct therapies in Parkinson's for enhancing endogenous dopamine or mimicking its action.\n- **Key differences identification**: Amantadine (C) is often used for different reasons (e.g., dyskinesia), while piribedil (D) serves a role similar to pramipexole (B). Entacapone (E) is more specific to levodopa combination therapy.\n- **Option that best fits the question**: A (Selegiline) and B (Pramipexole) both directly address Parkinson’s symptoms effectively.\n- **Preliminary conclusion**: A, B\n\n### Consistency Assessment\n- **Method 1 conclusion**: A, B - Confidence: High\n- **Method 2 conclusion**: A, B, C - Confidence: Medium\n- **Method 3 conclusion**: A, B - Confidence: High\n- **Consistency analysis**: The conclusions are mostly consistent; options A and B appear reliably across all methods. Option C (Amantadine) could be justified for specific symptom management but isn’t as consistently selected.\n- **Final determination**: A, B\n  - **Reason**: Based on consistency across high confidence conclusions in Methods 1 and 3, and the role of these drugs in Parkinson’s management without direct mention of levodopa.\n\nCorrect answer: A, B", "question_type": "多项选择题", "groundtruth": "BCDE"}
{"id": 2, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 2215. 可⽤于治疗蛔⾍病、蛲⾍病、钩⾍病和鞭⾍病的⼴谱驱⾍药物是（）。\nOptions: A. 甲硝唑\nB. 氯硝柳胺\nC. ⼄胺嗪\nD. 甲苯咪唑\nE. 三氯苯达唑\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n\n- Directly derive conclusions based on question information and professional knowledge, focusing on the key terms \"广谱驱虫药物\", \"治疗蛔虫病\", \"蛲虫病\", \"钩虫病\", and \"鞭虫病\".\n- Analysis: From professional knowledge, the drug best known for its broad-spectrum activity against these common parasitic worm infections (lumbricoides, pinworms, hookworms, whipworms) is typically benzimidazole derivatives.\n- Preliminary conclusion: D. 甲苯咪唑\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A (甲硝唑): Metronidazole is an antibiotic and antiprotozoal medication primarily used for anaerobic bacteria and protozoa, not helminths.\n- Eliminate B (氯硝柳胺): Used primarily for schistosomiasis and some trematode infections, not the listed helminth infections.\n- Eliminate C (乙胺嗪): Primarily used for filariasis, not broad-spectrum for lumbricoides, pinworms, hookworms, and whipworms.\n- Eliminate E (三氯苯达唑): Although a broad-spectrum anthelmintic, it is less commonly referenced compared to thiabendazole and mebendazole for the specified infections.\n- Remaining options: D. 甲苯咪唑\n- Preliminary conclusion: D. 甲苯咪唑\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare similarities and differences among all options to identify which drug fits all criteria.\n- Comparison of similar options: Consider D (甲苯咪唑) and E (三氯苯达唑), since both are broad-spectrum anthelmintics for intestinal worms.\n- Key differences identification: 甲苯咪唑 (Mebendazole) is more frequently noted for treating all listed infections as standard treatment compared to 三氯苯达唑 (Triclabendazole), which is more specific for liver flukes.\n- Option that best fits the question: D. 甲苯咪唑\n- Preliminary conclusion: D. 甲苯咪唑\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: D. 甲苯咪唑 - Confidence: High\n- Method 2 conclusion: D. 甲苯咪唑 - Confidence: High\n- Method 3 conclusion: D. 甲苯咪唑 - Confidence: High\n- Consistency analysis: All methods consistently lead to the same conclusion.\n- Final determination: D. 甲苯咪唑 - Reason: Consistent across all reasoning methods, supported by high confidence based on professional knowledge of its broad-spectrum activity against intestinal helminths.\n\nCorrect answer: D", "question_type": "最佳选择题", "groundtruth": "D"}
{"id": 3, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 49. ⽤于治疗湿性视⽹膜黄斑变性的药物是（）。\nOptions: A. 聚⼄⼆醇滴眼液\nB. 硫酸阿托品眼⽤凝胶\nC. 雷珠单抗注射液\nD. ⽑果芸⾹碱滴眼液\nE. 丙美卡因滴眼液\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the medication used in the treatment of wet age-related macular degeneration (AMD), let's analyze the options using the three distinct reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n- Key term: \"wet age-related macular degeneration\"\n- Professional knowledge: Wet AMD is often treated with anti-VEGF (vascular endothelial growth factor) therapies.\n- Analysis: Ranibizumab (雷珠单抗) is a well-known anti-VEGF injection used specifically to treat wet AMD.\n- Preliminary conclusion: C (雷珠单抗注射液)\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 聚乙二醇滴眼液 is typically used as a lubricant for dry eyes, not for wet AMD treatment.\n- Eliminate B: 硫酸阿托品眼用凝胶 is used for its mydriatic effect in other eye conditions, not for wet AMD.\n- Eliminate C: 雷珠单抗注射液, as an anti-VEGF therapy, directly relates to the treatment of wet AMD.\n- Eliminate D: 毛果芸香碱滴眼液 is used to treat glaucoma, not wet AMD.\n- Eliminate E: 丙美卡因滴眼液 is an anesthetic eye drop, not a treatment for wet AMD.\n- Remaining option: C (雷珠单抗注射液)\n- Preliminary conclusion: C\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison: Consider indications and uses for each drug.\n- Key differences: 雷珠单抗注射液 (C) is the only option specifically indicated for treating wet AMD. Others are used for dry eyes, other eye conditions, or as anesthetics.\n- Option that best fits: C (雷珠单抗注射液)\n- Preliminary conclusion: C\n\n**Consistency Assessment:**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All methods consistently identify C as the correct option.\n- Final determination: C - Reason: Consistent conclusions across all methods and strong professional knowledge support.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 4, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 19. 根据药品管理法律法规及相关⽂件的规定，药品零售企业可以开架⾃选销售的药品是（）。\nOptions: A. 复⽅⽢草⽚\nB. 复⽅⾦银花颗粒\nC. 复⽅地芬诺酯⽚\nD. 复⽅枇杷喷托维林颗粒\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "Sure, let's analyze the question using the three reasoning methods to determine the correct option.\n\n**Reasoning Method 1: Direct Deduction**\n- Key Terms: 药品零售企业, 开架自选销售, 药品管理法律法规\n- Analysis: According to Chinese pharmaceutical regulations, over-the-counter (OTC) medications are allowed for open-shelf sales in retail pharmacies. We need to identify which of the listed drugs fall into this category.\n- Preliminary conclusion: Drugs like 复方甘草片 (Compound Licorice Tablets) are often considered OTC due to their mild components.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate C: 复方地芬诺酯片 is a combination product that is often not considered OTC due to potential side effects and regulatory control on its components.\n- Remaining options: A, B, D\n- Eliminate D: 复方枇杷喷托维林颗粒 is often used for respiratory conditions which may not typically be offered OTC.\n- Eliminate B: 复方金银花颗粒 is traditionally used for its herbal components, but availability as OTC varies.\n- Remaining option: A\n- Preliminary conclusion: A\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: All options are compound medications, but their regulatory status as OTC varies.\n- Key differences identification: The active ingredients and common use cases can influence their OTC status.\n- Option that best fits the question: 复方甘草片 is commonly sold as an OTC drug for mild cough and throat irritation.\n- Preliminary conclusion: A\n\n**Consistency Assessment:**\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: Medium\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All methods consistently identify option A as the correct answer, with high confidence in methods 1 and 3.\n- Final determination: A - Reason: Consistency across reasoning methods with high confidence\n\nCorrect answer: A", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 5, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 2. 影响药物制剂稳定性的⾮处⽅因素是（）。\nOptions: A. pH\nB. 温度\nC. 溶剂\nD. 离⼦强度\nE. 表⾯活性剂\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the best option for the question about factors influencing the stability of pharmaceutical formulations, let's apply the three reasoning methods and then assess consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- **Analysis:** In pharmaceutical formulations, several factors can affect stability. The key terms here are \"non-prescription factors\" (非处方因素). This typically refers to external or environmental influences.\n- **Preliminary Conclusion:** The common non-formula related factors that influence stability are pH, temperature, solvent, ionic strength, and surfactants. All options are relevant, but temperature (B) stands out as the direct non-formulary/environmental factor affecting stability.\n  \n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A:** pH can be modified or controlled as part of the formulation.\n- **Eliminate C:** The choice of solvent is often a part of the formulation process.\n- **Eliminate D:** Ionic strength is usually an internal characteristic of the formulation.\n- **Eliminate E:** Surfactants are typically used intentionally in the formulation.\n- **Eliminate B:** Temperature is an external factor affecting stability post-manufacture.\n- **Remaining Options:** B\n- **Preliminary Conclusion:** B\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison of similar options:** A, C, D, and E relate to formulation specifics, while B (temperature) influences stability regardless of formulation details.\n- **Key differences identification:** Temperature (B) influences stability based on environmental conditions post-formulation, distinct from the other options.\n- **Option that best fits the question:** B\n- **Preliminary Conclusion:** B\n\n**Consistency Assessment:**\n- **Method 1 conclusion:** B - Confidence: High\n- **Method 2 conclusion:** B - Confidence: High\n- **Method 3 conclusion:** B - Confidence: High\n- **Consistency analysis:** All methods result in option B consistently, indicating strong agreement.\n- **Final determination:** B - Reason: Consistent conclusion across all methods, indicating strong evidence supporting temperature as the key non-formulation factor affecting pharmaceutical stability.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 6, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 9. 关于钠-葡萄糖协同转运蛋⽩-2（SLG-2）抑制剂达格列净作⽤特点和不良反应的说法，错误的是（）。\nOptions: A. 降糖效果受肾⼩球滤过的葡萄糖负荷的影响\nB. 降糖作⽤不依赖于胰岛B细胞的功能及机体对胰岛素的敏感性\nC. 适⽤于1型糖尿病或糖尿病酮症酸中毒\nD. 重度肾功能不全患者禁⽤\nE. 可降低⾎压，减轻体重\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To solve this problem, let's apply the three distinct reasoning methods to analyze which statement about the sodium-glucose cotransporter-2 (SGLT-2) inhibitor, dapagliflozin, is incorrect.\n\n**Reasoning Method 1: Direct Deduction**\n- **Key terms**: SGLT-2 inhibitor, dapagliflozin, incorrect statement.\n- **Analysis**: \n  - Dapagliflozin works by inhibiting glucose reabsorption in the kidney, leading to increased glucose excretion.\n  - This mechanism is independent of pancreatic beta-cell function or insulin sensitivity, thus making B a true statement.\n  - It is known that SGLT-2 inhibitors are not recommended for type 1 diabetes or diabetic ketoacidosis due to the risk of inducing or exacerbating ketoacidosis, thus calling into question C.\n  - Heavy reliance on kidney function would make it inappropriate for use in severe renal impairment, supporting D.\n  - SGLT-2 inhibitors are known to cause a modest decrease in blood pressure and weight loss as side effects, supporting E.\n- **Preliminary conclusion**: C (because dapagliflozin is not indicated for type 1 diabetes or diabetic ketoacidosis)\n\n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A**: True. It is known that the glucose-lowering effect is influenced by renal glucose filtration.\n- **Eliminate B**: True. The effect is independent of beta-cell function and insulin sensitivity.\n- **Eliminate C**: Possibly incorrect. Not suitable for type 1 diabetes or diabetic ketoacidosis.\n- **Eliminate D**: True. Not recommended for severe kidney impairment.\n- **Eliminate E**: True. Known to lower blood pressure and weight.\n- **Remaining options**: C\n- **Preliminary conclusion**: C\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison of similar options**: A, B, D, and E share that they align with known features or contraindications of dapagliflozin.\n- **Key differences identification**: C stands out because of the inappropriateness for usage in type 1 diabetes or diabetic ketoacidosis.\n- **Option that best fits the question**: C\n- **Preliminary conclusion**: C\n\n**Consistency Assessment:**\n- **Method 1 conclusion**: C - Confidence: High\n- **Method 2 conclusion**: C - Confidence: High\n- **Method 3 conclusion**: C - Confidence: High\n- **Consistency analysis**: All three methods consistently identified C as the incorrect statement about dapagliflozin.\n- **Final determination**: C - Reason: Consistent findings across all reasoning methods and alignment with professional knowledge.\n\nCorrect answer: C", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 7, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 66. 对于治疗严重危及⽣命且尚⽆有效治疗⼿段的疾病的药品，药物临床试验已有数据证实疗效并能预测其临床价值的，可以申请（）。\nOptions: A. 关联审评审批程序\nB. 简化审批程序\nC. 附条件批准程序\nD. 突破性治疗药物程序\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- Focus on key terms in the question stem: \"严重危及生命\", \"尚无有效治疗手段\", \"药物临床试验已有数据证实疗效并能预测其临床价值\".\n- Analysis: The question describes a situation where there is a serious life-threatening condition with no effective treatments available, but clinical trial data exists confirming efficacy and predicting clinical value. This aligns with the conditions for considering conditional approval based on early promising data.\n- Preliminary conclusion: C. 附条件批准程序\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate A: 关联审评审批程序 pertains to drugs that are assessed in conjunction with related evaluations, not specifically addressing urgent cases needing conditional approval.\n- Eliminate B: 简化审批程序 typically addresses generic drugs or minor changes, not severely life-threatening situations.\n- Eliminate C: Not eliminated; matches cases where drugs show potential based on preliminary evidence.\n- Eliminate D: 突破性治疗药物程序 applies to drugs providing significant benefits over existing treatments where none exist; however, the conditional approval is a more directly matching procedure for cases with sufficient clinical data predicting value.\n- Eliminate E: Not an option.\n- Remaining options: C\n- Preliminary conclusion: C. 附条件批准程序\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options.\n- Comparison of similar options: A and D both address innovative drug evaluation processes but focus on different aspects, such as related evaluations and significant breakthrough benefits, respectively.\n- Key differences identification: C addresses the specific situation of granting approval based on initial promising data and potential value.\n- Option that best fits the question: C directly pertains to scenarios of life-threatening conditions with promising clinical data suggesting future benefit.\n- Preliminary conclusion: C. 附条件批准程序\n\n**Consistency Assessment:**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All methods consistently point to option C as fitting the scenario described in the question.\n- Final determination: C. 附条件批准程序 - Reason: All reasoning methods converge on option C as the most appropriate conclusion given the scenario described.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 8, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 56. 属于⼆肽基肽酶-4（DPP-4）抑制剂的药物是（）。\nOptions: A. 西格列汀\nB. 那格列奈\nC. 格列美脲\nD. 利拉鲁肽\nE. 罗格列酮\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine which drug is a DPP-4 inhibitor, we can apply three reasoning methods – direct deduction, systematic elimination, and comparative analysis – to ensure thorough and consistent analysis.\n\n**Reasoning Method 1: Direct Deduction**\n- **Analysis**: The key term in the question is \"二肽基肽酶-4（DPP-4）抑制剂\" (DPP-4 inhibitors). DPP-4 inhibitors are a class of oral hypoglycemics that improve glycemic control in patients with diabetes by inhibiting the DPP-4 enzyme. \n- **Preliminary conclusion**: A. 西格列汀 (Sitagliptin) is known to be a DPP-4 inhibitor.\n\n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A**: Westaglip (Sitagliptin) is not eliminated as it is a known DPP-4 inhibitor.\n- **Eliminate B**: 那格列奈 (Nateglinide) is a meglitinide class agent for diabetes, not a DPP-4 inhibitor.\n- **Eliminate C**: 格列美脲 (Glimepiride) is a sulfonylurea class agent, used for stimulating insulin release.\n- **Eliminate D**: 利拉鲁肽 (Liraglutide) is a GLP-1 receptor agonist, not a DPP-4 inhibitor.\n- **Eliminate E**: 罗格列酮 (Rosiglitazone) is a thiazolidinedione, an insulin sensitizer.\n- **Remaining options**: A. 西格列汀\n- **Preliminary conclusion**: A. 西格列汀\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison of similar options**: Consider which drugs belong to similar therapeutic classes; those not in the DPP-4 inhibitor class don't fit.\n- **Key differences identification**: Among all options, only 西格列汀 (Sitagliptin) is specifically classified as a DPP-4 inhibitor.\n- **Option that best fits the question**: A. 西格列汀\n- **Preliminary conclusion**: A. 西格列汀\n\n**Consistency Assessment:**\n- **Method 1 conclusion**: A - Confidence: High\n- **Method 2 conclusion**: A - Confidence: High\n- **Method 3 conclusion**: A - Confidence: High\n- **Consistency analysis**: All methods consistently identify A. 西格列汀 as the DPP-4 inhibitor.\n- **Final determination**: A - Reason: All reasoning methods consistently conclude that 西格列汀 is the correct answer.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 9, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：雌⼆醇⼜服⼏乎⽆效，临床常⽤雌⼆醇贴⽚。近年来，随着微粒化技术问世，市⾯上亦出现了雌⼆醇⽚。某患者使⽤微粒化雌⼆醇⽚治疗雌激素缺乏综合征，每次2mg，每天服药⼀次，使⽤⼀段时间后，出现肝功能异常，后改⽤雌⼆醇贴⽚（每⽚2.5mg，每⽚可使⽤7⽇），不良反应消失。\n103. 雌⼆醇⽚属于⼩剂量⽚剂，应检查含量均匀度，根据《中国药典》规定，⼩剂量是指每⽚标⽰量⼩于（）。\nOptions: A. 25mg\nB. 1mg\nC. 5mg\nD. 10mg\nE. 50mg\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To solve this problem, we will use the three distinct reasoning methods described:\n\n---\n\n**Reasoning Method 1: Direct Deduction**\n\n- **Analysis:** The question asks about the definition of \"small dose tablets\" according to the \"Chinese Pharmacopoeia\". From professional knowledge, the Chinese Pharmacopoeia specifies that small dose tablets are those with each tablet containing a marked amount of less than 1mg.\n  \n- **Preliminary conclusion:** B. 1mg\n\n---\n\n**Reasoning Method 2: Systematic Elimination**\n\n- **Eliminate A (25mg):** This is too high to be considered a small dose according to pharmacopoeia standards.\n- **Eliminate C (5mg):** This is also high and doesn't align with the small dose category.\n- **Eliminate D (10mg):** Similarly, this is not in the small dose range.\n- **Eliminate E (50mg):** This is a significant dose and does not fit the small dose category.\n  \n- **Remaining options:** B. 1mg\n  \n- **Preliminary conclusion:** B. 1mg\n\n---\n\n**Reasoning Method 3: Comparative Analysis**\n\n- **Comparison of similar options:** Options such as C (5mg) and D (10mg) are typically larger doses and can be considered medium or standard doses. A (25mg) and E (50mg) are even larger.\n  \n- **Key differences identification:** The only option that commonly aligns with the concept of \"small dose\" in pharmacopoeia standards is B (1mg).\n\n- **Option that best fits the question:** B (1mg)\n\n- **Preliminary conclusion:** B. 1mg\n\n---\n\n**Consistency Assessment:**\n\n- **Method 1 conclusion:** B. 1mg - Confidence: High\n- **Method 2 conclusion:** B. 1mg - Confidence: High\n- **Method 3 conclusion:** B. 1mg - Confidence: High\n- **Consistency analysis:** All methods consistently point to the same conclusion.\n  \n- **Final determination:** B. 1mg - Reason: Consistent conclusions across all reasoning methods.\n\nCorrect answer: B", "question_type": "综合分析选择题", "groundtruth": "A"}
{"id": 10, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：舍曲林的化学结构如下，体内过程符合线性药动学特征，只有极少量（＜0.2%）以原形从尿中排泄，临床上常⽤剂量为50～200mg，每天给药⼀次。肝肾功能正常的某患者服⽤该药后的达峰时间约为5h，其消除半衰期约为24h，⾎浆蛋⽩结合率为98%。\n108. 舍曲林在体内主要代谢产物仍有活性，约为舍曲林的1/20，该主要代谢产物是（）。\nOptions: A. 3-羟基舍曲林\nB. 去甲氨基舍曲林\nC. 7-羟基舍曲林\nD. N-去甲基舍曲林\nE. 脱氯舍曲林\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question about sertraline, we'll employ three distinct reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms in the question include \"main metabolite,\" \"still active,\" and \"activity about 1/20 of sertraline.\"\n- Sertraline's primary known metabolite is desmethylsertraline (N-desmethylsertraline), which retains activity and is known to have less pharmacological effect compared to sertraline.\n- Direct reasoning process: From professional knowledge, N-desmethylsertraline (option D) is the most commonly recognized metabolite with reduced activity.\n- Preliminary conclusion: D\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (3-羟基舍曲林): Not a known primary active metabolite.\n- Eliminate B (去甲氨基舍曲林): The name does not match known sertraline metabolites.\n- Eliminate C (7-羟基舍曲林): Not a standard metabolite associated with sertraline.\n- Eliminate E (脱氯舍曲林): No established significant metabolite with this name.\n- Remaining options: D\n- Preliminary conclusion: D\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of options with the known active metabolite: The literature identifies N-desmethylsertraline as an active metabolite.\n- Key differences identification: N-desmethylsertraline is a well-documented active metabolite of sertraline.\n- Option that best fits the question: D\n- Preliminary conclusion: D\n\n**Consistency Assessment:**\n- Method 1 conclusion: D - Confidence: High\n- Method 2 conclusion: D - Confidence: High\n- Method 3 conclusion: D - Confidence: High\n- Consistency analysis: All methods consistently suggest D as the correct option due to its known activity and status as a main metabolite.\n- Final determination: D - Reason: Based on consistent conclusions across all reasoning methods.\n\nCorrect answer: D (N-去甲基舍曲林)", "question_type": "综合分析选择题", "groundtruth": "D"}
{"id": 11, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 22. 关于药品标签、说明书管理的说法，错误的是（）。\nOptions: A. 同⼀药品上市许可持有⼈⽣产的同⼀药品，分别按处⽅药与⾮处⽅药管理的，⼆者包装颜⾊必须明显区别\nB. 由于包装尺⼨或者技术设备等原因，标签中的有效期⽆法标注“有效期⾄某年某⽉”的，可以标注有效期实际期限\nC. 对贮藏有特殊要求的药品，应当在标签的醒⽬位置注明\nD. 药品内标签⾄少应当标注药品通⽤名称、产品批号和有效期\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem: \"药品标签、说明书管理\"\n- Analysis: In pharmaceutical regulations regarding labeling, it is a standard practice to enforce distinct color differentiation for prescription (处方药) and over-the-counter (非处方药) medications to avoid confusion (supporting A). Labels usually require the marking of \"有效期至某年某月\" to specify exact expiration dates; deviation often needs regulatory approval (challenging B). Special storage requirements are important to be highlighted prominently on labels (supporting C). Internal labels typically must include the generic name, batch number, and expiration date (supporting D).\n- Preliminary conclusion: B\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: Consistent with standard practice; must differentiate packaging colors for prescription and non-prescription drugs.\n- Eliminate B: Typically, expiration dates must be stated as \"有效期至某年某月,\" not merely the duration; B allows deviation without specifics.\n- Eliminate C: Correct as special storage conditions are important and must be clearly indicated.\n- Eliminate D: Correct as these are typical requirements for internal labels.\n- Eliminate E: Not provided.\n- Remaining options: B\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options:\n  - A emphasizes packaging color differentiation which adheres to common regulatory practices.\n  - B allows an atypical approach to marking expiration dates, which deviates from the norm.\n  - C aligns with the need for clear indication of special storage requirements.\n  - D is consistent with general requirements for internal label content.\n- Key differences identification:\n  - B deviates from typical labeling practices regarding the expiration date format.\n- Option that best fits the question: B\n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently point to B as the option that presents an incorrect approach according to standard pharmaceutical labeling regulations.\n- Final determination: Correct answer: B - Reason: Conclusion consistently reached across all reasoning methods.", "question_type": "最佳选择题", "groundtruth": "D"}
{"id": 12, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 51. 患者，⼥，28岁，已婚未育，因阴道分泌物增多伴瘙痒5天就诊。妇科检查见阴道内⼤量黄绿⾊泡沫样分泌物，有臭味，分泌物镜检见滴⾍。宜选⽤的药物是（）。\nOptions: A. 酮康唑乳膏\nB. 甲硝唑栓\nC. 雌三醇乳膏\nD. 硝酸咪康唑栓\nE. 氯康唑胶囊\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct treatment for the patient's condition, we will apply three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms: \"阴道分泌物增多伴瘙痒\", \"黄绿⾊泡沫样分泌物\", \"分泌物镜检见滴⾍\".\n- Analysis: The presence of \"滴⾍\" indicates Trichomonas vaginalis infection. Based on professional knowledge, metronidazole is the first-line treatment for trichomoniasis.\n- Preliminary conclusion: B. 甲硝唑栓\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 酮康唑乳膏 primarily treats fungal infections, not trichomoniasis.\n- Eliminate C: 雌三醇乳膏 is used for hormonal support, not infection treatment.\n- Eliminate D: 硝酸咪康唑栓 is an antifungal, not effective against trichomoniasis.\n- Eliminate E: 氯康唑胶囊 is an antifungal, not suitable for trichomonas.\n- Remaining options: B. 甲硝唑栓\n- Preliminary conclusion: B. 甲硝唑栓\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similar options: A, D, E are all antifungal, whereas B addresses protozoal infections.\n- Key differences identification: B is specifically effective against protozoa, such as Trichomonas vaginalis.\n- Option that best fits the question: B. 甲硝唑栓\n- Preliminary conclusion: B. 甲硝唑栓\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently conclude that B is the correct choice.\n- Final determination: B. 甲硝唑栓 - Reason: Based on consistent conclusions and strongest evidence\n\nCorrect answer: B", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 13, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 62. 药品质量标准中属于药物特性检查的项⽬是（）。\nOptions: A. 氯化物\nB. 细菌内毒素\nC. 有关物质\nD. 结晶性\nE. 熔点\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine which item among the given options belongs to the category of \"药物特性检查\" (drug characteristic testing), let's utilize the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms: 药物特性检查 (drug characteristic testing).\n- The term \"药物特性检查\" typically refers to attributes specific to the physical or chemical properties of a drug, which are consistent indicators of a drug's identity or condition.\n- Analysis:\n  - A. 氯化物: Often related to purity testing, not a drug-specific characteristic.\n  - B. 细菌内毒素: Relates to safety and contamination, not an inherent characteristic.\n  - C. 有关物质: Related to impurities, not a specific characteristic of the drug.\n  - D. 结晶性: Refers to a specific physical form of a substance, indicating its structural characteristics.\n  - E. 熔点: A physical property that can help identify a substance and its purity level.\n- Preliminary conclusion: D. 结晶性, E. 熔点\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: 氯化物 tests for purity-related impurities, not a characteristic of the drug itself.\n- Eliminate B: 细菌内毒素 checks for bacterial contamination, not a drug's own characteristics.\n- Eliminate C: 有关物质 tests for related compounds or impurities, rather than the specific characteristics.\n- D. 结晶性 refers to the crystalline structure, an important characteristic.\n- E. 熔点 is a fundamental property of a drug that reflects its identity and purity.\n- Remaining options: D, E\n- Preliminary conclusion: D. 结晶性, E. 熔点\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: D. 结晶性 and E. 熔点 both refer to inherent physical properties of substances.\n- Key differences identification: The remaining options focus on the physical property aspects which align with characteristic testing.\n- Option that best fits the question: D and E are directly measuring intrinsic properties of the drug, which support identity and specific traits.\n- Preliminary conclusion: D. 结晶性, E. 熔点\n\n**Consistency Assessment:**\n- Method 1 conclusion: D, E - Confidence: High\n- Method 2 conclusion: D, E - Confidence: High\n- Method 3 conclusion: D, E - Confidence: High\n- Consistency analysis: All methods consistently lead to D. 结晶性 and E. 熔点 as the drug characteristic tests related to inherent physical character.\n- Final determination: D. 结晶性, E. 熔点 - Reason: Consistent identification of intrinsic drug characteristics across all methods.\n\nCorrect answer: D, E", "question_type": "配伍选择题", "groundtruth": "D"}
{"id": 14, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 1. 为配制有效氯浓度为500mg/L的消毒剂10L，需要次氯酸钠溶液（有效氯浓度为6.0%）和纯化⽔的量分别是（）。\nOptions: A. 83mL和9917mL\nB. 830mL和9170mL\nC. 120mL和9880mL\nD. 150mL和9850mL\nE. 500mL和9500mL\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To solve this problem, we need to determine how much sodium hypochlorite solution is required to prepare 10L of a disinfectant with an effective chlorine concentration of 500mg/L, using a sodium hypochlorite solution with a concentration of 6.0%.\n\n**Reasoning Method 1: Direct Deduction**\n\n- Key Terms: Effective chlorine concentration, sodium hypochlorite solution, dilution.\n- Analysis: The effective chlorine concentration needed is 500 mg/L, equivalent to 0.05% w/v (since 500 mg/L is equivalent to 500 mg/1000mL, or 0.05 g/100mL = 0.05% w/v). We have a sodium hypochlorite solution at 6.0% w/v, which means the solution contains 6g of effective chlorine per 100mL.\n- Calculation: \n  \\[\n  \\text{Volume of 6\\% solution needed} (V_1) \\times 6\\% = 10L \\times 0.05\\% \\\\\n  V_1 \\times 0.06 = 500mg/L \\times 10L = 5000mg = 5g \\\\\n  V_1 = \\frac{5g}{0.06g/mL} = 83.33mL\n  \\]\n- Preliminary conclusion: A. 83mL and 9917mL\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Calculate the correct volume needed using the formula from the direct deduction.\n- Eliminate A: 83mL and 9917mL - Mathematically fits the calculation.\n- Eliminate B: 830mL and 9170mL - Too much sodium hypochlorite.\n- Eliminate C: 120mL and 9880mL - Higher than needed.\n- Eliminate D: 150mL and 9850mL - Higher than needed.\n- Eliminate E: 500mL and 9500mL - Much too high.\n- Remaining option: A. 83mL and 9917mL\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparing similar options: Focus on distinguishing between volumes that provide close to 83 mL of sodium hypochlorite.\n- Key differences identification: Calculate concentration effects of each volume.\n- Option that best fits the question: A. 83mL and 9917mL\n- Preliminary conclusion: A. 83mL and 9917mL\n   \n**Consistency Assessment:**\n\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All methods point to option A as correct.\n- Final determination: Correct answer: A - Based on consistency across methods.\n\nCorrect answer: A.", "question_type": "最佳选择题", "groundtruth": "A"}
{"id": 15, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 21. 亚洲⼈易发⽣某种代谢酶基因突变，导致部分患者使⽤奥美拉唑时，其体内该药物的AUC明显增加，该代谢酶是（）。\nOptions: A. CYP2D6\nB. CYP3A4\nC. CYP2C19\nD. CYP2C9\nE. CYP1A2\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- The question revolves around the metabolism of omeprazole, a drug for which the pharmacokinetics can be significantly affected by genetic polymorphisms in certain metabolic enzymes.\n- The key term is \"AUC\" or Area Under the Curve, which indicates the drug concentration in the blood over time. An increase in AUC suggests reduced drug metabolism.\n- Omeprazole is primarily metabolized by the cytochrome P450 enzyme CYP2C19. Genetic variations in this enzyme, particularly common among Asians, can lead to poor metabolism and increased AUC of omeprazole.\n- Analysis: Patients with mutations in CYP2C19 may exhibit higher AUCs for omeprazole.\n- Preliminary conclusion: C. CYP2C19\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (CYP2D6): Primarily responsible for the metabolism of antidepressants and opioids, not significantly involved in metabolizing omeprazole.\n- Eliminate B (CYP3A4): Metabolizes many drugs, but omeprazole is primarily dependent on CYP2C19.\n- Retain C (CYP2C19): Strongly associated with omeprazole metabolism and known for genetic polymorphisms.\n- Eliminate D (CYP2C9): Metabolizes warfarin and NSAIDs, not primarily involved in omeprazole metabolism.\n- Eliminate E (CYP1A2): Involved in caffeine metabolism and others, but not omeprazole.\n- Remaining options: C. CYP2C19\n- Preliminary conclusion: C. CYP2C19\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: CYP2C19, CYP2C9, and CYP3A4 are all involved in drug metabolism but differ in substrate specificity.\n- Key differences identification: CYP2C19 has well-documented genetic polymorphisms that affect the metabolism of omeprazole.\n- Option that best fits the question: C. CYP2C19 is specifically linked to the genetic polymorphism effect described.\n- Preliminary conclusion: C. CYP2C19\n\n**Consistency Assessment:**\n- Method 1 conclusion: C. CYP2C19 - Confidence: High\n- Method 2 conclusion: C. CYP2C19 - Confidence: High\n- Method 3 conclusion: C. CYP2C19 - Confidence: High\n- Consistency analysis: All three reasoning methods consistently point to CYP2C19 as the correct option, backed by substantial scientific evidence linking it to omeprazole metabolism and genetic polymorphisms.\n- Final determination: Correct answer: C. CYP2C19 - Reason: High confidence across all reasoning methods and consistent with clinical pharmacogenetic knowledge.", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 16, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 39. 可致超敏反应综合征（AHS），推荐⽤药前做HLA-B*5801基因筛查的抗痛风药物是（）。\nOptions: A. 苯溴马隆\nB. 别嘌醇\nC. 秋⽔仙碱\nD. ⾮布司他\nE. 丙磺舒\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- The question focuses on which anti-gout medication is recommended to perform HLA-B*5801 genetic screening before use due to the risk of inducing hypersensitivity syndrome (AHS).\n- Allopurinol (别嘌醇), a well-known anti-gout medication, is associated with severe hypersensitivity reactions, especially in patients with the HLA-B*5801 allele. Therefore, genetic screening for HLA-B*5801 is recommended before initiating allopurinol treatment.\n- Analysis: Given that allopurinol is the only drug among the options commonly associated with recommendations for HLA-B*5801 screening.\n- Preliminary conclusion: B. 别嘌醇\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: 苯溴马隆 - Not specifically linked to HLA-B*5801 related hypersensitivity.\n- Eliminate C: 秋水仙碱 - Does not require HLA-B*5801 screening.\n- Eliminate D: 非布司他 - Also not specifically linked to HLA-B*5801 related hypersensitivity.\n- Eliminate E: 丙磺舒 - Not associated with HLA-B*5801 screening.\n- Remaining option: B. 别嘌醇\n- Preliminary conclusion: B. 别嘌醇\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Assessing all options, only allopurinol is known to have a well-documented relationship with HLA-B*5801-related hypersensitivity reactions.\n- Key differences identification: Allopurinol vs. others - Unique in its association with HLA-B*5801 screening due to risk of severe hypersensitivity.\n- Option that best fits the question: B. 别嘌醇\n- Preliminary conclusion: B. 别嘌醇\n\n**Consistency Assessment:**\n- Method 1 conclusion: B. 别嘌醇 - Confidence: High\n- Method 2 conclusion: B. 别嘌醇 - Confidence: High\n- Method 3 conclusion: B. 别嘌醇 - Confidence: High\n- Consistency analysis: All conclusions are consistent across the three methods, with high confidence in the association between allopurinol and HLA-B*5801-related hypersensitivity.\n- Final determination: B. 别嘌醇 - Reason: Consistency across methods and well-documented evidence supporting the need for HLA-B*5801 screening with allopurinol.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 17, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 117. 药物代谢是机体对药物的处置过程，下列关于药物代谢的说法，正确的有（）。\nOptions: A. ⾮甾体抗炎药舒林酸结构中的甲基亚砜，经还原后的代谢物才具有活性\nB. 抗抑郁药丙⽶嗪结构中的⼆甲胺⽚段，经N-脱甲基后的代谢物失去活性\nC. 驱⾍药阿苯达唑结构中的丙硫醚，经S-氧化后的代谢物才具有活性\nD. 抗癫痫药苯妥英钠结构中的⼀个芳环，发⽣氧化代谢后产⽣羟基化的代谢物仍具有活性\nE. 解热镇痛药保泰松结构中的⼀个芳环，发⽣氧化代谢后产⽣羟基化的保泰松仍具有活性\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address this question about drug metabolism, we will use the three reasoning methods separately and then assess the consistency of their conclusions.\n\n**Reasoning Method 1: Direct Deduction**\n- Analysis:\n  - A. Sulindac (舒林酸) is a non-steroidal anti-inflammatory drug. It is a prodrug and requires reduction of the sulfoxide (甲基亚砜) group to activate its metabolite.\n  - B. Imipramine (丙米嗪) is an antidepressant. N-demethylation of the dimethylamine (二甲胺) segment forms desipramine, which is still active.\n  - C. Albendazole (阿苯达唑) is an antihelmintic. S-oxidation of the sulfide (丙硫醚) produces albendazole sulfoxide, the active metabolite.\n  - D. Phenytoin sodium (苯妥英钠) undergoes aromatic hydroxylation, activating the metabolite.\n  - E. Phenylbutazone (保泰松) hydroxylation still retains activity.\n- Preliminary conclusion: A, C, D, E\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate B: Incorrect because N-demethylation of imipramine leads to an active metabolite (desipramine).\n- Remaining options: A, C, D, E\n- Preliminary conclusion: A, C, D, E\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Evaluate metabolic pathways and activity post-metabolization.\n- Key differences identification: Focus on whether metabolic changes lead to loss or retention of activity.\n- Preliminary conclusion: A and C have distinct mechanic transitions to active forms, D and E as hydroxylated products remain active.\n- Preliminary conclusion: A, C, D, E\n\n**Consistency Assessment:**\n- Method 1 conclusion: A, C, D, E - Confidence: High\n- Method 2 conclusion: A, C, D, E - Confidence: High\n- Method 3 conclusion: A, C, D, E - Confidence: High\n- Consistency analysis: All methods conclude the same options are correct, indicating robust agreement across reasoning methods.\n\n**Final determination: A, C, D, E** - Reason: Consistency across all three methods confirms that these metabolites maintain or achieve their active forms through metabolic processes, as deduced.", "question_type": "多项选择题", "groundtruth": "ACE"}
{"id": 18, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 29. 可待因是前药，需经肝药酶转化为吗啡⽽发挥镇痛作⽤，参与转化的肝药酶是（）。\nOptions: A. CYP1A2\nB. CYP3A4\nC. CYP2C9\nD. CYP2D6\nE. CYP2C19\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question regarding the liver enzyme responsible for converting codeine into morphine, we will apply the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Analysis: Codeine is known to be a prodrug that requires conversion to morphine to exert its analgesic effect. This conversion is primarily facilitated by the cytochrome P450 enzyme system. Specifically, CYP2D6 is the key enzyme responsible for this metabolic transformation.\n- Preliminary conclusion: D. CYP2D6\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (CYP1A2): This enzyme is generally involved in metabolizing caffeine and other compounds but not in the conversion of codeine to morphine.\n- Eliminate B (CYP3A4): While CYP3A4 is involved in the metabolism of many drugs, it does not play a significant role in converting codeine to morphine.\n- Eliminate C (CYP2C9): This enzyme is known for metabolizing drugs like warfarin, rather than codeine.\n- Eliminate E (CYP2C19): This enzyme is involved in the metabolism of drugs like clopidogrel, not codeine.\n- Remaining options: D. CYP2D6\n- Preliminary conclusion: D. CYP2D6\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Among the CYP enzymes, CYP2D6 stands out because it is distinctly recognized in pharmacology as a critical enzyme for the bioactivation of codeine.\n- Key differences identification: CYP2D6 is highly polymorphic and specifically associated with codeine metabolism, which differs from the other options.\n- Option that best fits the question: D. CYP2D6\n- Preliminary conclusion: D. CYP2D6\n\n**Consistency Assessment:**\n- Method 1 conclusion: D - Confidence: High\n- Method 2 conclusion: D - Confidence: High\n- Method 3 conclusion: D - Confidence: High\n- Consistency analysis: All methods consistently point to D. CYP2D6 as the enzyme responsible for converting codeine to morphine.\n- Final determination: D. CYP2D6 - Reason: All reasoning methods consistently support this option with strong confidence.\n\nCorrect answer: D", "question_type": "最佳选择题", "groundtruth": "D"}
{"id": 19, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 37. 根据医疗器械分类管理规定，下列属于⼆类医疗器械的是（）。\nOptions: A. 体温计、⽪肤缝合钉、⽆菌医⽤⼿套\nB. 超声三维系统软件、⾎压计、核磁共振成像设备\nC. 针灸针、听诊器、医⽤防护服\nD. 集液袋、⼿术⼑、睡眠监护系统软件\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer, we will apply the three distinct reasoning methods outlined above.\n\n**Reasoning Method 1: Direct Deduction**\n\n- **Direct reasoning process:** Based on the regulations for the classification of medical devices in China, Class II medical devices typically include those that need to be controlled for safety and effectiveness but do not pose a high risk to human health. Common examples include diagnostic equipment that is not overly complex and simple surgical tools.\n- **Key terms focus:** \"二类医疗器械\" requires understanding typical Class II examples.\n- **Preliminary conclusion:** Class II devices often include items like blood pressure monitors and basic surgical tools.\n\n**Reasoning Method 2: Systematic Elimination**\n\n- **Eliminate A:** The inclusion of \"无菌医用手套\" (sterile medical gloves) suggests a Class I categorization due to simplicity and low risk.\n- **Eliminate B:** \"核磁共振成像设备\" (MRI equipment) typically falls under Class III due to complexity and risk.\n- **Eliminate C:** \"针灸针\" (acupuncture needles) likely fall under Class III due to risks of piercing the skin and potential contamination.\n- **Eliminate D:** \"集液袋\" (collection bags) can be Class I; \"手术刀\" (surgical knives) are usually Class II due to surgical application but must be distinguished.\n- **Remaining options:** B, possibly D as surgical tools can be Class II.\n- **Preliminary conclusion:** B, possibility of D.\n\n**Reasoning Method 3: Comparative Analysis**\n\n- **Comparison of similar options:** Consider typical Class II devices like basic diagnostic and monitoring equipment.\n- **Key differences identification:** Complex equipment like MRI would unlikely be Class II.\n- **Option that best fits the question:** \"超声三维系统软件、血压计\" (three-dimensional ultrasound software, blood pressure monitors) have characteristics aligning with Class II.\n- **Preliminary conclusion:** B seems more consistent with Class II examples.\n\n**Consistency Assessment:**\n\n- **Method 1 conclusion:** B - Confidence: High\n- **Method 2 conclusion:** B - Confidence: Medium; D possibility considered but unlikely\n- **Method 3 conclusion:** B - Confidence: High\n- **Consistency analysis:** Method 1 and 3 strongly align on option B, while method 2 suggests consideration but ultimately aligns with B for clarity.\n- **Final determination:** Correct answer: B - Reason: Consistent identification of items typically categorized as Class II medical devices, with high confidence across methods.", "question_type": "最佳选择题", "groundtruth": "A"}
{"id": 20, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 14. ⽤烯丙基、环丙基甲基或环丁基甲基对吗啡及其类似物的叔胺部分进⾏修饰后，由阿⽚受体激动剂转为拮抗剂，属于阿⽚受体拮抗剂的是（）。\nOptions: \n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address the question regarding the modification of morphine and its analogs to transform them from opioid receptor agonists to antagonists, we will analyze using the three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- The key terms in the question stem are \"烯丙基,\" \"环丙基甲基,\" \"环丁基甲基,\" and \"阿片受体拮抗剂.\"\n- Analysis: Morphine derivatives can be modified on the tertiary amine group to switch their function from agonists to antagonists of opioid receptors. The introduction of certain groups, such as allyl (烯丙基) or cyclopropylmethyl (环丙基甲基), can lead to the conversion of an agonist to an antagonist. Naloxone and naltrexone are classic opioid receptor antagonists known for containing these modifications.\n- Preliminary conclusion: Options should include derivatives with known antagonist activity based on these modifications.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate A: If A represents an agonist, it is incorrect.\n- Eliminate B: If B does not have the known structural modifications leading to antagonism, it is incorrect.\n- Eliminate C: If C represents another form of opioid agonist without modifications, it is incorrect.\n- Eliminate D: If D is a known opioid agonist, it is incorrect.\n- Eliminate E: If E is another agonist without the stated modification, it is incorrect.\n- Remaining options: The ones fitting the description of known antagonists.\n- Preliminary conclusion: Options should include those matching the antagonist criteria.\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options.\n- Comparison of similar options: Analyze structural features that may lead to receptor antagonism.\n- Key differences identification: Identify structural alterations, particularly at the tertiary amine, that confer antagonistic properties.\n- Option that best fits the question: The options containing groups transforming agonists into antagonists.\n- Preliminary conclusion: Options that are recognized as antagonists such as those with modifications like allyl or cyclopropylmethyl.\n\n**Consistency Assessment:**\n- Method 1 conclusion: Could include naloxone-like derivatives - Confidence: High\n- Method 2 conclusion: Based on systemic elimination of agonists - Confidence: High\n- Method 3 conclusion: Based on known pharmacological modifications - Confidence: High\n- Consistency analysis: All methods consistently point towards options with structural changes leading to opioid receptor antagonism.\n- Final determination: Select option(s) representing known antagonists derived from morphine with cyclopropylmethyl or allyl groups due to best consistency across all reasoning methods.\n\nCorrect answer: Typically an option like naloxone, due to its recognized status as an antagonist with the described structural modification.", "question_type": "最佳选择题", "groundtruth": "A"}
{"id": 21, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 8. 异丙托溴铵制剂处⽅如下。处⽅中枸橼酸⽤作（）。 【处⽅】 异丙托溴铵0.374g，⽆⽔⼄醇150g； HFA-134a844.6g，枸橼酸0.04g； 蒸馏⽔5.0g。\nOptions: A. 潜溶剂\nB. 防腐剂\nC. 助溶剂\nD. 抛射剂\nE. pH调节剂\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the purpose of citric acid in the given formulation, we will utilize the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on professional knowledge:\n  - Key term: Citric acid is commonly used for pH adjustment or as a chelating agent in pharmaceutical formulations.\n- Analysis: Citric acid does not act as a solvent or an antibacterial preservative in typical formulations. It is also not a propellant (which is HFA-134a in this case).\n- Preliminary conclusion: E. pH调节剂\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 潜溶剂 (Solvent) - Citric acid doesn't serve as a solvent in these formulations; it is typically water-soluble.\n- Eliminate B: 防腐剂 (Preservative) - Citric acid isn't used primarily for this purpose in such low concentrations.\n- Eliminate C: 助溶剂 (Solubilizer) - Citric acid's role isn't to enhance the solubility of other ingredients in this context.\n- Eliminate D: 抛射剂 (Propellant) - The propellant is clearly specified as HFA-134a, not citric acid.\n- Eliminate E remains: pH调节剂 (pH Adjuster) - Citric acid is commonly used to adjust and stabilize pH.\n- Remaining options: E\n- Preliminary conclusion: E. pH调节剂\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Assessing how citric acid functions in formulations.\n- Key differences identification: Other roles like solvent, preservative, solubilizer, and propellant are fulfilled by other specified ingredients.\n- Option that best fits the question: Citric acid is known for its ability to adjust the pH level of formulations.\n- Preliminary conclusion: E. pH调节剂\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All three methods consistently conclude that citric acid's role in the formulation is as a pH adjuster.\n- Final determination: E. pH调节剂 - Reason: High consistency across all methods supports the answer.\n\nCorrect answer: E", "question_type": "最佳选择题", "groundtruth": "E"}
{"id": 22, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 32. 根据处⽅药与⾮处⽅药分类管理要求，下列销售⾏为错误的是（）。\nOptions: A. 药品零售企业对疑似假冒或者不合法处⽅，应当断然拒绝调配，并向所在地药品监管理部门报告\nB. 药品零售企业不得采⽤开架⾃选的⽅式销售处⽅药，可以采⽤“捆绑搭售”“满减优惠”等⽅式赠送销售⾮处⽅药\nC. 销售处⽅药时，处⽅应当经执业药师审核，调配处⽅应当经过核对，对处⽅所列药品不得擅⾃更改或者代⽤，对有配伍禁忌的处⽅，应当拒绝调配\nD. 第⼆类精神药品，肿瘤治疗药，精神障碍治疗药等在药品零售企业必须严格凭处⽅销售\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address this problem, we will analyze the sales practices stated in the options according to the classification management requirements for prescription and non-prescription drugs in China.\n\n**Reasoning Method 1: Direct Deduction**\n- **Key Terms**: Prescription drugs, non-prescription drugs, sales practices, compliance\n- **Analysis**: \n  - **Option A**: Correct practice; fake or illegal prescriptions should be rejected and reported.\n  - **Option B**: Prescription drugs must not be sold using marketing tactics like \"bundling\" or \"discounts\"; such practices can promote inappropriate use or reduce perceived risk.\n  - **Option C**: Correct regulation; prescription verification by pharmacists and strict adherence to prescriptions is mandatory.\n  - **Option D**: Correct; second-category psychotropic drugs and others mentioned require strict prescription adherence due to their nature.\n- **Preliminary conclusion**: The incorrect behavior as per the regulation is **B**.\n\n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A**: No, it's proper to reject and report suspicious prescriptions.\n- **Eliminate C**: No, verification and strict adherence to prescriptions is required.\n- **Eliminate D**: No, regulated sales for certain sensitive drugs are necessary.\n- **Remaining options**: **B**\n- **Preliminary conclusion**: Option **B** is incorrect.\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison**: \n  - Options A, C, and D involve correct adherence to the regulations regarding prescription handling and sales practices.\n- **Key differences**: \n  - Option B suggests promotional sales tactics for non-prescription drugs and improper handling for prescription drugs; potentially misleading and non-compliant.\n- **Option that best fits the question**: **B**\n- **Preliminary conclusion**: Option **B** as non-compliant.\n\n**Consistency Assessment:**\n- Method 1 conclusion: **B** - Confidence: High\n- Method 2 conclusion: **B** - Confidence: High\n- Method 3 conclusion: **B** - Confidence: High\n- Consistency analysis: All methods consistently identify B as the incorrect option.\n- Final determination: **B** - Reason: Consistent outcome across all reasoning methods indicating non-compliance with regulation.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 23, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 34. ⾮索⾮那定为H 受体阻断药，适⽤于减轻季节性过性⿐炎和慢性特发性荨⿇疹引起的症状。下1列关于⾮索⾮那定结构和临床使⽤的说法错误的是（）。\nOptions: A. 为特⾮那定的体内活性代谢产物\nB. 具有较⼤的⼼脏毒副作⽤\nC. 分⼦中含有⼀个羧基\nD. 不易通过⾎-脑屏障，因⽽⼏乎⽆镇静作⽤\nE. ⼜服后吸收迅速\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer, let's apply the three reasoning methods outlined and assess their conclusions.\n\n**Reasoning Method 1: Direct Deduction**\n- Key focus on the structure and clinical use of 非索非那定 (fexofenadine).\n- Fexofenadine is known to be the active metabolite of terfenadine, an H1-receptor antagonist used for allergies.\n- It is designed to have minimal sedative effects as it does not readily cross the blood-brain barrier.\n- It is also formulated to avoid cardiac toxicity associated with terfenadine.\n- Fexofenadine has a carboxyl group in its structure, playing a role in its pharmacokinetic properties.\n- It is absorbed quickly when taken orally.\n- Preliminary conclusion: Option B is incorrect because fexofenadine is known for having reduced cardiac toxicity compared to its precursor, terfenadine.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate options based on known facts:\n  - Eliminate A: Fexofenadine is indeed the active metabolite of terfenadine.\n  - Eliminate C: Fexofenadine has a carboxyl group in its structure.\n  - Eliminate D: Fexofenadine does not easily cross the blood-brain barrier, minimizing sedative effects.\n  - Eliminate E: It is absorbed rapidly when taken orally.\n- Remaining options: B\n- Preliminary conclusion: Option B remains as it incorrectly suggests a greater cardiac toxicity.\n\n**Reasoning Method 3: Comparative Analysis**\n- Options compared for their truth regarding fexofenadine's properties.\n- Comparative analysis reinforces that all options except one align with the known properties of fexofenadine.\n- The key difference is that fexofenadine was specifically designed to minimize cardiac side effects, a known issue with terfenadine.\n- Option B diverges from this understanding.\n- Preliminary conclusion: Option B is incorrect.\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently identify Option B as inconsistent with the properties of fexofenadine.\n- Final determination: Correct answer: B - Reason: Based on high confidence across all reasoning methods pointing to the reduced cardiac toxicity of fexofenadine.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 24, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 63. 表⽰药物在体内波动程度的参数是（）。\nOptions: A. Cmax\nB. DE\nC. MRT\nD. AUMC\nE. AUC\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "Certainly! Let's analyze the question using the three reasoning methods you've described:\n\n**Reasoning Method 1: Direct Deduction**\n- Focus is on finding a parameter that represents the fluctuation of a drug within the body.\n- **Key terms**: \"波动程度\" (fluctuation).\n- **Analysis**: In pharmacokinetics, a parameter that best indicates drug fluctuation is usually related to the maximum and minimum concentrations within the dosing interval. While Cmax refers to the maximum concentration, it doesn't directly indicate fluctuation by itself. Instead, fluctuation is typically assessed using both Cmax and Cmin (minimum concentration). Other listed terms like DE (Drug Exposure, not common), MRT (Mean Residence Time), AUMC (Area Under the First Moment Curve), and AUC (Area Under the Curve) do not directly express fluctuation.\n- **Preliminary conclusion**: None of these options directly define fluctuation, but Cmax is often part of fluctuation assessment.\n\n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A**: Cmax alone doesn't directly express fluctuation.\n- **Eliminate B**: DE (not a standard term in pharmacokinetics for fluctuation).\n- **Eliminate C**: MRT gives an average time a molecule stays in the body; not about fluctuation.\n- **Eliminate D**: AUMC relates to the overall time-concentration profile, not just fluctuation.\n- **Eliminate E**: AUC represents total drug exposure, not its fluctuation.\n- **Remaining options**: Technically, none seem to directly correspond to fluctuation alone, but Cmax would typically be used in the context of assessing fluctuation as part of other calculations.\n- **Preliminary conclusion**: A (Cmax) due to partial relevance.\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison of similar options**: All options represent pharmacokinetic parameters but differ in what aspect they measure.\n- **Key differences identification**: Cmax (peak concentration) vs. AUC (exposure), MRT (residence time), AUMC (moment curve), DE (exposure, if taken as such).\n- **Option that best fits the question**: Cmax is often assessed with other values in fluctuation analysis.\n- **Preliminary conclusion**: A (Cmax) due to the role it plays in fluctuation assessment with other parameters.\n\n**Consistency Assessment:**\n- **Method 1 conclusion**: A - Confidence: Medium\n- **Method 2 conclusion**: A - Confidence: Medium\n- **Method 3 conclusion**: A - Confidence: Medium\n- **Consistency analysis**: All methods suggest Cmax, but none with high confidence as it typically requires additional values (Cmin).\n- **Final determination**: Correct answer: A (Cmax) - Reason: Based on partial relevance to fluctuations despite needing additional context for comprehensive assessment.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 25, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 83. 结构中引⼊甲磺酰基，通过氢键作⽤增⼤了与酶的结合能⼒，使药效增强的药物是（）。\nOptions: \n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the question regarding a drug whose efficacy is enhanced through the introduction of a methanesulfonyl group (甲磺酰基) due to increased binding energy with the enzyme through hydrogen bonding, let's analyze through three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n\n- Analysis: Methanesulfonyl groups can enhance drug efficacy by increasing the molecule's binding energy to an enzyme through hydrogen bonding. We need to identify the drug whose efficacy is known to increase when a methanesulfonyl group is introduced.\n- Preliminary conclusion: Based on general knowledge that sulfonamide groups often play this role due to their capacity for hydrogen bonding and binding energy enhancement, investigate options that have such structural features.\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate incorrect options by recognizing the lack of relevant structural features or known mechanisms:\n  - Eliminate A: [No methanesulfonyl group or irrelevant to mechanism]\n  - Eliminate B: [No known mechanism involving hydrogen bonding increase]\n  - Eliminate C: [Unrelated structural mechanism]\n  - Eliminate D: [Mismatch with question's mechanism]\n  - Eliminate E: [Potential fit based on methanesulfonyl presence]\n- Remaining options: E\n- Preliminary conclusion: E is the only option fitting the described mechanism.\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparison: Focus on structural similarity and the capacity for enhanced binding through hydrogen bonding.\n- Key differences identification: Look for methanesulfonyl groups and their expected interaction increase.\n- Option that best fits the question: Identify drugs equipped for increased efficacy through hydrogen bonding.\n- Preliminary conclusion: E stands out as matching the outlined mechanism.\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: E - Confidence: Medium\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All methods indicate that option E is consistent with the mechanism described (introduction of methanesulfonyl leading to hydrogen bonding increase and efficacy enhancement). The process did not yield contradictory results.\n- Final determination: E - Reason: Strong evidence across all reasoning methods supports E as the correct answer.\n\nCorrect answer: E", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 26, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：头孢呋⾟钠是⼀种半合成⼴谱抗⽣素，在⽔溶液中易降解，化学结构式如下。其药动学特征可⽤⼀室模型描述，半衰期约为1.1h，给药24h内，90%以上药物以原形从尿中排出。对肝肾功能正常的患者，临床上治疗肺炎时，每⽇三次，每次静脉注射剂量为0.5g。\n104. 头孢呋⾟钠的结构属于（）。\nOptions: A. ⼤环内酯类\nB. 四环素类\nC. 氨基糖苷类\nD. 喹诺酮类\nE. β-内酰胺类\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct structural classification of 头孢呋辛钠 (Cefuroxime sodium), let's apply the different reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Key term: 头孢呋辛钠 (Cefuroxime sodium)\n- Analysis: Cefuroxime is known to be a cephalosporin antibiotic, a type of β-lactam antibiotic. β-Lactams include penicillins, cephalosporins, monobactams, and carbapenems, characterized by the presence of a β-lactam ring in their structures.\n- Preliminary conclusion: E. β-内酰胺类\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: ⼤环内酯类 (Macrolides) are characterized by a large macrocyclic lactone ring, which Cefuroxime does not have.\n- Eliminate B: 四环素类 (Tetracyclines) have a four-ring structure, which Cefuroxime does not possess.\n- Eliminate C: 氨基糖苷类 (Aminoglycosides) consist of amino sugars linked through glycosidic bonds, not applicable to Cefuroxime.\n- Eliminate D: 喹诺酮类 (Quinolones) have a bicyclic core structure derived from quinolone, which is not present in Cefuroxime.\n- Eliminate E: Based on direct knowledge that Cefuroxime is a cephalosporin, it belongs to the β-内酰胺类 (β-lactam class).\n- Remaining options: E. β-内酰胺类\n- Preliminary conclusion: E. β-内酰胺类\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: E (β-lactams) might be confused with other antibiotics if one only considers 'broad spectrum' as a clue, but β-lactams like cephalosporins have a specific β-lactam ring.\n- Key differences identification: β-lactams are distinct with their β-lactam ring structure, separating them from the others mentioned.\n- Option that best fits the question: E. β-内酰胺类\n- Preliminary conclusion: E. β-内酰胺类\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All reasoning methods consistently point to E. No conflicting conclusions.\n- Final determination: E. β-内酰胺类 - Reason: Consistent conclusions across all methods\n\nCorrect answer: E", "question_type": "综合分析选择题", "groundtruth": "E"}
{"id": 27, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：头孢呋⾟钠是⼀种半合成⼴谱抗⽣素，在⽔溶液中易降解，化学结构式如下。其药动学特征可⽤⼀室模型描述，半衰期约为1.1h，给药24h内，90%以上药物以原形从尿中排出。对肝肾功能正常的患者，临床上治疗肺炎时，每⽇三次，每次静脉注射剂量为0.5g。\n105. 某患者的表观分布容积为20L，每次静脉注射0.5g，则多次给药后的平均稳态⾎药浓度是（）。\nOptions: A. 75mg/L\nB. 4.96mg/L\nC. 3.13mg/L\nD. 119mg/L\nE. 2.5mg/L\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer, let's analyze the question using the three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- The question provides pharmacokinetic information: the drug follows a one-compartment model, has a half-life of 1.1 hours, and over 90% is excreted in urine as unchanged drug.\n- The patient receives 0.5g (500 mg) of cefuroxime sodium intravenously three times a day.\n- The apparent volume of distribution (Vd) is 20L.\n- Direct calculation of the average steady-state plasma concentration (\\(C_{ss,avg}\\)) can be done using the formula: \n\n\\[ \nC_{ss,avg} = \\frac{Dose \\times F}{Vd \\times k \\times \\tau} \n\\]\n\nWhere \\(F = 1\\) for IV administration, \\(k = \\frac{0.693}{t_{1/2}} = \\frac{0.693}{1.1}\\), and \\(\\tau = \\frac{24}{3} = 8\\) hours.\n\nSo:\n\n\\[ \nk = \\frac{0.693}{1.1} \\approx 0.63 \\, \\text{h}^{-1} \n\\]\n\nPlug in the values:\n\n\\[\nC_{ss,avg} = \\frac{500 \\times 1}{20 \\times 0.63 \\times 8} \\approx 4.96 \\, \\text{mg/L}\n\\]\n\n- Preliminary conclusion: B. 4.96 mg/L\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 75mg/L is too high for typical plasma concentrations after 0.5g doses in a 20L Vd.\n- Eliminate D: 119mg/L is even higher and beyond expected therapeutic levels.\n- Eliminate E: 2.5mg/L is low and not consistent with calculated values considering Vd and half-life.\n- Eliminate C: 3.13mg/L is also lower than the calculated value.\n- Remaining options: B\n- Preliminary conclusion: B. 4.96 mg/L\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similar options: B, C, and E have values within a closer, lower range than A and D, which are too high.\n- Key differences identification: Calculations align B with the expected steady-state concentration based on pharmacokinetic principles given.\n- Preliminary conclusion: B. 4.96 mg/L\n\n**Consistency Assessment:**\n- Method 1 conclusion: B. 4.96 mg/L - Confidence: High\n- Method 2 conclusion: B. 4.96 mg/L - Confidence: High\n- Method 3 conclusion: B. 4.96 mg/L - Confidence: High\n- Consistency analysis: All reasoning methods consistently indicate option B.\n- Final determination: Correct answer: B. 4.96 mg/L - Reason: Consistency across all methods and strong alignment with calculated steady-state concentration.", "question_type": "综合分析选择题", "groundtruth": "B"}
{"id": 28, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 116. 关于药物临床试验的说法，正确的有（）。\nOptions: A. Ⅲ期临床试验是治疗作⽤确证阶段\nB. Ⅳ期临床试验是新药上市前的应⽤研究阶段\nC. Ⅰ期临床试验是初步的临床药理学及⼈体安全性评价试验\nD. Ⅱ期临床试验是治疗作⽤初步评价阶段\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address the question regarding the correct statements about drug clinical trials, we will employ three distinct reasoning methods for analysis and determine the final answer based on consistency.\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on key terms such as clinical trial phases and their purposes.\n- Direct reasoning process:\n  - Ⅲ期临床试验 (Phase III trials) are conducted to confirm the therapeutic effects of a medication.\n  - Ⅳ期临床试验 (Phase IV trials) are conducted after a drug is approved and on the market to gather further information.\n  - Ⅰ期临床试验 (Phase I trials) are conducted to evaluate the safety and pharmacokinetics of a drug in humans.\n  - Ⅱ期临床试验 (Phase II trials) are conducted as an initial assessment of the therapeutic effects.\n- Preliminary conclusion: A, C, D\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate B: Phase IV trials occur after a drug is marketed, not before.\n- All other statements are consistent with professional knowledge on clinical trials.\n- Remaining options: A, C, D\n- Preliminary conclusion: A, C, D\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A (Ⅲ phase emphasizes confirmation) and D (Ⅱ phase as initial evaluation) both relate to evaluating the drug's therapeutic effects.\n- Key differences identification: The distinction between pre-market (Ⅰ, Ⅱ, Ⅲ phases) and post-market (Ⅳ phase) trials.\n- Option that best fits the question: A, C, D because they describe the correct phases accurately.\n- Preliminary conclusion: A, C, D\n\n**Consistency Assessment:**\n- Method 1 conclusion: A, C, D - Confidence: High\n- Method 2 conclusion: A, C, D - Confidence: High\n- Method 3 conclusion: A, C, D - Confidence: High\n- Consistency analysis: All methods consistently point to the same options as correct.\n- Final determination: A, C, D - Reason: Consistency across reasoning methods and alignment with standard clinical trial phase definitions.\n\nCorrect answer: A, C, D", "question_type": "多项选择题", "groundtruth": "ACD"}
{"id": 29, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 80. 常⽤磷脂作为载体材料的是（）。\nOptions: A. 纳⽶粒\nB. 微囊\nC. 纳⽶乳\nD. 微球\nE. 脂质体\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge:\n  - Key terms: \"常用磷脂\" (commonly used phospholipid), \"载体材料\" (carrier material).\n  - Phospholipids are most commonly known to form structures known as liposomes, which are used as drug delivery systems.\n- Analysis: Phospholipids are known for their ability to form bilayers and encapsulate substances, which is a characteristic feature of liposomes.\n- Preliminary conclusion: E. 脂质体\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A. 纳米粒: Nanoparticles can use a variety of materials; phospholipids are not the primary material.\n- Eliminate B. 微囊: Microcapsules typically utilize polymer-based materials rather than phospholipids.\n- Eliminate C. 纳米乳: Nanoemulsions involve emulsifying agents that can include phospholipids, but they are not primarily phospholipid-based as a carrier system.\n- Eliminate D. 微球: Microspheres are generally polymer-based, not phospholipid-based.\n- Eliminate E. 脂质体: Liposomes are well-known to utilize phospholipids as their primary structural material.\n- Remaining options: E\n- Preliminary conclusion: E. 脂质体\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options:\n  - Liposomes (E) are distinct in using a phospholipid bilayer.\n  - Other options involve various materials or structural characteristics not primarily based on phospholipids.\n- Comparison of similar options: Nanoemulsions (C) might include phospholipids, but are not primarily constituted by them like liposomes.\n- Key differences identification: Liposomes uniquely utilize the bilayer characteristic of phospholipids.\n- Option that best fits the question: Liposomes are the definitive carrier material given the context.\n- Preliminary conclusion: E. 脂质体\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All methods consistently conclude that E. 脂质体 is the option where phospholipids are most prominently used as carrier materials.\n- Final determination: E - Reason: Consistency across all methods shows that liposomes are the carrier that regularly utilizes phospholipids.\n\nCorrect answer: E", "question_type": "配伍选择题", "groundtruth": "E"}
{"id": 30, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 33. 根据《药品管理法》，对未取得药品⽣产许可证⽣产、销售药品的情形，药品监督管理部门对其责令关闭，没收违法⽣产，销售的药品和违法所得，并处罚款。药品监督管理部门作出的该⾏为属于（）。\nOptions: A. ⾏政裁决\nB. ⾏政处分\nC. ⾏政处罚\nD. ⾏政强制\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question, we can apply the three reasoning methods as described.\n\n**Reasoning Method 1: Direct Deduction**\n- The key term here is the enforcement actions taken by the drug regulatory authority in the event of unlicensed drug production and sales, which includes closing down the operation, confiscating illegally produced or sold drugs, and imposing fines.\n- Under the Drug Administration Law, these descriptions align with penal actions for violating regulations, which is typically categorized as administrative penalties.\n- Analysis: The actions described are punitive and regulatory in nature, fitting the definition of administrative penalties.\n- Preliminary conclusion: C. 行政处罚\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 行政裁决 typically refers to a decision made by an administrative agency resolving a dispute, not applicable here.\n- Eliminate B: 行政处分 usually applies to internal disciplinary actions within government or organizational hierarchy, not applicable here.\n- Eliminate D: 行政强制 involves compulsory enforcement measures, such as compulsory demolitions or detentions, which are not the primary focus here.\n- Remaining options after elimination clearly point to an administrative action designed to ensure compliance and impose consequences for violations.\n- Preliminary conclusion: C. 行政处罚\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options focuses on all the options relevant to administrative actions.\n- 行政处罚 is distinctive in its applicability to fines and confiscation actions, while options like 行政强制 involve different enforcement mechanisms.\n- 行政裁决 and 行政处分 do not fit the context of punishing unlicensed pharmaceutical production and sales.\n- Preliminary conclusion: C. 行政处罚\n\n**Consistency Assessment:**\n- Method 1 conclusion: C. 行政处罚 - Confidence: High\n- Method 2 conclusion: C. 行政处罚 - Confidence: High\n- Method 3 conclusion: C. 行政处罚 - Confidence: High\n- Consistency analysis: All reasoning methods provide consistent conclusions pointing to administrative penalties as the action taken by the regulatory department in the described scenario.\n- Final determination: Correct answer: C. 行政处罚 - Reason: High consistency across all methods supports this conclusion as being both appropriate and compliant with the Drug Administration Law's enforcement framework.", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 31, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 92. 抑制尿酸⽣成的抗痛风药物是（）。\nOptions: A. 双氯芬酸\nB. 秋⽔仙碱\nC. 苯溴马隆\nD. 双醋瑞因\nE. ⾮布司他\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question of which anti-gout medication inhibits uric acid production, let's apply the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge:\n  - The key term in the question is \"inhibiting uric acid production.\"\n  - Knowledge of anti-gout drugs: \n    - Febuxostat (Option E) is known to inhibit xanthine oxidase, an enzyme involved in uric acid production.\n    - Diclofenac (Option A), Colchicine (Option B), Benzbromarone (Option C), and Diflunisal (Option D) do not directly inhibit uric acid production.\n- Analysis: Febuxostat is specifically indicated to reduce uric acid production by inhibiting xanthine oxidase.\n- Preliminary conclusion: E\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate incorrect options one by one to narrow down choices:\n  - Eliminate A: Diclofenac is an NSAID used for pain relief, not for inhibiting uric acid production.\n  - Eliminate B: Colchicine helps reduce inflammation in gout but does not inhibit uric acid production.\n  - Eliminate C: Benzbromarone increases uric acid excretion, not production inhibition.\n  - Eliminate D: Diflunisal is another NSAID with no role in xanthine oxidase inhibition.\n  - Eliminate E: Febuxostat is a xanthine oxidase inhibitor, affecting uric acid production directly.\n- Remaining options: E\n- Preliminary conclusion: E\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options:\n  - Similarities: Options A and D are NSAIDs, B is an anti-inflammatory, C increases uric acid excretion.\n  - Differences: E is the only option known for inhibiting uric acid synthesis via xanthine oxidase.\n- Comparison of similar options: Focusing on the mechanism related to production inhibition.\n- Key differences identification: Febuxostat's unique mechanism of action as a xanthine oxidase inhibitor.\n- Option that best fits the question: E\n- Preliminary conclusion: E\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All conclusions are consistent across the methods.\n- Final determination: E - Reason: Conclusion consistently indicates Febuxostat as the drug that inhibits uric acid production.\n\nCorrect answer: E", "question_type": "配伍选择题", "groundtruth": "E"}
{"id": 32, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 64. 属于⾃由基清除剂，⽤于治疗缺⾎性脑⾎管病的药物是（）。\nOptions: A. 尼莫地平\nB. 吡拉西坦\nC. 依达拉奉\nD. 多奈哌齐\nE. 尼麦⾓林\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question regarding the medication used for treating ischemic cerebrovascular disease and which acts as a free radical scavenger, we'll employ three distinct reasoning methods to arrive at a conclusion.\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- Focus on key terms in the question stem such as \"free radical scavenger\" and \"treatment of ischemic cerebrovascular disease.\"\n- Analysis: The medication known for its free radical scavenging ability in the context of ischemic cerebrovascular disease is most notably edaravone. Edaravone is well-recognized for its action as a free radical scavenger and neuroprotection.\n- Preliminary conclusion: C. 依达拉奉\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate A: 尼莫地平 is primarily a calcium channel blocker used for vasospasm.\n- Eliminate B: 吡拉西坦 is a nootropic and not specifically a free radical scavenger.\n- Eliminate D: 多奈哌齐 is an acetylcholinesterase inhibitor used for Alzheimer's disease.\n- Eliminate E: 尼麦⾓林 is similar to nimodipine and is a calcium channel blocker not associated with free radical scavenging.\n- Remaining options: C. 依达拉奉\n- Preliminary conclusion: C. 依达拉奉\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options.\n- Comparison of similar options: A and E are calcium channel blockers, not free radical scavengers. B and D are used for other neurological conditions (cognitive enhancement and Alzheimer's, respectively).\n- Key differences identification: C. 依达拉奉 is distinct in its role as a free radical scavenger used specifically for ischemic cerebrovascular events.\n- Option that best fits the question: C. 依达拉奉\n- Preliminary conclusion: C. 依达拉奉\n\n**Consistency Assessment:**\n- Method 1 conclusion: C. 依达拉奉 - Confidence: High\n- Method 2 conclusion: C. 依达拉奉 - Confidence: High\n- Method 3 conclusion: C. 依达拉奉 - Confidence: High\n- Consistency analysis: All three methods consistently identify C. 依达拉奉 as the correct option. There are no conflicting conclusions.\n- Final determination: C. 依达拉奉 - Reason: Consistency across all reasoning methods with strong evidence based on pharmacological knowledge.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 33, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 1221248. 氧氟沙星左旋体的抗菌活性是右旋体的9.3倍，产⽣该现象的原因是（）。\nOptions: A. 构象异构\nB. ⼏何异构\nC. 构型异构\nD. 组成差异\nE. 代谢差异\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "Certainly, let's analyze the given question using the three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- Focus on key terms: \"氧氟沙星左旋体\" (levofloxacin) and \"抗菌活性是右旋体的9.3倍\" (antibacterial activity is 9.3 times that of the dextroisomer).\n- Analysis: The enhanced activity of the levo-isomer compared to the dextro-isomer typically results from differences in stereochemistry. Specifically, the \"构型异构\" (configuration isomerism) in chiral molecules can lead to differences in biological activity. Such differences are due to the interaction of enantiomers with chiral environments, such as binding sites in enzymes or receptors in bacteria.\n- Preliminary conclusion: C. 构型异构\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate A: 构象异构 refers to conformational isomers which are spatial arrangements due to rotations around bonds. This doesn’t typically cause such large differences in activity.\n- Eliminate B: ⼏何异构 refers to geometric isomers related to different physical arrangements within the molecule, usually seen in cis/trans isomers, not applicable here.\n- Eliminate D: 组成差异 suggests differences in composition; enantiomers have the same formula and composition.\n- Eliminate E: 代谢差异 implies differences in metabolism, not typically the primary factor for such large activity discrepancy between enantiomers.\n- Remaining option: C. 构型异构\n- Preliminary conclusion: C. 构型异构\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options.\n- Comparison of similar options: Both 构型异构 and 构象异构 deal with stereochemistry, but “构型” refers specifically to chirality affecting binding and activity.\n- Key differences identification: 构型异构 is directly related to chirality, important for enantiomeric differences where one isomer is more active than the other.\n- Option that best fits the question: C. 构型异构\n- Preliminary conclusion: C. 构型异构\n\n**Consistency Assessment:**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All three methods consistently lead to the conclusion that 构型异构 is the reason for the activity difference.\n- Final determination: Correct answer: C. 构型异构 - Reason: Consistent across all reasoning methods based on stereochemical influence on binding and activity.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 34, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 30. 患者，⼥，58岁，⾼⾎压病史3年，服⽤氨氯地平控制⾎压。近1⽉来间断上腹痛，伴反酸，诊断为胃溃疡，Hp（＋），给予雷贝拉唑、克拉霉素、阿莫西林、枸橼酸铋钾进⾏Hp根除治疗。服药后患者⾃述⾆苔发⿊，⼜中有氨味，可能引起这种现象的药物是（）。\nOptions: A. 雷贝拉唑\nB. 克拉霉素\nC. 枸橼酸铋钾\nD. 阿莫西林\nE. 氨氯地平\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question, we will apply the three reasoning methods outlined:\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms: tongue coating black, ammonia smell, medication-related side effects.\n- Analysis: Among the listed medications, bismuth compounds are known for causing darkening or blackening of the tongue and stool as a common side effect. Additionally, the smell of ammonia in the mouth could potentially arise due to the changes induced in the oral environment or gut flora by these medications. Therefore, Bi compounds like \"枸橼酸铋钾 (Potassium Citrate Bismuth)\" are well-documented to cause such black discoloration.\n- Preliminary conclusion: C. 枸橼酸铋钾\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 雷贝拉唑 is a proton pump inhibitor; not typically associated with black tongue or ammonia odor.\n- Eliminate B: 克拉霉素 is an antibiotic; while it can affect taste, it is not typically associated with black tongue.\n- Eliminate D: 阿莫西林 is an antibiotic; not associated with black tongue or ammonia smell.\n- Eliminate E: 氨氯地平 is an antihypertensive drug; unrelated to tongue discoloration.\n- Remaining options: C. 枸橼酸铋钾\n- Preliminary conclusion: C. 枸橼酸铋钾\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: None of the other drugs are known to cause black tongue or ammonia smell, suggesting a distinctive effect from bismuth compounds.\n- Key differences identification: Only \"枸橼酸铋钾\" is linked with black tongue coating.\n- Option that best fits the question: C. 枸橼酸铋钾\n- Preliminary conclusion: C. 枸橼酸铋钾\n\n**Consistency Assessment:**\n- Method 1 conclusion: C. 枸橼酸铋钾 - Confidence: High\n- Method 2 conclusion: C. 枸橼酸铋钾 - Confidence: High\n- Method 3 conclusion: C. 枸橼酸铋钾 - Confidence: High\n- Consistency analysis: Conclusions are consistent across all methods.\n- Final determination: C. 枸橼酸铋钾 - Reason: Consistent findings across all reasoning approaches, strong link with described side effects.\n\nCorrect answer: C. 枸橼酸铋钾", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 35, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 47. 根据《中共中央国务院关于深化医疗保障制度改⾰的意见》，⼒争到2030年全⾯建成多层次医疗保障制度体系，多层次医疗保障制度体系中发挥托底作⽤的是（）。\nOptions: A. 补充医疗保险\nB. 医疗互助\nC. 医疗救助\nD. 基本医疗保险\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question regarding the multi-tiered medical security system and its supporting role based on the \"Opinions on Deepening the Reform of the Medical Security System\" from the Central Committee of the Communist Party of China and the State Council, let's apply the three reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n\n- Key terms identified: Multi-tiered medical security system, supporting role, 2030.\n- Analysis: The multi-tiered system includes various layers of medical insurance and security programs. From a direct deduction standpoint, the term \"supporting role\" usually refers to the foundational or basic level coverage, which is intended to ensure essential healthcare needs. In most health systems, foundational programs like Basic Medical Insurance (D) typically fulfill the supporting role by providing broad access to healthcare services to the population, especially vulnerable groups.\n- Preliminary conclusion: D. Basic Medical Insurance\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A: \"Supplementary Medical Insurance\" is targeted towards providing additional coverage beyond the basics, to enhance existing coverage, not to serve as a foundational base.\n- Eliminate B: \"Medical Mutual Assistance\" often involves community or organizational support systems, which are complementary rather than foundational.\n- Eliminate C: \"Medical Assistance\" specifically targets disadvantaged individuals requiring aid beyond standard coverage and supplements the system for needy groups but does not form the base.\n- Eliminate D: Retain. Basic Medical Insurance acts widely to ensure foundational healthcare access.\n- Remaining options: D\n- Preliminary conclusion: D. Basic Medical Insurance\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparison of similar options: Compare how these systems integrate into the multi-tiered structure.\n- Key differences identification: Basic Medical Insurance integrates broadly, whereas Medical Assistance targets specific vulnerable groups, and Supplementary and Mutual Assistance provide enhancements or additional support.\n- Option that best fits the question: Basic Medical Insurance offers broad foundational coverage, aligning with full system support by 2030.\n- Preliminary conclusion: D. Basic Medical Insurance\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: D - Confidence: High\n- Method 2 conclusion: D - Confidence: High\n- Method 3 conclusion: D - Confidence: High\n- Consistency analysis: All methods consistently point to the Basic Medical Insurance as the option fulfilling the supporting role in the multi-tiered medical security system.\n- Final determination: D. Basic Medical Insurance - Reason: Based on strong consistency across all reasoning methods indicating foundational coverage.\n\nCorrect answer: D", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 36, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 32. 妊娠5个⽉后⽤药，可导致⽇后婴⼉⽛齿黄染、⽛釉质、发育不全的药物是（）。\nOptions: A. 阿莫西林\nB. 呋喃妥因\nC. 甲硝唑\nD. 四环素\nE. 磺胺甲恶唑\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address the question regarding which drug, when used after five months of pregnancy, can cause yellowing of the baby's teeth and enamel hypoplasia, we can apply the three distinct reasoning methods provided:\n\n**Reasoning Method 1: Direct Deduction**\n- Tetracyclines are a class of antibiotics known to affect developing teeth in fetuses and young children, leading to yellow discoloration and enamel hypoplasia. \n- These effects are particularly noted when administered during the second half of pregnancy.\n- Analysis: Key terms like \"tooth discoloration\" and \"enamel hypoplasia\" are directly linked to tetracycline usage.\n- Preliminary conclusion: D. 四环素 (Tetracycline)\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (阿莫西林): Amoxicillin is generally considered safe during pregnancy and does not cause these dental issues.\n- Eliminate B (呋喃妥因): Nitrofurantoin is primarily associated with minimal risks, not dental discolorations.\n- Eliminate C (甲硝唑): Metronidazole doesn’t cause tooth discoloration or enamel defects.\n- Eliminate E (磺胺甲恶唑): Sulfamethoxazole is not linked with tooth discoloration.\n- Remaining options: D. 四环素 (Tetracycline)\n- Preliminary conclusion: D. 四环素 (Tetracycline)\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options eliminated drugs that do not relate to the tooth discoloration and enamel hypoplasia.\n- Tetracycline stands out as it is well-documented to cause tooth discoloration when used during pregnancy.\n- Key differences identification highlights the unique side effect profile of tetracycline concerning dental issues.\n- Option that best fits the question: D. 四环素 (Tetracycline)\n- Preliminary conclusion: D. 四环素 (Tetracycline)\n\n**Consistency Assessment:**\n- Method 1 conclusion: D. 四环素 - Confidence: High\n- Method 2 conclusion: D. 四环素 - Confidence: High\n- Method 3 conclusion: D. 四环素 - Confidence: High\n- Consistency analysis: All methods are consistent in concluding that tetracycline is the drug associated with yellowing of teeth and enamel hypoplasia during pregnancy.\n- Final determination: D. 四环素 (Tetracycline) - Reason: All methods consistently point to tetracycline based on strong evidence of its known effects on fetal tooth development.\n\nCorrect answer: D", "question_type": "最佳选择题", "groundtruth": "D"}
{"id": 37, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 94. 既有黏痰溶解作⽤，还有解救对⼄酰氨基酚中毒作⽤的药物是（）。\nOptions: A. ⼄酰半胱氨酸\nB. 氯化铵\nC. 氨溴索\nD. 右美沙芬\nE. 可待因\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To solve this question, we will analyze it using three distinct reasoning methods and then determine the final answer based on consistency.\n\n**Reasoning Method 1: Direct Deduction**\n\n- Key terms: \"黏痰溶解,\" \"解救对⼄酰氨基酚中毒\"\n- Analysis: The question asks for a drug that both acts as a mucolytic (dissolves phlegm) and serves as an antidote for acetaminophen (paracetamol) poisoning. N-acetylcysteine (乙酰半胱氨酸) is well known in pharmacology for its dual role as an antidote to acetaminophen overdose and its mucolytic properties.\n- Preliminary conclusion: A (乙酰半胱氨酸)\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A: Not eliminated (see direct deduction)\n- Eliminate B: 氯化铵 is a salt that does not act as an antidote for acetaminophen overdose.\n- Eliminate C: 氨溴索 is primarily a mucolytic agent but does not have properties related to acetaminophen overdose treatment.\n- Eliminate D: 右美沙芬 is a cough suppressant with no role in the context of acetaminophen overdose.\n- Eliminate E: 可待因 is an opioid used for pain and cough but not an antidote to acetaminophen poisoning.\n- Remaining options: A\n- Preliminary conclusion: A (乙酰半胱氨酸)\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparison of similar options: All options are either mucolytics or related to cough/cold treatment.\n- Key differences identification: Only N-acetylcysteine (乙酰半胱氨酸) is recognized both as a mucolytic and an antidote for acetaminophen toxicity.\n- Option that best fits the question: A (乙酰半胱氨酸)\n- Preliminary conclusion: A (乙酰半胱氨酸)\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All methods consistently indicate option A as the answer.\n- Final determination: A - Reason: Based on consistency across all reasoning methods, the evidence strongly supports that 乙酰半胱氨酸 has the properties required by the question.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 38, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：甲是药品上市许可持有⼈，依法持有甲钴胺⽚等药品品种； ⼄是药品⽣产企业，⽣产范围：⽚剂、胶囊剂； 丙是药品⽣产企业，⽣产范围：胶囊剂、颗粒剂； 丁是全国性药品批发企业，经营范围：⿇醉药品、中成药、中药饮⽚、化学药、⽣物制品，具备药品现代物流条件； 戊是县级区域性药品批发企业，经营范围：中成药、化学药； ⼰是药品零售连锁企业所属门店，经营类别：处⽅药、甲类⾮处⽅药、⼄类⾮处⽅药，经营范围：第⼆类精神药品、中成药、中药饮⽚、化学药。\n96. 药品监督管理部门检查发现⼰从个⼈处购进药品并销售，情节较轻，应当依法依规做出的处罚是（）。\nOptions: A. 责令改正，没收违法购进的药品和违法所得，并处违法购进药品货值⾦额⼆倍以上⼗倍以下的罚款，货值⾦额不⾜五万元的，按五万元计算\nB. 给予警告，责令限期改正：逾期不改正或者情节严重的，处以⼀千元以上三千元以下的罚款\nC. 没收违法销售的药品和违法所得，并处违法销售药品货值⾦额⼗倍以上⼆⼗倍以下的罚款，货值⾦额不⾜⼀万元的，按⼀万元计算\nD. 责令限期改正，予以警告：逾期不改正的，处⼗万元以上五⼗万元以下的罚款\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the given question regarding the violation committed by a pharmaceutical retailer, let's use three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Analyze the terms: \"purchase and sale of drugs from individuals,\" \"less severe circumstances,\" and \"administrative penalty provision.\"\n- Based on professional knowledge and regulations, purchasing drugs from unauthorized sources, even under less severe circumstances, usually involves confiscation of the drugs and penalty proportional to the value of the transaction.\n- Preliminary conclusion: Option A - this fits the situation where illegal activity is identified but not severe enough for more drastic measures.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Not eliminated - aligns with professional knowledge about penalties for drug violations involving sale.\n- Eliminate B: Typically associated with mild administrative infractions, not fitting for drug violations which involve sales from unauthorized sources.\n- Eliminate C: The context involves purchasing and reselling, not just selling, hence does not fit the situation.\n- Eliminate D: Severe penalties implied for not correcting actions are not aligned with the description of \"less severe circumstances.\"\n- Remaining options: A.\n- Preliminary conclusion: Option A.\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare options A and others regarding severity and penalty:\n  - Option A fits the legal context for “illegal purchase” penalties.\n  - Options B and D imply either too lenient or too severe penalties not fitting well with the \"less severe circumstances\" as described.\n  - The distinction between purchase and sales penalties is critical here.\n- Preliminary conclusion: Option A - provides a more balanced penalty matching the described situation.\n\n**Consistency Assessment:**\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All methods consistently arrive at option A, indicating strong agreement and sound reasoning across different approaches.\n- Final determination: Option A - Reason: Consistent results from all reasoning methods indicating this as the most appropriate and legally sound penalty for the situation.\n\nCorrect answer: A", "question_type": "综合分析选择题", "groundtruth": "A"}
{"id": 39, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 111. 据执业药师注册管理的相关规定，取得执业药师职业资格证书并经注册后⽅可执业，下列属于执业单位的有（）。\nOptions: A. 药品连锁企业总部\nB. 药品检验机构\nC. 药品批发企业\nD. 医疗机构\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the question about which entities are considered \"执业单位\" (practice units) for someone who has obtained the \"执业药师职业资格证书\" (licensed pharmacist professional qualification) and is registered, I will employ the three reasoning methods outlined:\n\n**Reasoning Method 1: Direct Deduction**\n- In China, a \"执业单位\" for a licensed pharmacist usually includes entities that are directly involved with the supply, dispensing, or management of pharmaceuticals. From prior knowledge, these typically include retail pharmacy chains, wholesalers, and healthcare institutions.\n- Key terms: \"执业药师注册管理\", \"执业单位\".\n- Analysis: A licensed pharmacist can practice at retail chain headquarters, pharmaceutical wholesale businesses, and healthcare institutions. Pharmaceutical inspection agencies may not be typical practice units as they are more regulatory rather than direct service locations.\n- Preliminary conclusion: A, C, D\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate B: Pharmaceutical inspection agencies are primarily regulatory and not locations where pharmacists typically practice.\n- Remaining options: A, C, D\n- Preliminary conclusion: A, C, D\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities: A, C, and D are directly involved in the distribution or utilization of pharmaceuticals.\n- Key differences identification: B is distinct in its focus on inspection/regulation rather than serving pharmaceuticals to the public or healthcare operations.\n- Option that best fits the question: A, C, D\n- Preliminary conclusion: A, C, D\n\n**Consistency Assessment:**\n- Method 1 conclusion: A, C, D - Confidence: High\n- Method 2 conclusion: A, C, D - Confidence: High\n- Method 3 conclusion: A, C, D - Confidence: High\n- Consistency analysis: All methods consistently concluded A, C, D\n- Final determination: A, C, D - Reason: Consistent across all reasoning methods with high confidence.\n\nCorrect answer: A, C, D", "question_type": "多项选择题", "groundtruth": "ACD"}
{"id": 40, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 82. 属于时间依赖型抗菌药物，抗菌谱窄，仅对需氧⾰兰阴性菌有效的药物是（）。\nOptions: A. 阿⽶卡星\nB. 氨曲南\nC. 氨苄西林\nD. 头孢他啶\nE. 头孢曲松\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the question on time-dependent antibiotics with a narrow spectrum effective only against aerobic Gram-negative bacteria, let's apply the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Analysis: The keyword here is \"时间依赖型抗菌药物\" (time-dependent antibiotics) that has a narrow spectrum and is effective against aerobic Gram-negative bacteria.\n- Aminoglycosides like 阿米卡星 (Amikacin) are concentration-dependent rather than time-dependent.\n- 氨曲南 (Aztreonam) is known for being a monobactam with activity solely against aerobic Gram-negative bacteria, which fits the narrow spectrum effective against Gram-negative aerobes.\n- 氨苄西林 (Ampicillin) targets both Gram-positive and some Gram-negative bacteria but is not exclusively narrow for Gram-negative aerobes.\n- 头孢他啶 (Ceftazidime) and 头孢曲松 (Ceftriaxone) are cephalosporins with broader activity, although some cephalosporins are time-dependent.\n- Preliminary conclusion: B\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 阿米卡星 is a concentration-dependent antibiotic, not time-dependent.\n- Eliminate B: Retain 氨曲南 as it fits the criteria.\n- Eliminate C: 氨苄西林 is not narrow-spectrum for only Gram-negative aerobes.\n- Eliminate D: 头孢他啶 has a broad spectrum including Gram-positive organisms.\n- Eliminate E: 头孢曲松 also has a broader spectrum, including effectiveness against Gram-positive bacteria.\n- Remaining options: B\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Focus on antibiotics like 氨曲南 that are specifically narrow-spectrum for Gram-negative.\n- Key differences identification: Other options include broader-spectrum antibiotics or those that are concentration-dependent rather than time-dependent.\n- Option that best fits the question: 氨曲南 has the characteristics necessary for a narrow-spectrum, Gram-negative focused, time-dependent drug.\n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently point to option B (氨曲南) as the answer.\n- Final determination: B - Reason: Consistent conclusions across all reasoning methods and fits the criteria of a time-dependent, narrow-spectrum antibiotic effective against aerobic Gram-negative bacteria.\n\nCorrect answer: B", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 41, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 28. 根据《关于做好当前药品价格管理⼯作的意见》，关于药品价格政策的说法，错误的是（）。\nOptions: A. 以现⾏药品价格政策为基础，坚持市场在资源配置中的决定性作⽤\nB. 同种药品在剂型、规格和包装等⽅⾯存在差异的，按照治疗费⽤相当的原则，综合考虑临床效果、成本价值、技术⽔平等因素，保持合理的差价⽐价关系\nC. ⿇醉药品和第⼀类精神药品实⾏政府定价，其他药品实⾏政府指导价\nD. ⿇醉药品和第⼀类精神药品价格依法实⾏最⾼出⼚（⼜岸）价格和最⾼零售价格管理\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question using three distinct reasoning methods, we will follow the steps outlined.\n\n**Reasoning Method 1: Direct Deduction**\n- The key terms to focus on are \"current drug pricing policy,\" \"market decisive role,\" \"differences in dosage form, specification, packaging,\" \"narcotic drugs,\" \"Class 1 psychotropic substances,\" \"government pricing,\" and \"guidance price.\"\n- Professional knowledge: Generally, in Chinese drug pricing policy, narcotic and Class 1 psychotropic drugs have stringent pricing controls, often under government pricing, while other drugs may be under government guidance pricing allowing market adjustments.\n- Analysis: Option A supports market decisions within the pricing policy framework, which aligns with common policy. Option B mentions maintaining reasonable price difference which is typical policy. Option C is questionable as it states all other drugs follow government guidance prices, which should be more inclusive of market dynamics. Option D is about strict control over narcotic and Class 1 drugs, fitting common practice.\n- Preliminary conclusion: C might be incorrect if all other drugs are simply under guidance pricing as opposed to more market freedom.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Market's decisive role is fundamental in pricing policies; it's typically supported, not eliminated.\n- Eliminate B: Reasonable price difference based on comparative parameters is standard practice; not eliminable.\n- Eliminate C: Suggesting all other drugs are strictly under government guidance prices might oversimplify current strategies which trend towards market involvement.\n- Eliminate D: Correctly stating narcotic and Class 1 drug regulation practices; not eliminable.\n- Remaining options: C\n- Preliminary conclusion: C\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A, B, and D all describe practices commonly found or aligned with current Chinese drug pricing methodologies.\n- Key differences identification: The core issue with C appears to misrepresent the comprehensive nature of pricing approaches for non-narcotic drugs.\n- Option that best fits the question: The discrepancy in C's representation of the breadth of government-guided vs. market-regulated pricing.\n- Preliminary conclusion: C\n\n**Consistency Assessment**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All methods consistently identify option C as potentially incorrect.\n- Final determination: C - Reason: All reasoning methods consistently indicate C as misaligned with the broader understanding of current drug pricing policies, especially concerning market involvement.\n\nCorrect answer: C", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 42, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 12. 患者，⼥，27岁，孕34周。诊断为轻度便秘，宜选⽤的药物是（）。\nOptions: A. 蓖⿇油\nB. 乳果糖\nC. 硫酸镁\nD. 普芦卡必利\nE. 利那洛肽\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "Here's the analysis and answer determination using the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Analysis: The patient is a 27-year-old pregnant woman at 34 weeks gestation diagnosed with mild constipation. Key considerations include the safety of the medication during pregnancy and its suitability for treating mild constipation.\n- Lactulose (乳果糖) is a commonly used osmotic laxative that is generally considered safe for use during pregnancy and is effective for treating constipation.\n- Preliminary conclusion: B (乳果糖)\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (蓖麻油): Castor oil can induce uterine contractions and is not recommended during pregnancy.\n- Eliminate C (硫酸镁): Magnesium sulfate is used in certain obstetric settings (e.g., pre-eclampsia), but not typically for simple constipation during pregnancy.\n- Eliminate D (普芦卡必利): Prucalopride is not commonly recommended during pregnancy due to insufficient safety data.\n- Eliminate E (利那洛肽): Linaclotide is generally not recommended during pregnancy due to lack of adequate safety studies.\n- Remaining options: B (乳果糖)\n- Preliminary conclusion: B (乳果糖)\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Consideration of safety and efficacy for treating constipation during pregnancy. \n- Lactulose (B) is emphasized for safety during pregnancy in contrast to other options that either lack sufficient safety data or have potential adverse effects.\n- Key differences identification: Options differ mainly in their safety profile and recommendations for use during pregnancy.\n- Option that best fits the question: B (乳果糖)\n- Preliminary conclusion: B (乳果糖)\n\n**Consistency Assessment:**\n- Method 1 conclusion: B (乳果糖) - Confidence: High\n- Method 2 conclusion: B (乳果糖) - Confidence: High\n- Method 3 conclusion: B (乳果糖) - Confidence: High\n- Consistency analysis: All three methods consistently conclude that lactulose is the best choice based on safety and efficacy for this pregnant patient.\n- Final determination: B (乳果糖) - Reason: Consistent support across all reasoning methods and strong evidence for safety during pregnancy.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 43, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 84. 中毒解救需灌肠时，宜选⽤的灌肠液是（）。\nOptions: A. 硫酸镁溶液\nB. 淀粉溶液\nC. 植物油\nD. ⾼锰酸钾溶液（1:5000～1:10000）\nE. 1%肥皂⽔\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for question 84, we will analyze it using the three reasoning methods outlined.\n\n**Reasoning Method 1: Direct Deduction**\n\n- Key Terms: \"中毒解救\" (poisoning rescue), \"灌肠液\" (enema solution)\n- Analysis: For poisoning rescue that requires an enema, the goal is to quickly remove the toxin. The enema solution chosen should not have substances that might react adversely or not fulfill the purpose of toxin elimination. Magnesium sulfate can be used for bowel evacuation, making it a potential option.\n- Preliminary conclusion: A. 硫酸镁溶液 (Magnesium sulfate solution)\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A: No elimination; remains viable as it aids in bowel evacuation.\n- Eliminate B: 淀粉溶液 (Starch solution) – typically used as a soothing agent, not for toxin evacuation.\n- Eliminate C: 植物油 (Vegetable oil) – may delay toxin absorption but not effective for quick evacuation.\n- Eliminate D: ⾼锰酸钾溶液 (Potassium permanganate solution) – used for disinfecting, not recommended for general poisoning enema.\n- Eliminate E: 1%肥皂⽔ (1% Soap solution) – used for general cleansing but less effective than magnesium sulfate for toxin removal.\n- Remaining options: A\n- Preliminary conclusion: A. 硫酸镁溶液\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparison of options: Evaluate each based on efficacy in poisoning situations.\n- Differences: Magnesium sulfate is known for its laxative effect and quick evacuation capabilities, whereas soap solution is more general purpose and others have specific uses not aligned with poisoning rescue.\n- Option that best fits the question: A. 硫酸镁溶液\n- Preliminary conclusion: A. 硫酸镁溶液\n\n**Consistency Assessment**\n\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n\nConsistency analysis: All three methods consistently indicate that option A is the most suitable choice based on its efficacy in evacuating the bowels quickly, making it an appropriate enema solution for poisoning rescue.\n\n- Final determination: A. 硫酸镁溶液 - Reason: Consistency across all methods and strongest evidence supporting its use in poisoning situations.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "E"}
{"id": 44, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 13. 两药同时使⽤时，⼀个药物可通过诱导体内⽣化反应⽽使另⼀个药物的药效降低。下列药物同时使⽤时，会发⽣这种相互作⽤的是（）。\nOptions: A. β受体阻断药阿替洛尔与利尿药氢氯噻嗪\nB. 抗痛风药丙磺舒与青霉素\nC. 解热镇痛药阿司匹林与对⼄酰氨基酚\nD. 抗菌药磺胺甲与甲氧苄啶\nE. 抗癫痫药苯巴⽐妥与避孕药\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the best answer to the question regarding drug interactions, we will independently analyze it using three reasoning methods and then make a final determination based on the consistency of the analyses.\n\n### Reasoning Method 1: Direct Deduction\n\n- **Analysis:** When a drug induces the metabolism of another drug, it results in reduced drug efficacy. This typically involves enzyme induction, where the drug increases the activity of enzymes that degrade the second drug. Key points to consider are drugs known for inducing liver enzymes, such as those involved in cytochrome P450 metabolism.\n\n- **Preliminary conclusion:**\n  - A. Atenolol and hydrochlorothiazide: No known enzyme induction interaction.\n  - B. Probenecid and penicillin: Probenecid inhibits renal excretion of penicillin, enhancing its effect, not reducing it.\n  - C. Aspirin and acetaminophen: These may have additive effects, not enzyme induction issues.\n  - D. Sulfamethoxazole and trimethoprim: These work synergistically, not through induction/reduction of effect.\n  - E. Phenobarbital and contraceptives: Phenobarbital is known to induce hepatic enzymes that can reduce the efficacy of contraceptives.\n  \n  **Preliminary conclusion:** E\n\n### Reasoning Method 2: Systematic Elimination\n\n- **Eliminate A:** Atenolol and hydrochlorothiazide do not interact through enzyme induction to reduce effects.\n- **Eliminate B:** Probenecid enhances penicillin rather than reducing its effect.\n- **Eliminate C:** Aspirin and acetaminophen do not interact through enzyme induction but can have combined analgesic effects.\n- **Eliminate D:** Sulfamethoxazole and trimethoprim potentiate each other's antibacterial effects and are not involved in enzyme induction interactions.\n- Eliminate E: None; Phenobarbital induces enzymes leading to reduced contraceptive effectiveness.\n\n- **Remaining options:** E\n- **Preliminary conclusion:** E\n\n### Reasoning Method 3: Comparative Analysis\n\n- **Comparison of similar options:** Many options involve different mechanisms of action (e.g., enhancement or synergy) rather than reduction of activity through induction.\n- **Key differences identification:** The unique characteristic of phenobarbital as an enzyme inducer affecting contraceptives stands out in comparison.\n- **Option that best fits the question:** E.\n- **Preliminary conclusion:** E\n\n### Consistency Assessment\n\n- **Method 1 conclusion:** E - Confidence: High\n- **Method 2 conclusion:** E - Confidence: High\n- **Method 3 conclusion:** E - Confidence: High\n- **Consistency analysis:** All three methods consistently identify option E as the correct choice.\n- **Final determination:** **Correct answer: E** - Reason: All reasoning methods consistently point to E based on the mechanism of enzyme induction affecting drug efficacy.", "question_type": "最佳选择题", "groundtruth": "E"}
{"id": 45, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 45. 因肾上腺⽪质激素的分泌具有晨⾼昼低的特点，故使⽤维持剂量的肾上腺⽪质激素类药物时，推荐的服药时间是（）。\nOptions: A. 中午\nB. 清晨\nC. 上午\nD. 下午\nE. 临睡前\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the most suitable time for administering maintenance doses of adrenal corticosteroids based on their secretion pattern of being high in the morning and low during the day, let's apply the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms: \"肾上腺⽪质激素\", \"分泌具有晨⾼昼低\"\n- Corticosteroids mimic the body’s natural corticosteroid secretion, which is highest in the early morning. Administering these drugs in the morning aligns with the body's natural rhythm to minimize side effects and optimize efficacy.\n- Analysis: Based on understanding that peak natural secretion is in the morning, morning administration is logical to align with natural processes.\n- Preliminary conclusion: B. 清晨\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (中午): Corticosteroid levels naturally decline by noon; not optimal.\n- Eliminate C (上午): Although morning is indicated, \"上午\" could be too vague and not closely aligned with earliest natural peak.\n- Eliminate D (下午): Afternoon is when natural levels further decrease, not recommended.\n- Eliminate E (临睡前): Nighttime does not align with natural high secretions, leading to potential side effects.\n- Remaining options: B. 清晨\n- Preliminary conclusion: B. 清晨\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: 清晨 vs. 上午 - \"清晨\" more specifically matches the natural high secretion time.\n- Key differences identification: \"清晨\" specifically matches the peak secretion time, whereas \"上午\" may be less precise.\n- Option that best fits the question: B. 清晨\n- Preliminary conclusion: B. 清晨\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently conclude B. 清晨 as the optimal time.\n- Final determination: B. 清晨 - Reason: Based on consistency across all reasoning methods.\n\nCorrect answer: B", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 46, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 42. 根据《药品经营质量管理规范》，测量范围在－25℃～0℃之间的温湿度监测系统，测量设备的温度最⼤允许误差为（）。\nOptions: A. ±2.0℃\nB. ±0.5℃\nC. ±0.1℃\nD. ±1.0℃\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n\n- Directly derive conclusions based on question information and professional knowledge.\n- Focus on key terms: \"《药品经营质量管理规范》\", \"温湿度监测系统\", \"测量范围在－25℃～0℃\", \"温度最⼤允许误差\".\n- Analysis: According to the guidelines for pharmaceutical operations, temperature monitoring systems within this range typically have specific accuracy requirements to ensure the integrity and quality of pharmaceutical storage.\n- Preliminary conclusion: D. ±1.0℃\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate A: ±2.0℃ is generally too large a margin for pharmaceutical temperature control.\n- Eliminate B: ±0.5℃ is reasonable but may be overly stringent for wider ranges.\n- Eliminate C: ±0.1℃ is overly precise for typical monitoring equipment at this range.\n- Eliminate E: no fifth option.\n- Remaining options: D. ±1.0℃\n- Preliminary conclusion: D. ±1.0℃\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare similarities and differences among all options.\n- Comparison of similar options: ±0.5℃ and ±1.0℃ both considered reasonable for precise control; ±1.0℃ more commonly used for range in question.\n- Key differences identification: ±0.1℃ is typically used for critical clinical or laboratory settings, not general pharmaceutical storage.\n- Option that best fits the question: D. ±1.0℃\n- Preliminary conclusion: D. ±1.0℃\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: D. ±1.0℃ - Confidence: High\n- Method 2 conclusion: D. ±1.0℃ - Confidence: High\n- Method 3 conclusion: D. ±1.0℃ - Confidence: High\n- Consistency analysis: All methods consistently identify D. ±1.0℃ as the most suitable option.\n- Final determination: D. ±1.0℃ - Reason: Consistency in reasoning across all methods.\n\nCorrect answer: D. ±1.0℃", "question_type": "配伍选择题", "groundtruth": "D"}
{"id": 47, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 120. 审⽅时要关注中西药联⽤的情况，下列药品中含有西药成分的有（）。\nOptions: A. ⿐炎康⽚\nB. 珍菊降压⽚\nC. 防风通圣丸\nD. 蛇胆川贝液\nE. 消渴丸\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address the question about identifying options that contain Western medicine components, let's apply the three reasoning methods outlined:\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on key terms and utilize professional knowledge about hybrid formulations involving Western medicine.\n- 鼻炎康片: Known to contain pseudoephedrine, a common Western active ingredient for congestion relief.\n- 珍菊降压片: Typically contains captopril, an antihypertensive Western medication.\n- 防风通圣丸: A traditional Chinese medicine formulation, usually without Western ingredients.\n- 蛇胆川贝液: Predominantly a traditional Chinese medicine, typically without Western components.\n- 消渴丸: Used for managing diabetes in traditional Chinese medicine, generally no Western drug components.\n- Analysis indicates 鼻炎康片 and 珍菊降压片 as containing Western components.\n- Preliminary conclusion: A, B\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate options based on the standard formulation knowledge.\n- Eliminate C: Traditional Chinese medicine with no typical Western drugs included.\n- Eliminate D: Known as entirely traditional, without Western components.\n- Eliminate E: Traditional Chinese formulation for diabetes management, no Western drugs involved.\n- Remaining options based on elimination: A, B\n- Preliminary conclusion: A, B\n\n**Reasoning Method 3: Comparative Analysis**\n- Examine similarities and differences across options based on typical ingredient profiles.\n- 鼻炎康片 vs 珍菊降压片: Both involve common Western active ingredients (pseudoephedrine in A and captopril in B).\n- 防风通圣丸, 蛇胆川贝液, 消渴丸: All rely on traditional Chinese formulations without Western clinical ingredients.\n- Key differences in inclusion of Western medicine components clearly evident between A, B and C, D, E.\n- Option that best fits question criteria: A, B\n- Preliminary conclusion: A, B\n\n**Consistency Assessment:**\n- Method 1 conclusion: A, B - Confidence: High\n- Method 2 conclusion: A, B - Confidence: High\n- Method 3 conclusion: A, B - Confidence: High\n- Consistency analysis: All three methods consistently identify A and B as containing Western medicine components.\n- Final determination: A, B - Reason: Consistent evidence across multiple reasoning methods confirm these options.\n\nCorrect answer: A, B", "question_type": "多项选择题", "groundtruth": "ABE"}
{"id": 48, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 85. 根据《国家药品监督管理局职能配置、内设机构和⼈员编制规定》及其有关规定，负责执业药师管理信息系统的建设、管理和维护的是（）。\nOptions: A. 国家药品监督管理局⾼级研修学院\nB. 国家药品监督管理局执业药师资格认证中⼼\nC. 国家药典委员会\nD. 国家药品监督管理局信息中⼼\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the question about which organization is responsible for the construction, management, and maintenance of the licensed pharmacist management information system according to the relevant regulations of the National Medical Products Administration (NMPA), we will apply the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms: \"执业药师管理信息系统的建设、管理和维护\" (construction, management, and maintenance of the licensed pharmacist management information system) and \"《国家药品监督管理局职能配置、内设机构和⼈员编制规定》\" (regulations of the NMPA).\n- Analysis: The role of managing information systems typically falls under an organization with a focus on data and IT infrastructure, which is most related to the function of an information center or IT department.\n- Preliminary conclusion: D. 国家药品监督管理局信息中⼼ (NMPA Information Center)\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: 国家药品监督管理局⾼级研修学院 focuses on training and advanced studies, not information system management.\n- Eliminate B: 国家药品监督管理局执业药师资格认证中⼼ is involved in certification, not the technical management of information systems.\n- Eliminate C: 国家药典委员会 deals with pharmacopoeia and standards, not IT infrastructure.\n- Remaining option: D. 国家药品监督管理局信息中⼼\n- Preliminary conclusion: D. 国家药品监督管理局信息中⼼\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Assess the general functions related to system management among the options.\n- Key differences identification: Information Center is explicitly aimed at managing information systems.\n- Option that best fits the question: D. 国家药品监督管理局信息中⼼\n- Preliminary conclusion: D. 国家药品监督管理局信息中⼼\n\n**Consistency Assessment:**\n- Method 1 conclusion: D. Confidence: High\n- Method 2 conclusion: D. Confidence: High\n- Method 3 conclusion: D. Confidence: High\n- Consistency analysis: All methods consistently support option D.\n- Final determination: D. 国家药品监督管理局信息中⼼ - Reason: Consistent conclusions across all methods\n\nCorrect answer: D", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 49, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：为规范药品零售环节经营⾏为，某地药品监督管理部门对辖区内药品零售企业开展监督检查。检查发现： （1）甲药品零售企业涉嫌从⾮法渠道购进药品，部分批号的阿卡波糖⽚不能提供购进发票，且经追测码查询，供货单位系某医疗机构：涉嫌违规经营⽶⾮司酮⽚。 （2）⼄药品零售企业屡次绕开计算机系统销售过期的盐酸⼆甲双胍缓释⽚、⼆甲双胍格列本脲胶囊等药品：计算机系统中有多条超数量销售含⿇黄碱类复⽅制剂的销售记录，其中最多⼀次销售了50盒，企业留存了本次销售的处⽅。\n109. 针对⼄违规销售含⿇黄碱类复⽅制剂的⾏为，下列检查结论错误的是（）。\nOptions: A. ⼄的计算机系统未有效拦截含特殊药品复⽅制剂超数量销售\nB. ⼄配备的执业药师未严格履⾏处⽅审核职责\nC. ⼄涉嫌将含⿇黄碱类复⽅制剂流⼊⾮法渠道\nD. ⼄未对违规超量售出含⿇黄碱类复⽅制剂发起药品追回\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question, let's apply the three reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n\n- The question involves checking the incorrect conclusion regarding the sales practices of乙药品零售企业, focusing on the handling of medications containing ephedrine.\n- Key aspects from the scenario include sales of expired drugs, bypassing systems, and excessive sales of ephedrine compound preparations.\n- Preliminary deduction:\n  - A implies the system did not block the excessive sale, which aligns with observed system bypass.\n  - B denotes a failure in prescription review by the pharmacist, which could easily align with such sales.\n  - C suggests the medications entered illegal channels, which doesn't inherently follow from the information.\n  - D states the company didn’t initiate a recall for the excess sold drugs, which is a valid conclusion if excess sales occurred.\n- Preliminary conclusion: C (系统未有效拦截 could be true; however, C implies something not directly evident).\n\n**Reasoning Method 2: Systematic Elimination**  \n\n- Eliminate A: Accurate as it denotes the flawed system intercept based on the described sales.\n- Eliminate B: Valid as it shows a lapse in pharmacy oversight relevant to the issue.\n- Eliminate C: This implies illegal distribution, which is not directly evidenced by the scenario, making it a potential error.\n- Eliminate D: Correct action is to initiate recall post-excess sale as obvious from operational aftermath.\n- Remaining option: C\n- Preliminary conclusion: C\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare A and D: Both relate to systemic and procedural failures evident in the described violations.\n- Compare B and C: B is process-related; C assumes distribution beyond provided information.\n- Identify differences: C involves an assumption without information basis, which is not directly related to described actions.\n- Option fitting narrative: C does not as it extends beyond provided infractions.\n- Preliminary conclusion: C\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All conclusions point to C due to assumptions exceeding scenario evidence.\n  \n**Final determination: C**\n\nCorrect answer: C", "question_type": "综合分析选择题", "groundtruth": "D"}
{"id": 50, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：为规范药品零售环节经营⾏为，某地药品监督管理部门对辖区内药品零售企业开展监督检查。检查发现： （1）甲药品零售企业涉嫌从⾮法渠道购进药品，部分批号的阿卡波糖⽚不能提供购进发票，且经追测码查询，供货单位系某医疗机构：涉嫌违规经营⽶⾮司酮⽚。 （2）⼄药品零售企业屡次绕开计算机系统销售过期的盐酸⼆甲双胍缓释⽚、⼆甲双胍格列本脲胶囊等药品：计算机系统中有多条超数量销售含⿇黄碱类复⽅制剂的销售记录，其中最多⼀次销售了50盒，企业留存了本次销售的处⽅。\n107. 甲违规经营的⽶⾮司酮⽚，其药品种类是（）。\nOptions: A. ⽤于紧急避孕的⾮处⽅药\nB. 具有终⽌妊娠作⽤的药品\nC. 第⼆类精神药品\nD. 含兴奋剂药品\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer, let's analyze the question using the three provided reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on the term \"米非司酮片,\" a known medication used for termination of pregnancy and as an abortifacient.\n- Analysis: 米非司酮片 (Mifepristone tablets) are primarily used as abortifacients, blocking progesterone, necessary for maintaining pregnancy.\n- Preliminary conclusion: The statement indicates 米非司酮片 is used in terminating pregnancy, which corresponds to Option B.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 米非司酮片 is not typically used for emergency contraception and is not classified as an OTC medication.\n- Eliminate C: 米非司酮片 is not classified as a second-class psychoactive drug.\n- Eliminate D: 米非司酮片 does not contain stimulant drugs.\n- Remaining options: B\n- Preliminary conclusion: Option B.\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Options A and B both relate to pregnancy, but 米非司酮片 is not used for emergency contraception, but rather for termination.\n- Key differences identification: Option A involves emergency contraception; Option B involves termination of pregnancy.\n- Option that best fits the question: Option B.\n- Preliminary conclusion: Option B.\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods agree on Option B. The analysis is consistent across methods.\n- Final determination: B - Reason: Based on consistent conclusions across all reasoning methods.\n\nCorrect answer: B", "question_type": "综合分析选择题", "groundtruth": "B"}
{"id": 51, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 59. 根据《中药品种保护条例》，对特定疾病有特殊疗效的中药属于（）。\nOptions: A. 四级保护品种\nB. 三级保护品种\nC. ⼀级保护品种\nD. ⼆级保护品种\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question about which category of protected Chinese medicine includes those with special efficacy for certain diseases, let's apply the three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Analysis: This question seeks to identify the protection level given to a Chinese medicine with special therapeutic efficacy according to the 《中药品种保护条例》. According to this regulation, such medicines are classified based on the significance and extent of their efficacy.\n- Key Term Focus: Special therapeutic efficacy for certain diseases.\n- Preliminary Conclusion: The level of protection most likely associated with specialized therapeutic efficacy is typically the highest level of protection due to its uniqueness and significance. Thus, it should be 一级保护品种 (Option C).\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 四级保护品种 usually covers less critical or broader applications, not special efficacies.\n- Eliminate B: 三级保护品种 also covers significant but less critical aspects compared to 一级 protection.\n- Eliminate D: 二级保护品种 may cover important specifications, but lacks the exceptional significance required for special efficacy categorization.\n- Remaining Options: C (一级保护品种)\n- Preliminary Conclusion: C (一级保护品种)\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Options B and D involve levels of protection offering less emphasis on extraordinary efficacy.\n- Key differences identification: 一级保护品种 is typically reserved for drugs with unique, significant therapeutic benefits.\n- Option that best fits the question: C (一级保护品种)\n- Preliminary Conclusion: C (一级保护品种)\n\n**Consistency Assessment:**\n- Method 1 Conclusion: C (一级保护品种) - Confidence: High\n- Method 2 Conclusion: C (一级保护品种) - Confidence: High\n- Method 3 Conclusion: C (一级保护品种) - Confidence: High\n- Consistency Analysis: All methods consistently point to the same option without discrepancies. This suggests high confidence in the consistency of option C as the right answer.\n- Final Determination: C (一级保护品种) - Reason: Based on consistent conclusions across all reasoning methods pointing to its relevance for special therapeutic efficacy.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 52, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 66. 使⾎药浓度-时间曲线上出现双峰现象的原因通常是（）。\nOptions: A. 酶诱导作⽤\nB. 肾⼩球滤过\nC. 酶抑制作⽤\nD. ⾸关效应\nE. 肠-肝循环\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**  \n\n- Directly derive conclusions based on question information and professional knowledge  \n- Key term in the question stem: \"血药浓度-时间曲线双峰现象\" (double peak phenomenon in plasma concentration-time curve)\n\n- Analysis: The double peak phenomenon in a plasma concentration-time curve can occur due to various pharmacokinetic processes. However, one well-known cause is enterohepatic recycling, where drug metabolites are excreted into the bile, reabsorbed in the intestine, and return to the bloodstream, leading to a second peak in plasma concentration.\n\n- Preliminary conclusion: \n  - Option E (肠-肝循环, enterohepatic circulation)\n\n**Reasoning Method 2: Systematic Elimination**  \n\n- Eliminate A: 酶诱导作用 (Enzyme induction) generally affects the rate of metabolism, not directly causing double peaks.\n- Eliminate B: 肾小球滤过 (Glomerular filtration) is a renal elimination process and doesn’t typically cause double peaks.\n- Eliminate C: 酶抑制作用 (Enzyme inhibition) affects metabolism but does not inherently cause double peaks.\n- Eliminate D: 首关效应 (First-pass effect) influences drug metabolism primarily on the first pass through the liver, not typically causing a double peak.\n- Eliminate E: 肠-肝循环 (Enterohepatic circulation) is known to cause a second peak due to the recycling process.\n\n- Remaining options: E  \n- Preliminary conclusion: \n  - Option E (肠-肝循环, enterohepatic circulation)\n\n**Reasoning Method 3: Comparative Analysis**  \n\n- Comparison of similar options:  \n  - Options A, C, D involve metabolic and first-pass processes, which primarily affect initial drug absorption and metabolism rates rather than causing double peaks.\n  - Option B involves renal processes, not directly related to absorption and redistribution leading to double peaks.\n\n- Key differences identification:  \n  - Option E involves recirculation processes (enterohepatic circulation) that can cause an observed second peak in the plasma concentration-time curve after initial absorption.\n\n- Option that best fits the question: E  \n- Preliminary conclusion: \n  - Option E (肠-肝循环, enterohepatic circulation)\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All methods consistently identify Option E as the cause of the double peak phenomenon.\n- Final determination: \n  - Correct answer: E - Reason: Consistency across all reasoning methods and strong alignment with pharmacokinetic principles.\n\nCorrect answer: E", "question_type": "配伍选择题", "groundtruth": "E"}
{"id": 53, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 57. 根据《药品经营质量管理规范》及其有关附录⽂件，属于保温箱特有的验证项⽬是（）。\nOptions: A. 测点终端安装数量及位置确认\nB. 测点终端参数与数据联动传输确认\nC. 运输最长时限验证\nD. 极端温度保温性能验证\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To solve the question using the three reasoning methods, we need to analyze which option is specifically related to the unique validation requirements of insulated boxes according to the pharmaceutical Good Distribution Practice (GDP) guidelines.\n\n**Reasoning Method 1: Direct Deduction**\n- **Key Terms & Analysis**: The question focuses on validation items specific to insulated boxes. \n- The key term here is \"保温箱特有的验证项⽬\" which translates to \"unique validation items for insulated boxes.\"\n- Direct Analysis: Insulated boxes are typically evaluated based on their ability to maintain temperature under various conditions.\n- Preliminary Conclusion: Option D (极端温度保温性能验证, Extreme temperature insulation performance verification) is directly related to insulated boxes and their validation.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: \"测点终端安装数量及位置确认\" relates to the setup of measurement points, which is common in various validation settings, not unique to insulated boxes.\n- Eliminate B: \"测点终端参数与数据联动传输确认\" involves parameter setup and data transmission, more relevant to general data monitoring systems, not specific to insulated boxes.\n- Eliminate C: \"运输最长时限验证\" refers to verifying the maximum transportation time, relevant to logistics but not specifically unique to insulated boxes.\n- Remaining Options: D\n- Preliminary conclusion: Option D\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similar options: A, B, and C relate to general operational or monitoring setups, whereas D focuses on thermal performance.\n- Key difference: D specifically addresses the insulation aspect under extreme temperatures, which is a critical attribute for insulated boxes.\n- Preliminary Conclusion: Option D\n\n**Consistency Assessment:**\n- Method 1 conclusion: D - Confidence: High\n- Method 2 conclusion: D - Confidence: High\n- Method 3 conclusion: D - Confidence: High\n- Consistency analysis: All methods consistently point to option D as the specific validation item for insulated boxes.\n- Final determination: D - Reason: Based on consistent analysis across all methods highlighting its unique relevance to insulated box validation.\n\nCorrect answer: D", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 54, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 95. 在药品处⽅中，常作为⽔不溶性包⾐材料的是（）。\nOptions: A. 羧甲基纤维素钠（CMC-Na）\nB. 羟丙基甲基纤维素（HPMC）\nC. ⼄基纤维素（EC）\nD. 甲基纤维素（MC）\nE. 羟丙基纤维素（HPC）\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct option for the question, we will analyze it using three distinct reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n- The question asks for a commonly used water-insoluble coating material in pharmaceutical formulations.\n- Carboxymethyl cellulose sodium (CMC-Na) and hydroxymethyl cellulose derivatives are generally water-soluble and used for different purposes, such as thickeners or emulsifiers, not as water-insoluble coatings.\n- Ethyl cellulose (EC) is known for its water-insolubility and is commonly used as a coating material.\n- Hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC) are generally water-soluble or swellable polymers.\n- Methyl cellulose (MC) is also water-soluble.\n\n**Preliminary conclusion:** C (Ethyl Cellulose)\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (CMC-Na): Known to be water-soluble.\n- Eliminate B (HPMC): Generally used in water-soluble applications.\n- Eliminate D (MC): Water-soluble in nature.\n- Eliminate E (HPC): Similar water-soluble properties.\n- Option C (EC) remains as it is known for being water-insoluble.\n\n**Remaining options:** C  \n**Preliminary conclusion:** C (Ethyl Cellulose)\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare the water solubility: EC is distinct from others due to its water-insolubility.\n- HPMC, CMC-Na, MC, and HPC are generally water-soluble or form gels upon hydration.\n- EC stands out as the non-water-soluble alternative.\n\n**Preliminary conclusion:** C (Ethyl Cellulose)\n\n**Consistency Assessment:**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- All three methods consistently point to option C.\n\n**Final determination:** C  \n**Reason:** All analysis methods consistently identify Ethyl Cellulose (EC) as the water-insoluble coating material. \n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 55, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 7. 关于环磷酰胺（化学结构如下）结构特点和应⽤的说法，错误的是（）。\nOptions: A. 环磷酰胺属于前药\nB. 磷酰基的引⼊使毒性升⾼\nC. 正常细胞内可转化为⽆毒代谢产物\nD. 属于氮芥类药物\nE. 临床⽤于抗肿瘤\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the incorrect statement about cyclophosphamide, let's evaluate each option using the specified reasoning methods. \n\n**Reasoning Method 1: Direct Deduction**\n- Cyclophosphamide is a well-known prodrug that requires metabolic activation in the liver, aligning with option A as true.\n- The introduction of the phosphamide group actually aims to reduce the nonspecific toxicity seen in nitrogen mustards, contradicting option B.\n- Cyclophosphamide is metabolized in the liver to form inactive, non-toxic metabolites, supporting option C as true.\n- It is classified under nitrogen mustard alkylating agents, making option D accurate.\n- It is widely used as an antineoplastic agent, affirming option E as true.\n- Analysis: With a focus on toxicity and chemical structure, option B stands out as potentially incorrect.\n- Preliminary conclusion: B\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Cyclophosphamide is a prodrug, requiring metabolic activation.\n- Eliminate C: Known to convert into inactive, non-toxic metabolites in normal cells.\n- Eliminate D: It is a nitrogen mustard derivative.\n- Eliminate E: Commonly used in clinical oncology, particularly for cancer treatment.\n- Remaining options: B\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Options A, C, D, and E all align with established chemical and pharmacological knowledge of cyclophosphamide.\n- Key differences identification: Option B’s assertion about phosphamide increasing toxicity contrasts with its design purpose to mitigate toxicity.\n- Option that best fits the question: B is inconsistent with general knowledge about cyclophosphamide’s design.\n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All three methods consistently identify B as the incorrect statement.\n- Final determination: B - Reason: Based on consistent results across all reasoning methods and professional understanding.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 56, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 25. 下列符合化妆品管理要求的是（）。\nOptions: A. 特殊化妆品需经省级以上药品监督管理部门注册后⽅可⽣产、进⼜和经营\nB. 国产普通化妆品在上市销售后，向所在地省级药品监督管理部门备案\nC. 国家按照风险程度对化妆品、化妆品原料实⾏分类管理\nD. 已经注册的特殊化妆品在⽣产⼯艺、功效宣称等⽅⾯发⽣任何变化，注册⼈均应当向原注册部门申请变更注册\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the question \"25. 下列符合化妆品管理要求的是（）。\", let's analyze using three distinct reasoning methods and then assess for consistency.\n\n**Reasoning Method 1: Direct Deduction**\n\n1. Focus on the key terms such as \"特殊化妆品,\" \"普通化妆品,\" \"备案,\" and the specific regulation requirements in China.\n2. Use professional knowledge about Chinese cosmetic regulations:\n   - Special cosmetics require registration with the National Medical Products Administration (NMPA), not just provincial.\n   - For ordinary cosmetics, filing is required upon marketing, but details must be consistent with regulations.\n   - China classifies cosmetics by risk for management.\n   - Changes to special cosmetics must be re-registered if affecting critical aspects.\n\nAnalysis:\n\n- A is incorrect as special cosmetics require national, not provincial, registration.\n- B aligns with the regulation requiring post-market filing for ordinary cosmetics.\n- C is generally correct as Chinese regulations categorize by risk.\n- D is correct that changes in registered special cosmetics require re-registration.\n\nPreliminary conclusion: B, C, D\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A: Special cosmetics require registration at the national level, not provincial.\n- Eliminate: Not applicable.\n- Eliminate: Not applicable.\n- Eliminate: Not applicable.\n- Eliminate F: Options beyond E not provided.\n\nRemaining options potentially correct: B, C, D\nPreliminary conclusion: B, C, D\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare similarities: B, C, and D all align with the regulatory framework requirements for cosmetics in some aspect.\n- Difference analysis:\n  - B highlights filing requirements for domestic ordinary cosmetics.\n  - C emphasizes classification by risk, a general policy.\n  - D states necessary actions for changes in special cosmetics, aligning with regulatory requirements.\n\nOption that best fits based on broad applicability: C\nPreliminary conclusion: C\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: B, C, D - Confidence: Medium\n- Method 2 conclusion: B, C, D - Confidence: High\n- Method 3 conclusion: C - Confidence: Medium\n\nConsistency analysis: Methods 1 and 2 suggest B, C, D based on specific compliance requirements, while Method 3 emphasizes a broader regulatory strategy applicable universally. Method 3's focus may miss specific local filing requirements but reaffirms classification by risk.\n\nFinal determination: Correct answer: C - Reason: C is universally applicable, consistent across frameworks, and aligns best with the comparative analysis over all options.", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 57, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 4. 抗哮喘药沙丁胺醇的化学结构式如下，其化学⾻架属于（）。\nOptions: A. 芳基丙酸类\nB. 芳氧丙醇胺类\nC. ⼆氢吡啶类\nD. 苯⼆氮卓类\nE. 苯⼄醇胺类\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address the question regarding the chemical structure classification of Salbutamol, a drug used for asthma treatment, apply the three distinct reasoning methods as follows:\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on key terms: Salbutamol, chemical structure, chemical skeletal classification.\n- Salbutamol's structure is well-known to be based on β2-adrenergic receptor agonists with a phenethylamine skeleton.\n- Analysis: Salbutamol contains a benzene ring attached to an ethanolamine group, which matches the structure typical of phenethylamine derivatives.\n- Preliminary conclusion: E. 苯乙醇胺类\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (芳基丙酸类): Salbutamol does not have a propionic acid group.\n- Eliminate B (芳氧丙醇胺类): Salbutamol structure lacks an ether linkage directly in the main skeletal structure.\n- Eliminate C (二氢吡啶类): Salbutamol does not contain a dihydropyridine ring.\n- Eliminate D (苯二氮卓类): The structure of Salbutamol lacks the benzodiazepine ring.\n- Eliminate E: As per the analysis above, this matches the ethanolamine aspect of Salbutamol.\n- Remaining options: E. 苯乙醇胺类\n- Preliminary conclusion: E. 苯乙醇胺类\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: E is distinct in referencing ethanolamine, which is part of Salbutamol's known structure.\n- Key differences: Options A, B, C, and D contain functional groups or ring structures not present in Salbutamol.\n- Option that best fits: E matches the classification through typical functional groups and skeletal structure.\n- Preliminary conclusion: E. 苯乙醇胺类\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All methods consistently point to option E.\n- Final determination: E. 苯乙醇胺类 - Reason: Consistent conclusions across all methods, high confidence based on known structure.\n\nCorrect answer: E. 苯乙醇胺类", "question_type": "最佳选择题", "groundtruth": "E"}
{"id": 58, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 58. 头孢曲松钠与乳酸钠林格注射液直接混合，可导致（）。\nOptions: A. 产⽣⽓体\nB. 溶液变⾊\nC. 微浑浊或沉淀\nD. 产⽣胶状不溶物\nE. 药物分解、降解速度加快\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question using three distinct reasoning methods, let's look into each method one by one.\n\n**Reasoning Method 1: Direct Deduction**\n- Analysis: The question concerns the mixing of ceftriaxone (头孢曲松钠) with Ringer's lactate solution (乳酸钠林格注射液). From professional knowledge, ceftriaxone can form precipitates when mixed with calcium-containing solutions, due to the formation of ceftriaxone-calcium salts. Ringer's lactate contains calcium, so mixing these can lead to precipitation.\n- Preliminary conclusion: C. 微浑浊或沉淀 (Slight turbidity or precipitate).\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 产⽣⽓体 (Gas production) - There is no gas production associated with the chemical interaction of ceftriaxone and Ringer's lactate.\n- Eliminate B: 溶液变⾊ (Solution discoloration) - There is no evidence or documented interaction causing discoloration when these solutions are mixed.\n- Eliminate D: 产⽣胶状不溶物 (Gelatinous insoluble substances) - Typically, the reaction forms solid precipitates, not gelatinous substances.\n- Eliminate E: 药物分解、降解速度加快 (Increased decomposition/degradation rate) - The reaction leads to precipitation, not an increase in the degradation rate of the drug.\n- Remaining options: C. 微浑浊或沉淀\n- Preliminary conclusion: C. 微浑浊或沉淀\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A, B, D, and E describe gas production, discoloration, gelatinous formations, and increased degradation, none of which are typically observed in this interaction.\n- Key differences identification: C specifically addresses physical changes which are chemical precipitation, a known issue when these substances are mixed.\n- Option that best fits the question: C. 微浑浊或沉淀\n- Preliminary conclusion: C. 微浑浊或沉淀\n\n**Consistency Assessment:**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All methods consistently indicate option C as the conclusion.\n- Final determination: Correct answer: C - Reason: Consistently supported by direct deduction, systematic elimination, and comparative analysis, reflecting known pharmaceutical reaction data.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 59, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 65. 属于⼄酰胆碱酯酶抑制剂，⽤于改善脑功能及抗记忆障碍的药物是（）。\nOptions: A. 尼莫地平\nB. 吡拉西坦\nC. 依达拉奉\nD. 多奈哌齐\nE. 尼麦⾓林\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question, \"65. 属于乙酰胆碱酯酶抑制剂，用于改善脑功能及抗记忆障碍的药物是（）。\", we will use the three distinct reasoning methods as described.\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- Key term: \"乙酰胆碱酯酶抑制剂\" (acetylcholinesterase inhibitor), a class of drugs used to improve brain function and counter memory disorders.\n- Analysis: Among common drugs used in neurological contexts, Donepezil (多奈哌齐) is well-known as an acetylcholinesterase inhibitor used in Alzheimer's disease to enhance cognitive function and improve memory.\n- Preliminary conclusion: D. 多奈哌齐\n\n**Reasoning Method 2: Systematic Elimination**\n- Evaluate each option to exclude incorrect ones:\n  - Eliminate A: 尼莫地平 is a calcium channel blocker mainly used for cerebral vasodilation, not an acetylcholinesterase inhibitor.\n  - Eliminate B: 吡拉西坦 is a nootropic agent with different mechanisms, not specifically an acetylcholinesterase inhibitor.\n  - Eliminate C: 依达拉奉 is an antioxidant used for stroke and ALS, not an acetylcholinesterase inhibitor.\n  - Eliminate D: Not eliminated as Donepezil (多奈哌齐) is known to be an acetylcholinesterase inhibitor.\n  - Eliminate E: 尼麦角林 is used for improving brain function via different mechanisms, not an acetylcholinesterase inhibitor.\n- Remaining options: D. 多奈哌齐\n- Preliminary conclusion: D. 多奈哌齐\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options:\n  - D. 多奈哌齐 is specifically indicated as an acetylcholinesterase inhibitor among these options. Others have different primary uses that do not align with the inhibitory function on acetylcholinesterase.\n- Key differences identification: The primary action as acetylcholinesterase inhibition is specific to Donepezil.\n- Option that best fits the question: D. 多奈哌齐\n- Preliminary conclusion: D. 多奈哌齐\n\n**Consistency Assessment:**\n- Method 1 conclusion: D. 多奈哌齐 - Confidence: High\n- Method 2 conclusion: D. 多奈哌齐 - Confidence: High\n- Method 3 conclusion: D. 多奈哌齐 - Confidence: High\n- Consistency analysis: All methods consistently indicate D. 多奈哌齐 as the choice with strong, well-known evidence supporting its role as an acetylcholinesterase inhibitor.\n- Final determination: D. 多奈哌齐 - Reason: Consistent conclusions across all methods.\n\nCorrect answer: D", "question_type": "配伍选择题", "groundtruth": "D"}
{"id": 60, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 18. 某患者上呼吸道感染，⽤氨苄西林治疗⼀周，未见明显好转，后改⽤舒他西林，症状得到改善。关于舒他西林结构和临床使⽤的说法，错误的是（）。\nOptions: A. 为⼀种前体药物\nB. 给药后，在体内⾮特定酯酶的作⽤下⽔解成氨苄西林和舒巴坦\nC. 对β-内酰胺醇的稳定性强于氨苄西林\nD. 抗菌效果优于氨苄西林，原因是它在体内⽣成的两种药物都有较强的抗菌活性\nE. 可以⼜服，且⼜服后吸收迅速\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n\n- Directly derive conclusions based on question information and professional knowledge: The question asks about the structure and clinical use of sultamicillin, focusing on the incorrect statement. Sultamicillin is a prodrug formed by combining ampicillin and sulbactam. It is metabolized in the body to release these two active components. Sulbactam enhances the efficacy of ampicillin by inhibiting beta-lactamase.\n- Focus on key terms in the question stem: \"Prodrug,\" \"hydrolysis,\" \"beta-lactam stability,\" \"antibacterial effect,\" \"oral administration.\"\n- Analysis: Sultamicillin is indeed a prodrug (A). It is hydrolyzed to release ampicillin and sulbactam, not to ampicillin and \"β-内酰胺醇 (beta-lactam alcohol)\" (B is incorrect). The stability description (C) requires specific knowledge; while sulbactam does stabilize ampicillin from beta-lactamase, it's not to increase beta-lactam stability, more so to prevent degradation by enzymes. Antimicrobial effect is enhanced due to sulbactam's inhibition of beta-lactamase, but not solely because both components are highly active (D requires careful consideration). Sultamicillin can be absorbed orally (E).\n- Preliminary conclusion: B\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A: True, sultamicillin is a prodrug, so can be eliminated.\n- Eliminate B: Incorrect, the hydrolysis occurs to produce ampicillin and sulbactam, not \"β-内酰胺醇.\"\n- Eliminate C: While sulbactam provides some stability, the statement regarding \"beta-lactam alcohol\" stability compared to ampicillin is misleading and more detailed information is needed.\n- Eliminate D: Simplification required for expanding details on the combined efficacy but is somewhat valid given sulbactam does provide better efficacy.\n- Eliminate E: True, sultamicillin is fast absorbed orally.\n- Remaining options: B and possibly C\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare similarities and differences among all options: Focused on prodrug properties, degradation pathways, stability, effectiveness, and absorption.\n- Comparison of similar options: A, E are directly valid due to known pharmacokinetic properties. B and C involve chemistry details that need careful introspection.\n- Key differences identification: B incorrectly identifies hydrolysis products, while differences in beta-lactam stability (C) require clarification regarding contexts.\n- Option that best fits the question: B\n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently identify option B as the incorrect statement.\n- Final determination: B - Reason: Based on consistency in identifying incorrect claim regarding hydrolysis products.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "D"}
{"id": 61, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 14. 属于长效β 肾上腺素受体激动剂，可⽤于哮喘长期维持治疗的药物是（）。2\nOptions: A. 噻托溴铵\nB. 特布他林\nC. 布地奈德\nD. 孟鲁司特\nE. 福莫特罗\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer, we will analyze the question using the three distinct reasoning methods: Direct Deduction, Systematic Elimination, and Comparative Analysis.\n\n**Reasoning Method 1: Direct Deduction**\n- The question asks for a long-acting beta-adrenergic receptor agonist used for long-term maintenance treatment of asthma.\n- Key terms: \"长效β肾上腺素受体激动剂\", \"哮喘长期维持治疗\".\n- Analysis: Long-acting beta-agonists (LABAs) are used as part of asthma management for long-term control. Formoterol is well-known as a LABA for asthma maintenance.\n- Preliminary conclusion: E. 福莫特罗\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (噻托溴铵): Not a beta agonist; it's a long-acting anticholinergic.\n- Eliminate B (特布他林): It's a short-acting beta-agonist, not suitable for long-term maintenance.\n- Eliminate C (布地奈德): It's a corticosteroid, not a beta-agonist.\n- Eliminate D (孟鲁司特): It's a leukotriene receptor antagonist, not a beta-agonist.\n- Eliminate E (福莫特罗): None of the criteria for elimination apply; it is a LABA used for long-term maintenance.\n- Remaining options: E. 福莫特罗\n- Preliminary conclusion: E. 福莫特罗\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options:\n  - A, B, C, and D are not LABAs.\n  - E (福莫特罗) fits the criteria as a LABA used for long-term asthma maintenance.\n- Key differences identification: Formoterol stands out as the long-acting beta agonist, suitable for chronic asthma management.\n- Option that best fits the question: E. 福莫特罗\n- Preliminary conclusion: E. 福莫特罗\n\n**Consistency Assessment:**\n- Method 1 conclusion: E. 福莫特罗 - Confidence: High\n- Method 2 conclusion: E. 福莫特罗 - Confidence: High\n- Method 3 conclusion: E. 福莫特罗 - Confidence: High\n- Consistency analysis: All methods consistently identify option E as the correct answer.\n- Final determination: E. 福莫特罗 - Reason: Consistency across all reasoning methods.\n\nCorrect answer: E", "question_type": "最佳选择题", "groundtruth": "E"}
{"id": 62, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 48. ⽤于治疗⼲眼症的药物是（）。\nOptions: A. 聚⼄⼆醇滴眼液\nB. 硫酸阿托品眼⽤凝胶\nC. 雷珠单抗注射液\nD. ⽑果芸⾹碱滴眼液\nE. 丙美卡因滴眼液\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To address the question about the treatment for dry eye disease, we will apply the three reasoning methods as requested:\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on the key term \"治疗干眼症的药物\" (treatment for dry eye disease).\n- Within ophthalmology, the treatment for dry eye often involves lubricating eye drops or artificial tears. Polyethylene glycol (聚乙二醇) is commonly used as a lubricant in eye drops and artificial tears for this condition.\n- Preliminary conclusion: A\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Cannot eliminate, as 聚乙二醇滴眼液 fits the treatment for dry eye.\n- Eliminate B: 硫酸阿托品眼用凝胶 is typically used for mydriasis (dilation of the pupil) and not for dry eye.\n- Eliminate C: 雷珠单抗注射液 is used for age-related macular degeneration and other retinal diseases, not for dry eye.\n- Eliminate D: 毛果芸香碱滴眼液 is used for reducing intraocular pressure in glaucoma patients, not for dry eye.\n- Eliminate E: 丙美卡因滴眼液 is a local anesthetic used for numbing purposes in eye procedures, not for dry eye.\n- Remaining options: A\n- Preliminary conclusion: A\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare options based on their intended therapeutic use.\n- 聚乙二醇滴眼液 is specifically used for lubrication of the ocular surface.\n- Other drugs (B, C, D, E) have alternative primary functions like inducing mydriasis, treating retinal diseases, managing glaucoma, or providing local anesthesia, respectively.\n- Key differences identification: Only option A is directly relevant to dry eye treatment.\n- Option that best fits the question: A\n- Preliminary conclusion: A\n\n**Consistency Assessment:**\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All methods consistently point to option A as the correct answer, with high confidence.\n- Final determination: A - Reason: Consistent conclusions across all reasoning methods, based on polyethylene glycol's use as a lubrication for dry eye treatment.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 63, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 33. 患者，⼥，28岁，因痤疮就诊，给予异维A酸胶囊。关于该患者⽤药教育的说法，错误的是（）。\nOptions: A. 治疗期间及停药后3个⽉内应做好避孕措施\nB. 治疗期间若发⽣⽪肤黏膜⼲燥，应减量或停药\nC. 不良反应常见，但停药后绝⼤多数可恢复\nD. 治疗最初2个⽉可能导致肝酶异常，必要时检查肝功能\nE. 部分患者⽤药2～4周时出现⼀过性⽪疹加重现象\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question \"关于该患者⽤药教育的说法，错误的是\" regarding isotretinoin capsule for acne treatment, we will apply the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Isotretinoin is known for serious teratogenic effects; hence, contraception during and after treatment is critical.\n- Skin and mucous dryness is a known side effect, often managed rather than warranting immediate dose reduction/cessation unless severe.\n- Most side effects are reversible post-treatment.\n- Monitoring liver enzymes is advised as isotretinoin can affect liver function, particularly in the initial stages.\n- Transient worsening of acne/rash can occur as the body adjusts.\n- Analysis: Option B stands out, as managing dryness doesn't necessarily require dosage changes.\n- Preliminary conclusion: B\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: Correct, as isotretinoin is teratogenic.\n- Eliminate C: Correct, as most side effects resolve post-treatment.\n- Eliminate D: Correct, as monitoring liver function aligns with known practice.\n- Eliminate E: Correct, as transient worsening is acknowledged during early use.\n- Remaining options: B\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: All options discuss common isotretinoin management strategies. Only B suggests dose alteration for mucous dryness, which is generally managed with alternative methods unless severe.\n- Key differences identification: B diverges from typical management, where dose adjustment isn't the first approach to mild side effects like dryness.\n- Option that best fits the question: B\n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently identify B as the incorrect statement regarding isotretinoin usage.\n- Final determination: B - Reason: Consistent conclusion across methods suggests strong confidence that B is the erroneous statement concerning isotretinoin patient education.\n\nCorrect answer: B", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 64, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 61. 属于维⽣素K拮抗剂的抗凝⾎药物是（）。\nOptions: A. 依诺肝素\nB. 氯吡格雷\nC. 华法林\nD. 利伐沙班\nE. 达⽐加群酯\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n\n- Key terms: \"维生素K拮抗剂\" (Vitamin K antagonist), \"抗凝血药物\" (anticoagulant).\n- Direct analysis: Vitamin K antagonists are a specific class of anticoagulant drugs that work by inhibiting the effects of vitamin K, which is necessary for the synthesis of certain coagulation factors. The most famous and commonly used vitamin K antagonist is warfarin (华法林).\n- Preliminary conclusion: C. 华法林\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A (依诺肝素): It's a low molecular weight heparin, not a vitamin K antagonist.\n- Eliminate B (氯吡格雷): It's an antiplatelet agent, not a vitamin K antagonist.\n- Eliminate D (利伐沙班): It's a direct factor Xa inhibitor, not a vitamin K antagonist.\n- Eliminate E (达比加群酯): It's a direct thrombin inhibitor, not a vitamin K antagonist.\n- Remaining options: C. 华法林\n- Preliminary conclusion: C. 华法林\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparison of similar options: A, D, and E are all modern anticoagulants but with different mechanisms unrelated to vitamin K. B is an antiplatelet agent.\n- Key differences identification: Only warfarin (华法林) is known as a vitamin K antagonist among the given options.\n- Option that best fits the question: C. 华法林\n- Preliminary conclusion: C. 华法林\n\n**Consistency Assessment**\n\n- Method 1 conclusion: C. 华法林 - Confidence: High\n- Method 2 conclusion: C. 华法林 - Confidence: High\n- Method 3 conclusion: C. 华法林 - Confidence: High\n- Consistency analysis: All three methods consistently point to option C. 华法林 as the correct answer.\n- Final determination: C. 华法林 - Reason: Consistent conclusions across all reasoning methods.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 65, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 81. 在体外⽆活性，需要在体内⽔解开环发挥活性的药物是（）。\nOptions: \n\nPlease output: Correct answer: [option letters]\n", "model_answer": "In order to determine the correct answer for the given question, \"在体外⽆活性，需要在体内⽔解开环发挥活性的药物是\", let us apply the three distinct reasoning methods outlined.\n\n**Reasoning Method 1: Direct Deduction**\n- **Analysis**: The key terms in the question are \"在体外无活性\" (inactive in vitro) and \"体内水解开环\" (activated by hydrolysis in vivo). A pharmaceutical with these characteristics is typically a prodrug that requires metabolic conversion to its active form.\n- **Preliminary conclusion**: Identifying drugs known for their prodrug status could provide options. \n\n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A**: If drug A is known to be active both in vitro and in vivo, it does not match the criteria of the question.\n- **Eliminate B**: Option B, if active in vitro without requiring conversion, should be eliminated.\n- **Eliminate C**: If C requires no metabolic conversion in vivo to be active, it should also be eliminated.\n- **Eliminate D**: D can be eliminated if it does not undergo in vivo hydrolysis.\n- **Eliminate E**: If E is active in vitro without conversion, it should be eliminated.\n- **Remaining options**: Drugs matching the descriptions of being prodrugs.\n- **Preliminary conclusion**: Prodrug options.\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison of similar options**: Options known for having similar metabolic pathways should be compared.\n- **Key differences identification**: Focus on the requirement of in vivo activation via hydrolysis.\n- **Option that best fits the question**: Compare options that are recognized as prodrugs.\n- **Preliminary conclusion**: Prodrugs that are inactive in vitro and require hydrolysis in vivo.\n\n**Consistency Assessment:**\n- **Method 1 conclusion**: Prodrugs that require in vivo hydrolysis.\n- **Confidence**: High\n- **Method 2 conclusion**: Prodrugs after systematic elimination.\n- **Confidence**: High\n- **Method 3 conclusion**: Prodrugs from the comparison.\n- **Confidence**: High\n- **Consistency analysis**: All methods consistently indicate the drug is a prodrug activated by hydrolysis in vivo.\n- **Final determination**: Correct answer based on consistency and strongest evidence.\n\nCorrect answer: [option letter matching known prodrug characteristics] (usual prodrugs include those like Omeprazole, Enalapril, which is turned active through metabolic conversion).", "question_type": "配伍选择题", "groundtruth": "D"}
{"id": 66, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：患者，男，58岁，有⾼⾎压、冠⼼病、⾼脂⾎症、便秘、⾻关节炎和胃溃疡病史，2年前接受冠脉⽀架植⼊术。近⽇，患者先后在⼼内科、消化科、⾻科就诊，开具药品如下：\n98. 关于该患者药物治疗⽅案的说法，错误的是（）。\nOptions: A. 美托洛尔会影响阿司匹林的抗⾎⼩板活性，应停⽤\nB. 阿托伐他汀钙⽤于冠⼼病的治疗，需长期规律⽤药\nC. 如⼤便次数规律（如每⽇1次），聚⼄⼆醇4000散可按需使⽤\nD. 同时使⽤双氯芬酸钠与阿司匹林会增加消化道出⾎风险，两药不宜合⽤\nE. 麝⾹保⼼丸和复⽅丹参⽚均属活⾎剂，选⽤其中⼀种即可\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question and determine the incorrect statement regarding the patient's medication regimen, we will apply the three reasoning methods independently and assess consistency among the conclusions.\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms to focus on in the question are related to the interactions and therapeutic uses of the medications prescribed.\n- Analysis: Based on professional pharmaceutical knowledge:\n  - Metoprolol, a beta-blocker, does not directly impact the antiplatelet activity of aspirin.\n  - Atorvastatin is commonly used for coronary heart disease and requires long-term use.\n  - Polyethylene glycol 4000 is used for constipation, and its usage can be adjusted based on regular bowel movements.\n  - Diclofenac and aspirin can both increase the risk of gastrointestinal bleeding when used together.\n  - Shexiang Baoxin Pills (麝香保心丸) and Compound Danshen Tablets (复方丹参片) are both used for blood circulation; typically, one is sufficient.\n- Preliminary conclusion: Option A is incorrect—Metoprolol does not impact aspirin's antiplatelet activity.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Incorrect statement as metoprolol does not impact the antiplatelet activity of aspirin.\n- Eliminate B: Atorvastatin is indeed used for coronary heart disease and recommended for long-term use; correct statement.\n- Eliminate C: Polyethylene glycol 4000 can be used as needed if bowel movement is regular; correct statement.\n- Eliminate D: Using diclofenac and aspirin together does increase risk of gastrointestinal bleeding; correct statement.\n- Eliminate E: Both Shexiang Baoxin Pills and Compound Danshen Tablets increase blood flow, choosing one is sufficient; correct statement.\n- Remaining options: A\n- Preliminary conclusion: Option A is incorrect.\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among options:\n  - A involves incorrect drug interaction information.\n  - B involves a treatment guideline for statins.\n  - C addresses the usage of a laxative based on bowel habits.\n  - D involves risk assessment of combined NSAID use.\n  - E involves redundant therapy with blood circulation agents.\n- Key differences identification: Only option A presents incorrect pharmaceutical knowledge about metoprolol and aspirin.\n- Option that best fits the question: Option A\n- Preliminary conclusion: Option A is incorrect.\n\n**Consistency Assessment:**\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All three reasoning methods consistently identify Option A as incorrect.\n- Final determination: A - Reason: Consistent conclusion across all reasoning methods with high confidence.\n\nCorrect answer: A", "question_type": "综合分析选择题", "groundtruth": "A"}
{"id": 67, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：甲是药品零售连锁企业所属门店，经营类别：处⽅药、甲类⾮处⽅药、⼄类⾮处⽅药，经营范围：第⼆类精神药品、⽣物制品、化学药、中成药、中药饮⽚。 ⼄是药品零售企业，经营类别：处⽅药、甲类⾮处⽅药、⼄类⾮处⽅药，经营范围：⽣物制品、化学药、中成药。 丙是药品零售企业，经营类别：⼄类⾮处⽅药，经营范围：⽣物制品、化学药、中成药。\n104. 根据处⽅药与⾮处⽅药分类管理规定，结合题⽬提供的信息，下列做法正确的是（）。\nOptions: A. 甲在经营场所内开架销售中药饮⽚百合、枸杞⼦\nB. 甲营业期间，⼀⽼⼈⾝体不适欲购买处⽅药速效救⼼丸，经询问发现⽼⼈有冠⼼病史，执业药师在没有处⽅的情况下，依然向其销售了该处⽅药，并建议其⽴即就诊\nC. ⼄建⽴处⽅药销售的处⽅管理制度，要求对售出的处⽅药处⽅进⾏抄录，处⽅原件返还消费者\nD. ⼄的执业药师在凭处⽅向个⼈消费者销售处⽅药时，结合其表状的疾病症状，告知其该处⽅药与另⼀处⽅药联合购买可以享受优惠\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To answer this question, I will analyze each option using the three reasoning methods and determine the final answer based on consistency.\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on key terms: prescription drugs, non-prescription drugs, sales regulations.\n- Analysis:\n  - A: Open-shelf sales of traditional Chinese medicine should comply with related regulations; non-prescription traditional medicine like Baihe and Gouqizi can generally be sold open-shelf.\n  - B: Prescription drugs like Suxiao Jiuxin Wan should not be sold without prescriptions, except in emergencies under specific guidelines and supervision.\n  - C: Establishing a prescription drug management system requiring transcription is correct, and returning original prescriptions is a common practice.\n  - D: Pharmacists should not suggest combining prescription drugs for discounts, as it might lead patients to use unnecessary medication.\n\n- Preliminary conclusion: A and C\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: Valid since traditional Chinese medicine can be sold openly per regulations.\n- Eliminate B: Incorrect because prescription drugs cannot be sold without a prescription.\n- Eliminate C: Valid as it aligns with prescription management regulations.\n- Eliminate D: Incorrect due to unethical promotion and potential irresponsibility.\n- Remaining options: A and C\n- Preliminary conclusion: A and C\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Both A and C follow appropriate regulations, while B and D violate prescription drug rules.\n- Key differences identification: A involves open-shelf sales, while C involves prescription management, which are different but both compliant with regulations.\n- Option that best fits the question: A and C\n- Preliminary conclusion: A and C\n\n**Consistency Assessment:**\n- Method 1 conclusion: A and C - Confidence: High\n- Method 2 conclusion: A and C - Confidence: High\n- Method 3 conclusion: A and C - Confidence: High\n- Consistency analysis: All methods consistently indicate that both A and C are correct.\n- Final determination: A, C - Reason: Both options comply with the regulations, consistently supported by all reasoning methods.\n\nCorrect answer: A, C", "question_type": "综合分析选择题", "groundtruth": "A"}
{"id": 68, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 99. 可被肝药酶CYP2C9和CYP3A4代谢，代谢产物仍具降压活性的ARB类药物是（）。\nOptions: A. 福⾟普利\nB. 缬沙坦\nC. 厄贝沙坦\nD. 氯沙坦\nE. 卡托普利\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question regarding an ARB (angiotensin receptor blocker) drug metabolized by liver enzymes CYP2C9 and CYP3A4, whose metabolites also possess antihypertensive activity, let's apply the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on key terms such as \"CYP2C9,\" \"CYP3A4,\" \"ARB,\" and \"active metabolites.\"\n- Analysis: ARBs are known as losartan, valsartan, irbesartan, candesartan, etc. They can be metabolized by these liver enzymes. Losartan is distinguished as being metabolized by both CYP2C9 and CYP3A4, and its primary metabolite (EXP3174) retains substantial antihypertensive activity.\n- Preliminary conclusion: D. 氯沙坦 (Losartan)\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 福辛普利 (Fosinopril) - It's an ACE inhibitor, not an ARB.\n- Eliminate B: 缬沙坦 (Valsartan) - Not primarily metabolized by CYP2C9/CYP3A4, and its metabolites do not have significant activity.\n- Eliminate C: 厄贝沙坦 (Irbesartan) - Not primarily metabolized by CYP2C9/CYP3A4 to active metabolites.\n- Eliminate E: 卡托普利 (Captopril) - Also an ACE inhibitor, not an ARB.\n- Remaining options: D. 氯沙坦 (Losartan)\n- Preliminary conclusion: D. 氯沙坦 (Losartan)\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Review ARBs and their metabolism by CYP2C9/CYP3A4.\n- Key differences identification: Losartan is unique among the options as its metabolite has active antihypertensive effects.\n- Option that best fits the question: D. 氯沙坦 (Losartan)\n- Preliminary conclusion: D. 氯沙坦 (Losartan)\n\n**Consistency Assessment:**\n- Method 1 conclusion: D. 氯沙坦 (Losartan) - Confidence: High\n- Method 2 conclusion: D. 氯沙坦 (Losartan) - Confidence: High\n- Method 3 conclusion: D. 氯沙坦 (Losartan) - Confidence: High\n- Consistency analysis: All methods consistently identify losartan as the drug metabolized by CYP2C9 and CYP3A4 into active metabolites.\n- Final determination: D. 氯沙坦 (Losartan) - Reason: Consistent conclusions across all reasoning methods based on professional knowledge.\n\nCorrect answer: D. 氯沙坦 (Losartan)", "question_type": "配伍选择题", "groundtruth": "D"}
{"id": 69, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 87. 作⽤于⼆肽基肽酶4（DPP-4），为嘧啶⼆酮衍⽣物，适⽤于治疗2型糖尿病的药物是（）。\nOptions: A. 阿格列汀\nB. 罗格列酮\nC. 达格列净\nD. 格列吡嗪\nE. 那格列奈\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the question regarding the medication that acts on dipeptidyl peptidase-4 (DPP-4) and is a pyrimidinedione derivative used for the treatment of type 2 diabetes, let's analyze using the three reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n\n- Key Term: \"Dipeptidyl peptidase-4 (DPP-4) inhibitor\", \"pyrimidinedione derivative\", \"type 2 diabetes\".\n- Known Information: DPP-4 inhibitors are a class of oral hypoglycemics.\n- Direct Reasoning: Medications that are known DPP-4 inhibitors used for type 2 diabetes treatment include Alogliptin, Sitagliptin, Saxagliptin, and Linagliptin. Alogliptin specifically is a pyrimidinedione derivative.\n- Preliminary conclusion: A. 阿格列汀 (Alogliptin)\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate B (罗格列酮): It is a thiazolidinedione and not a DPP-4 inhibitor.\n- Eliminate C (达格列净): It is an SGLT2 inhibitor and not a DPP-4 inhibitor.\n- Eliminate D (格列吡嗪): It is a sulfonylurea class medication and not a DPP-4 inhibitor.\n- Eliminate E (那格列奈): It is a meglitinide and not a DPP-4 inhibitor.\n- Remaining options: A. 阿格列汀\n- Preliminary conclusion: A. 阿格列汀\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparative analysis of options indicates differences in drug classes used for diabetes.\n- Alogliptin (A) fits the criteria as a DPP-4 inhibitor that is a pyrimidinedione derivative.\n- Key Differences Identification: Other options belong to different classes (thiazolidinediones, SGLT2 inhibitors, sulfonylureas, and meglitinides).\n- Option that best fits the question: A. 阿格列汀\n- Preliminary conclusion: A. 阿格列汀\n\n**Consistency Assessment**\n\n- Method 1 conclusion: A. 阿格列汀 - Confidence: High\n- Method 2 conclusion: A. 阿格列汀 - Confidence: High\n- Method 3 conclusion: A. 阿格列汀 - Confidence: High\n- Consistency analysis: All methods consistently indicate A. 阿格列汀 as the correct answer.\n- Final determination: A. 阿格列汀 - Reason: Consistent conclusion across all reasoning methods with high confidence.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 70, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 52. 属于⿇醉药品的是（）。\nOptions: A. 氨酚待因⽚\nB. 氨酚氢可酮⽚\nC. 氢可酮\nD. 氯胺酮\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine which of the options are classified as narcotics:\n\n**Reasoning Method 1: Direct Deduction**\n\n- **Analysis**: Narcotics, often known as opioids or substances with morphine-like effects, are characterized by their analgesic and sedative properties. The key terms involve understanding the drugs listed and their classifications.\n- **Preliminary Conclusion**: Option C. 氢可酮 (Hydrocodone) is well-known as a narcotic used in pain relief.\n\n**Reasoning Method 2: Systematic Elimination**\n\n- **Eliminate A**: 氨酚待因⽚ (Acetaminophen + Codeine) - While codeine is an opioid, it's not typically categorized as a \"narcotic\" in the same stringent sense as pure opioids.\n- **Eliminate B**: 氨酚氢可酮⽚ (Acetaminophen + Hydrocodone) - Contains hydrocodone, which is narcotic; however, it is in combination, might lead to classification confusion.\n- **Eliminate D**: 氯胺酮 (Ketamine) - Used for anesthesia and is a dissociative anesthetic, not classified strictly as a narcotic.\n- **Remaining Options**: C. 氢可酮\n- **Preliminary Conclusion**: Option C\n\n**Reasoning Method 3: Comparative Analysis**\n\n- **Comparison of similar options**: Options B (Acetaminophen + Hydrocodone) and C (Hydrocodone) contain hydrocodone, but pure hydrocodone is universally recognized as a narcotic.\n- **Difference Analysis**: Pure substances are often more strictly classified in narcotic terms than combinations with non-narcotic agents. \n- **Option that best fits the question**: Option C\n- **Preliminary Conclusion**: Option C\n\n**Consistency Assessment**\n\n- **Method 1 Conclusion**: Option C - Confidence: High\n- **Method 2 Conclusion**: Option C - Confidence: High\n- **Method 3 Conclusion**: Option C - Confidence: High\n- **Consistency Analysis**: All methods consistently point to option C as the correct choice.\n- **Final Determination**: Option C - Reason: There is high consistency across all reasoning methods, confirming hydrogen is classified as a narcotic.\n\n**Correct answer: C**", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 71, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 20. 关于⽹络销售药品管理的说法，错误的是（）。\nOptions: A. 药品零售企业不得通过⽹络销售含⿇黄碱类复⽅制剂等国家有专门管理要求的药品\nB. 药品⽹络销售者，应当对配送药品的质量安全负责，保障药品储存、运输过程符合《药品经营质量管理规范》的相关要求\nC. 药品⽹络交易第三⽅平台提供者，应当依法对申请⼊驻经营的药品上市许可持有⼈、药品经营企业的有关资质等进⾏审核，保证其符合法定要求，并对发⽣在平台上的药品经营⾏为进⾏管理\nD. 特殊情形下，第⼆类精神药品、毒性中药饮⽚、蛋⽩同化制剂和肽类激素等药品可以通过⽹络交易\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer, let's apply the three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Focus on key terms: 网络销售药品管理, 错误的.\n- Analyzing each option:\n  - Option A: Regulations typically restrict the online sale of certain controlled substances, like 麻黄碱类复方制剂, due to their potential for abuse. This statement aligns with common regulations and is likely true.\n  - Option B: It is standard for any drug seller, including online, to ensure the quality and safety of drugs during storage and transport, adhering to 药品经营质量管理规范, so this statement is true.\n  - Option C: Third-party platforms are usually required to verify the qualifications of entities selling or listing drugs, consistent with regulatory oversight responsibilities, making this statement true.\n  - Option D: The sale of second category psychiatric drugs, toxic traditional Chinese medicine slices, anabolic steroids, and peptide hormones online is highly regulated and typically not allowed due to their risks, making this statement likely false.\n- Preliminary conclusion: D\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Aligns with common regulatory practices (True, not the error).\n- Eliminate B: Common regulation compliance (True, not the error).\n- Eliminate C: Ensures lawful compliance by platforms (True, not the error).\n- Eliminate D: Contradicts typical strict regulations against selling such drugs online (False, likely the error).\n- Remaining option: D\n- Preliminary conclusion: D\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A, B, and C describe standard regulatory practices ensuring safety and compliance, whereas D introduces an unusual exception for highly controlled drugs.\n- Key differences identification: Option D suggests possibilities that are typically tightly controlled and restricted, conflicting with standard practices.\n- Option that best fits the question: D\n- Preliminary conclusion: D\n\n**Consistency Assessment:**\n- Method 1 conclusion: D - Confidence: High\n- Method 2 conclusion: D - Confidence: High\n- Method 3 conclusion: D - Confidence: High\n- Consistency analysis: All methods consistently identify D as the error based on current regulations and practices.\n- Final determination: D - Reason: Consistency across all reasoning methods and strong alignment with professional knowledge and regulatory standards.\n\nCorrect answer: D", "question_type": "最佳选择题", "groundtruth": "D"}
{"id": 72, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 28. 不属于阿昔洛韦适应证的是（）。\nOptions: A. 单纯疱疹\nB. 带状疱疹\nC. 免疫缺陷者⽔痘\nD. 病毒性急性视⽹膜坏死\nE. ⼄型流感\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine which option does not belong to the indications for acyclovir, let's analyze using the three reasoning methods mentioned:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- Focus on key terms in the question stem: \"阿昔洛韦适应证\" (acyclovir indications).\n- Analysis: Acyclovir is an antiviral medication primarily used to treat infections caused by herpes viruses, including herpes simplex virus (HSV) and varicella-zoster virus (VZV). Common indications include treatment of herpes simplex (A), herpes zoster (B), chickenpox (C) in immune-compromised individuals, and sometimes viral acute retinal necrosis (D), which can be caused by herpes viruses. It is not used for treating influenza viruses, particularly type B influenza (E).\n- Preliminary conclusion: E\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate A: Not eliminated; acyclovir is commonly used for herpes simplex.\n- Eliminate B: Not eliminated; acyclovir treats herpes zoster.\n- Eliminate C: Not eliminated; acyclovir can be used for chickenpox in immunocompromised individuals.\n- Eliminate D: Not eliminated; acyclovir is sometimes used for viral acute retinal necrosis.\n- Eliminate E: Acyclovir is not indicated for any type of influenza, including type B.\n- Remaining options: E\n- Preliminary conclusion: E\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options.\n- Comparison of similar options: A, B, C, and D are all related to herpes viruses, which acyclovir targets.\n- Key differences identification: Option E is related to influenza, which is caused by a different class of viruses (orthomyxoviruses).\n- Option that best fits the question: E does not fit as acyclovir is not used for influenza treatment.\n- Preliminary conclusion: E\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All three methods consistently concluded option E as the correct answer.\n- Final determination: E - Reason: Based on consistent elimination and compatibility with known indications for acyclovir.\n\nCorrect answer: E", "question_type": "最佳选择题", "groundtruth": "E"}
{"id": 73, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 67. 根据《处⽅管理办法》，为门诊⼀般患者开具头孢克洛缓释⽚，每张处⽅（）。\nOptions: A. 不得超过15⽇常⽤量\nB. 不得超过7⽇常⽤量\nC. 为⼀次常⽤量\nD. 不得超过3⽇常⽤量\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question regarding prescribing cefaclor extended-release tablets according to outpatient prescription management guidelines, we'll apply the three reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n- The key term here is \"头孢克洛缓释片\" (cefaclor extended-release tablets) and \"处方管理办法\" (prescription management guidelines).\n- Direct reasoning process: According to prescription guidelines for outpatient medications, especially antibiotics like cefaclor, prescriptions typically follow a rule of providing medication for a certain duration of usual treatment. Extended-release forms are generally given for longer durations compared to immediate-release forms. However, for standard outpatient prescriptions, regulations typically limit antibiotics to prevent misuse.\n- Preliminary conclusion: B. 不得超过7日常用量\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Usually applies to chronic medications, not antibiotics or acute treatments.\n- Eliminate B: Common guideline for acute treatment courses, particularly for antibiotics, restricting to a one-week supply to manage bacterial resistance and side effects.\n- Eliminate C: 不为一次常用量 as it does not prescribe a specific duration, which is atypical for antibiotic regulations.\n- Eliminate D: Applies to acute symptom relief medications, not typically for antibiotics.\n- Remaining options: B\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A and B both involve a limitation on the number of days. In outpatient antibiotic prescriptions, a similar approach applies.\n- Key differences identification: B (7 days) aligns with common practices for antibiotics in outpatient settings; longer durations like A would not be typical.\n- Option that best fits the question: B. 不得超过7日常用量 \n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All conclusions are consistent across methods.\n- Final determination: B. 不得超过7日常用量 - Reason: Consistent prescription guideline for antibiotics limiting to a week's duration for outpatient settings.\n\nCorrect answer: B", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 74, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 72. 深静脉⾎栓的溶栓治疗，宜选⽤的药物是（）。\nOptions: A. 达⽐加群酯\nB. 氯吡格雷\nC. 尿激酶\nD. 依诺肝素钠\nE. 华法林\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct medication for thrombolytic therapy in deep vein thrombosis (DVT), let's analyze the options using the three reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms in the question stem: \"深静脉⾎栓\" (deep vein thrombosis), \"溶栓治疗\" (thrombolytic therapy)\n- Direct reasoning process: Thrombolytic therapy for DVT involves using agents that can actively break down blood clots. Key thrombolytic agents are typically fibrinolytics like tissue plasminogen activator (tPA), streptokinase, or urokinase.\n- Preliminary conclusion: Based on the knowledge that urokinase (尿激酶) is a thrombolytic agent, Option C (尿激酶) is the appropriate choice.\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A (达⽐加群酯): Dabigatran is an anticoagulant, not a thrombolytic.\n- Eliminate B (氯吡格雷): Clopidogrel is an antiplatelet drug, not effective for thrombolysis.\n- Eliminate D (依诺肝素钠): Enoxaparin is a low molecular weight heparin, used for anticoagulation, not for thrombolysis.\n- Eliminate E (华法林): Warfarin is an anticoagulant, unsuitable for immediate thrombolytic therapy.\n- Remaining options: C (尿激酶)\n- Preliminary conclusion: Option C (尿激酶)\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Anticoagulants (达⽐加群酯, 依诺肝素钠, 华法林) vs. antiplatelet (氯吡格雷) vs. thrombolytic (尿激酶)\n- Key differences identification: Only one option is actually a thrombolytic agent capable of actively dissolving clots, which is urokinase.\n- Option that best fits the question: C (尿激酶)\n- Preliminary conclusion: Option C (尿激酶)\n\n**Consistency Assessment:**\n- Method 1 conclusion: C (尿激酶) - Confidence: High\n- Method 2 conclusion: C (尿激酶) - Confidence: High\n- Method 3 conclusion: C (尿激酶) - Confidence: High\n- Consistency analysis: All methods consistently identify C (尿激酶) as the correct answer.\n- Final determination: C (尿激酶) - Reason: Consistent high-confidence conclusion across all reasoning methods.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 75, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 113. 关于胃⾷管反流病患者应⽤含铝抗酸药⽤药教育的说法，正确的有（）。\nOptions: A. 长期服⽤可能会引起低磷⾎症\nB. 易引起腹泻\nC. 可快速缓解症状，对溃疡愈合⼏乎⽆作⽤\nD. 可增加⼼⾎管事件发⽣风险\nE. 与其他药物合⽤，通常要间隔2⼩时\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question about the correct statements regarding the use of aluminum-containing antacids in gastroesophageal reflux disease (GERD) patients, let's apply the three outlined reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n\n- Aluminum-containing antacids can bind phosphate in the gut, leading to potential hypophosphatemia with long-term use.\n- These antacids are typically associated with constipation rather than diarrhea; magnesium-based ones more commonly cause diarrhea.\n- Aluminum-containing antacids can provide quick symptomatic relief but have minimal effect on ulcer healing.\n- No strong evidence links aluminum antacids directly to an increased risk of cardiovascular events.\n- Aluminum-containing antacids can affect the absorption of other medications, hence a commonly recommended practice is to separate their use from other drugs by about 2 hours.\n\nBased on these deductions, the correct statements are:\n- A. 长期服⽤可能会引起低磷⾎症\n- C. 可快速缓解症状，对溃疡愈合⼏乎⽆作⽤\n- E. 与其他药物合⽤，通常要间隔2⼩时\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate B: Usually not associated with diarrhea; aluminum tends to cause constipation.\n- Eliminate D: No strong linkage to increased cardiovascular events.\n- Remaining options:\n  - A: Consistent with hypophosphatemia risk.\n  - C: Consistent with fast symptom relief and limited ulcer healing.\n  - E: Consistent with the recommendation of dosing separation with other medications.\n\nPreliminary conclusion: A, C, E\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare options based on known effects of aluminum antacids:\n  - A vs D: A is consistent with known metabolic effects, unlike speculative cardiovascular risks.\n  - B vs C: C aligns with known symptomatic relief properties; B is inconsistent with typical side effects.\n  - E stands alone in addressing drug interaction management, relevant and standard advice.\n\nOption that best fits the question: A, C, E\n\nPreliminary conclusion: A, C, E\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: A, C, E - Confidence: High\n- Method 2 conclusion: A, C, E - Confidence: High\n- Method 3 conclusion: A, C, E - Confidence: High\n- Consistency analysis: All methods lead to the same conclusion without contradiction.\n\nFinal determination: A, C, E - Reason: Consistent conclusions across all reasoning methods confirm the correctness of these options.\n\nCorrect answer: A, C, E", "question_type": "多项选择题", "groundtruth": "ACE"}
{"id": 76, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 84. 根据《国家药品监督管理局职能配置、内设机构和⼈员编制规定》及其有关规定，负责组织开展执业药师考前培训、继续教育的是（）。\nOptions: A. 国家药品监督管理局⾼级研修学院\nB. 国家药品监督管理局执业药师资格认证中⼼\nC. 国家药典委员会\nD. 国家药品监督管理局信息中⼼\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To solve the question, we'll apply the three reasoning methods as follows:\n\n**Reasoning Method 1: Direct Deduction**\n- The question asks which organization is responsible for organizing pre-exam training and continuing education for licensed pharmacists, according to the regulations of the National Medical Products Administration (NMPA).\n- Key term: \"执业药师考前培训、继续教育\" (pre-exam training and continuing education for licensed pharmacists).\n- Analysis: Knowing the roles of relevant institutions, the entity specifically tasked with the continuing education and training of licensed pharmacists is likely involved in the certification or educational regulation of pharmacists.\n- Preliminary conclusion: The most directly relevant option is likely to be B. 国家药品监督管理局执业药师资格认证中⼼ (National Medical Products Administration Licensed Pharmacist Qualification Certification Center).\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: 主要负责高端人才的培养，与日常执业药师培训可能不直接相关.\n- Eliminate C: 负责药典的制定和药品标准，不涉及执业药师培训.\n- Eliminate D: 信息中心主要处理信息管理、收集、发布，与教育职能无关.\n- Remaining options: B.\n- Preliminary conclusion: B.\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A and B might both be involved in educational activities through their respective capacities.\n- Key differences identification: A is more focused on advanced research and high-level training rather than specific professional certification.\n- Option that best fits the question: B is the one directly tied to licensing and organizing professional education.\n- Preliminary conclusion: B.\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently point to option B as the correct answer.\n- Final determination: B - Reason: Much consistency across all reasoning methods with high confidence.\n\nCorrect answer: B.", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 77, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 95520. 原形⽆效，需经代谢后产⽣活性的药物是（）。\nOptions: A. 甲苯磺丁脲\nB. 管萘洛尔\nC. 氯吡格雷\nD. 地西泮\nE. 丙⽶嗪\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- The question asks for a prodrug that is inactive until metabolized. \n- Key term: \"经代谢后产⽣活性的药物\" (a drug that becomes active after metabolism).\n- Analysis: Clopidogrel (C) is known as a prodrug that requires metabolic activation to produce its effect.\n- Preliminary conclusion: C\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: 甲苯磺丁脲 (Tolbutamide) is an active drug, not a prodrug.\n- Eliminate B: 管萘洛尔 (Nadolol) is a non-selective beta-blocker used in its active form.\n- Eliminate C: Chloropyridogrel (Clopidogrel) is a prodrug.\n- Eliminate D: 地西泮 (Diazepam) is active without metabolism.\n- Eliminate E: 丙⽶嗪 (Promethazine) is an active drug, not a prodrug.\n- Remaining options: C\n- Preliminary conclusion: C\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Focus on drugs known for requiring metabolic activation.\n- Key differences identification: Among the options, Clopidogrel is a well-known prodrug that is activated metabolically.\n- Option that best fits the question: C\n- Preliminary conclusion: C\n\n**Consistency Assessment:**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All methods consistently identified option C as the correct answer.\n- Final determination: C - Reason: All reasoning methods consistently point to Clopidogrel as a prodrug that requires metabolic activation.\n\nCorrect answer: C", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 78, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 50. 患者，男，35岁，近⽇出现⾜趾间⽪肤瘙痒、⽔泡样⽪疹，宜选⽤的药物是（）。\nOptions: A. 酮康唑乳膏\nB. 甲硝唑栓\nC. 雌三醇乳膏\nD. 硝酸咪康唑栓\nE. 氯康唑胶囊\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question, let's apply the three reasoning methods independently and reach a conclusion:\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms: \"足趾间\", \"皮肤瘙痒\", and \"水泡样皮疹\" suggest a common symptom of athlete's foot (tinea pedis), which is a fungal infection.\n- Direct reasoning process: Antifungal agents are typically used to treat fungal infections like athlete's foot. Based on the symptoms and professional knowledge, the appropriate treatment would be with an antifungal cream.\n- Preliminary conclusion: A. 酮康唑乳膏 is an antifungal cream suitable for treating fungal infections of the skin.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate B: 甲硝唑栓 - Mainly used for bacterial and protozoal infections, not skin fungal infections.\n- Eliminate C: 雌三醇乳膏 - Hormone replacement therapy, not used for fungal infections.\n- Eliminate D: 硝酸咪康唑栓 - Usually used in vaginal applications, not suitable for foot fungal infections.\n- Eliminate E: 氯康唑胶囊 - While an antifungal, it's a systemic treatment, typically not first-line for localized skin fungal infections.\n- Remaining options: A. 酮康唑乳膏\n- Preliminary conclusion: A\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Eliminate options that don't directly deal with fungal skin infections.\n- Key differences identification: Focus on localized topical antifungal treatments. Options A and E are antifungal, but A is more specific for topical application.\n- Option that best fits the question: A. 酮康唑乳膏\n- Preliminary conclusion: A\n\n**Consistency Assessment:**\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All conclusions consistently point to the same option, A.\n- Final determination: A. 酮康唑乳膏 - Reason: Consistent conclusion across all methods and strongest evidence for treating athlete's foot topically.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 79, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 2118. 患者，⼥，65岁。诊断为⾻质疏松症，给予鲑降钙素注射液治疗，⽤药期间需注意的事项有（）。\nOptions: A. 应当注意有⽆⽪下和⽛龈出⾎\nB. 必须补充⾜量的钙剂和维⽣素D\nC. 对蛋⽩质过敏者，使⽤前需做⽪肤敏感试验\nD. 可能出现低⾎糖反应\nE. 常出现⾯部潮红的不良反应\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question of what considerations need to be taken into account when administering salmon calcitonin injection to a 65-year-old female patient diagnosed with osteoporosis, we'll apply the three distinct reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n- Salmon calcitonin is used to treat osteoporosis. Key considerations often involve ensuring effective use and monitoring for side effects. \n- There's established knowledge that patients on calcitonin often require additional calcium and Vitamin D supplements to enhance treatment effectiveness (Option B).\n- Calcitonin may cause side effects such as flushing and potential allergic reactions since it is a protein-based drug (Options C and E).\n- Analysis: B, C, and E are considerations supported by known pharmacological information.\n- Preliminary conclusion: B, C, E\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Subcutaneous and gingival bleeding are not known side effects or considerations associated with calcitonin use. \n- Eliminate D: Hypoglycemia is not associated with calcitonin. \n- B: Supplementation of calcium and vitamin D is recommended, so retain B.\n- C: Patients with protein allergies may experience reactions, requiring skin sensitivity tests, so retain C.\n- E: Facial flushing is a common side effect, so retain E.\n- Remaining options: B, C, E\n- Preliminary conclusion: B, C, E\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison reveals that some options specifically address the biochemical interaction of the drug (like supplementary needs in B) and potential allergic reactions (tested by C) or side effects (commonly appearing in E).\n- Differences: Options A and D relate to consequences not commonly recognized with calcitonin.\n- Option that best fits the question based on physiological interactions and side effects: B, C, E.\n- Preliminary conclusion: B, C, E\n\n**Consistency Assessment:**\n- Method 1 conclusion: B, C, E - Confidence: High\n- Method 2 conclusion: B, C, E - Confidence: High\n- Method 3 conclusion: B, C, E - Confidence: High\n- Consistency analysis: All methods consistently lead to the same conclusion based on clinical knowledge of salmon calcitonin.\n- Final determination: B, C, E - Reason: Consistent conclusions backed by pharmacological evidence.\n\nCorrect answer: B, C, E", "question_type": "多项选择题", "groundtruth": "BCE"}
{"id": 80, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 36. 可⼲扰转录过程和阻⽌RNA合成的抗肿瘤药物是（）。\nOptions: A. 顺铂\nB. 塞替派\nC. 丝裂霉素\nD. 多柔⽐星\nE. 长春瑞滨\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "Question Type: 最佳选择题  \nQuestion: 36. 可干扰转录过程和阻止RNA合成的抗肿瘤药物是（）。\n\n**Reasoning Method 1: Direct Deduction**  \n- Directly derive conclusions based on question information and professional knowledge:  \nThe question asks for an antitumor drug that interferes with transcription and stops RNA synthesis. Based on professional knowledge, drugs that intercalate into DNA or inhibit enzymes involved in transcription are relevant.  \n- Analysis: Among the listed options, doxorubicin (多柔比星) is known for intercalating into DNA and interfering with the enzyme topoisomerase II during transcription.  \n- Preliminary conclusion: D. 多柔比星\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A. 顺铂: Known for forming DNA cross-links, hindering replication rather than transcription directly.\n- Eliminate B. 塞替派: Not commonly associated with directly interfering with transcription or RNA synthesis.\n- Eliminate C. 丝裂霉素: Functions mainly as an alkylating agent causing cross-links between DNA strands.\n- Eliminate D. 多柔比星: Interferes with transcription by intercalating into DNA and inhibiting RNA synthesis.\n- Eliminate E. 长春瑞滨: Primarily disrupts microtubule formation during cell division, not transcription.\n- Remaining options: D. 多柔比星\n- Preliminary conclusion: D. 多柔比星\n\n**Reasoning Method 3: Comparative Analysis**  \n- Comparison of similar options: Drugs that interfere with DNA can potentially affect RNA synthesis if they intercalate or inhibit enzymes specific to transcription.  \n- Key differences identification: Doxorubicin (多柔比星) is well-known for its action on DNA/RNA via intercalation and inhibition of topoisomerase II, a critical enzyme in transcription.  \n- Option that best fits the question: D. 多柔比星\n- Preliminary conclusion: D. 多柔比星\n\n**Consistency Assessment:**  \n- Method 1 conclusion: D. 多柔比星 - Confidence: High  \n- Method 2 conclusion: D. 多柔比星 - Confidence: High  \n- Method 3 conclusion: D. 多柔比星 - Confidence: High  \n- Consistency analysis: The conclusions are consistent across all reasoning methods. Doxorubicin (多柔比星) is consistently identified as the drug that can interfere with transcription and stop RNA synthesis due to its mode of action.  \n- Final determination: D. 多柔比星 - Reason: Consistent results supported by strong evidence across all reasoning methods.\n\nCorrect answer: D.", "question_type": "最佳选择题", "groundtruth": "D"}
{"id": 81, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 40. 兼有抑菌作⽤的⿐⽤减充⾎剂是（）。\nOptions: A. 呋⿇滴⿐液\nB. 赛洛唑啉滴⿐液\nC. 羟甲唑啉⿐喷剂\nD. ⿇黄碱滴⿐液\nE. 左氧氟沙星滴⿐液\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer, we will apply the three reasoning methods as described.\n\n**Reasoning Method 1: Direct Deduction**\n- Analysis: The question asks for a nasal decongestant that also has antibacterial properties. In the options, only one of them has known antibacterial properties.\n- Professional knowledge: Levofloxacin (left out as \"左氧氟沙星\") is a well-known fluoroquinolone antibiotic with established antibacterial activity.\n- Preliminary conclusion: E (Left Oxofloxacin Nasal Drops)\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: 呋麻滴鼻液 (Naphazoline nasal drops) are primarily for decongestion and do not have antibacterial properties.\n- Eliminate B: 赛洛唑啉滴鼻液 (Xylometazoline nasal drops) are used for nasal congestion without antibacterial activity.\n- Eliminate C: 羟甲唑啉鼻喷剂 (Oxymetazoline nasal spray) is a decongestant without antibacterial properties.\n- Eliminate D: 麻黄碱滴鼻液 (Ephedrine nasal drops) focuses on decongestant effects, not antibacterial.\n- Remaining options: E\n- Preliminary conclusion: E\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A, B, C, and D are primarily nasal decongestants without broad-spectrum antibacterial properties.\n- Key differences identification: E (Levofloxacin) is both a decongestant due to its anti-inflammatory properties and an antibacterial agent, setting it apart from the other options.\n- Option that best fits the question: E\n- Preliminary conclusion: E\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All methods consistently indicate option E as the correct answer. There is no contradiction among the methods.\n- Final determination: E - Reason: Consistent conclusion across all reasoning methods based on the presence of antibacterial properties in Levofloxacin.\n\nCorrect answer: E", "question_type": "最佳选择题", "groundtruth": "A"}
{"id": 82, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 56. 哺乳期妇⼥使⽤，可致男婴乳房增⼤的药物是（）。\nOptions: A. 复⽅炔诺酮\nB. 依那普利\nC. 胰岛素\nD. 复⽅磺胺甲唑\nE. 莫西沙星\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine which medication can cause gynecomastia (breast enlargement) in male infants during breastfeeding, let's analyze the options using the three reasoning methods provided.\n\n**Reasoning Method 1: Direct Deduction**\n- **Analysis:** Gynecomastia in infants is usually associated with hormonal influences such as those from drugs with estrogenic effects or those that affect hormonal balances. Key terms include lactation, male infants, and breast enlargement.\n- **Preliminary conclusion:** A. 复方炔诺酮 (a contraceptive and hormonal preparation containing norethindrone, which can have estrogenic effects).\n\n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A:** Cannot eliminate 复方炔诺酮 as it might cause gynecomastia.\n- **Eliminate B:** 依那普利 is an ACE inhibitor and does not typically cause gynecomastia.\n- **Eliminate C:** 胰岛素 does not cause gynecomastia.\n- **Eliminate D:** 复方磺胺甲唑 is an antibiotic and does not cause gynecomastia.\n- **Eliminate E:** 莫西沙星 is an antibiotic (fluoroquinolone) and does not cause gynecomastia.\n- **Remaining options:** A\n- **Preliminary conclusion:** A\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison of similar options:** The most likely category here involves hormones or estrogenic compounds.\n- **Key differences identification:** Only 复方炔诺酮 is hormone-related, potentially affecting breast tissue.\n- **Option that best fits the question:** A\n- **Preliminary conclusion:** A\n\n**Consistency Assessment:**\n- **Method 1 conclusion:** A - Confidence: High\n- **Method 2 conclusion:** A - Confidence: High\n- **Method 3 conclusion:** A - Confidence: High\n- **Consistency analysis:** All methods consistently point to option A as the correct choice.\n- **Final determination:** A - Reason: Based on consistency across all methods and strongest evidence that hormonal preparations could cause this effect.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 83, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 76. 氨氯地平的妊娠毒性分级是（）。\nOptions: A. X级\nB. A级\nC. C级\nD. D级\nE. B级\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct pregnancy toxicity classification of amlodipine, let's analyze it using the three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- Amlodipine is a calcium channel blocker commonly used to treat high blood pressure and angina.\n- According to professional knowledge, drugs in pregnancy are categorized into classes based on risk assessment. Amlodipine is not considered to have severe risks but is not completely safe either during pregnancy.\n- Analysis: The FDA has classified amlodipine in pregnancy category C, which means that animal studies have shown an adverse effect on the fetus, and there are no adequate studies in humans, but potential benefits may warrant use despite potential risks.\n- Preliminary conclusion: C\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A (X级): Drugs that have demonstrated fetal abnormalities or risks which outweigh potential benefits are classified here. Amlodipine does not fall into this category.\n- Eliminate B (A级): Drugs that show no risk in controlled human studies. Amlodipine does not fall into this category.\n- Eliminate D (D级): Drugs with evidence of human fetal risk, but potential benefits may warrant use. Amlodipine is not in this category.\n- Eliminate E (B级): Drugs with no evidence of risk in animal studies or controlled human studies. Amlodipine is not in this category.\n- Remaining options: C\n- Preliminary conclusion: C\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Look at C (C级) and D (D级), as they both acknowledge certain risks but allow for consideration given potential benefits.\n- Key differences identification: C (Animal studies show risk; benefits may warrant use), D (Human studies show risk; benefits may still warrant use). Amlodipine has shown risk in animal studies, aligning it more with C rather than D.\n- Option that best fits the question: C\n- Preliminary conclusion: C\n\n**Consistency Assessment:**\n- Method 1 conclusion: C - Confidence: High\n- Method 2 conclusion: C - Confidence: High\n- Method 3 conclusion: C - Confidence: High\n- Consistency analysis: All methods consistently conclude option C.\n- Final determination: C - Reason: Based on the consistent findings across all reasoning methods.\n\nCorrect answer: C", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 84, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 21. 关于疫苗流通管理的说法，错误的是（）。\nOptions: A. 疫苗上市许可持有⼈在销售疫苗时，应当提供加盖其印章的批签发证明复印件或者电⼦⽂件\nB. 疫苗上市许可持有⼈应当按照采购合同约定，向疾病防控制机构和接种单位直接供应疫苗\nC. 疫苗上市许可持有⼈应当按照规定，建⽴真实、准确完整的销售记录，并保存⾄疫苗有效期满后不少于五年备查\nD. 疾病预防控制机构、接种单位应当建⽴疫苗定期检查制度\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question about which statement is incorrect regarding vaccine distribution management, we will employ the three described reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n- Key Terms: \"疫苗流通管理,\" \"错误的\"\n- Analyzing each statement with professional knowledge of vaccine management protocols:\n  - A: Vaccine marketing authorization holders must provide certified batch release proof when selling vaccines.\n  - B: They should supply vaccines directly to disease control agencies and vaccination units as per the procurement contract.\n  - C: They must maintain accurate sales records, retaining them for at least five years post-vaccine expiry for inspection.\n  - D: Disease prevention and control institutions should establish periodic vaccine inspection systems.\n- Based on professional knowledge, each statement seems aligned with standard practices except potentially for one specific aspect.\n- Preliminary Conclusion: There's a need for more detailed inspection—hold determination until further analysis.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate based on professional regulations:\n  - Eliminate A: True. Providing batch release certification is a regulatory requirement.\n  - Eliminate B: True. Direct supply based on contracts aligns with standard practices.\n  - Eliminate C: Requires factual sales records retention, typically true for compliance.\n  - Analyze D: The institution of regular inspection systems is generally correct; however, the statement's veracity depends on specific regulatory details.\n- Preliminary Conclusion: D could contain discrepancies in the specifics of \"定期检查制度.\"\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities/differences among options:\n  - A, B, C are focused on specific responsibilities and documentation of vaccine handling.\n  - D focuses on institutional process establishment.\n- Differentiate: A, B, C are standard procedural requirements. D may have interpretational flexibility that might not align with universal practices.\n- Preliminary Conclusion: Option D seems least aligned with the specificity required in the other options.\n\n**Consistency Assessment:**\n- Method 1 conclusion: Uncertain; more context needed - Confidence: Medium-Low\n- Method 2 conclusion: D as potential misfit - Confidence: Medium\n- Method 3 conclusion: D appears divergent - Confidence: Medium\n- Consistency Analysis: Methods 2 and 3 converge on D showing signs of inconsistency in context precisely. Method 1's shadow of doubt suggests possible alignment.\n- Final Determination: Correct answer: D - Reason: Most consistent pointing to invalidity under evaluated definitions and frameworks within the professional regulatory context.", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 85, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：秦某是⼀所中医药⼤学中医学专业硕⼠毕业⽣，已获得硕⼠学位，在校期间学过中药材知识和栽培技术，具有中药材辨识能⼒。临近毕业时，准备参加执业药师职业资格考试，但因专业⼯作年限不符合报名条件，未能参加考试。 秦某的⽼家在边远⼭区，交通不便，为解决家乡群众看病难题，毕业后主动返乡当村医。平时除给乡邻治病之外，还在⾃家地⾥种植地产中药材。\n95. 根据《中医药法》，关于秦某种植地产中药材的说法，正确的是（）。\nOptions: A. 销售给当地的中药饮⽚⽣产企业\nB. 将⾃产中药材加⼯成中药制剂⽅便村民使⽤\nC. 在其开设的诊所中煎汤药给村民治病\nD. 种植仅供⾃⽤的医疗⽤毒性中药材\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question regarding Qin's ability to plant and use local Chinese medicinal materials according to the \"Law of Traditional Chinese Medicine,\" we'll employ three distinct reasoning methods and then determine the final answer based on consistency.\n\n**Reasoning Method 1: Direct Deduction**\n- Key Terms: \"种植地产中药材,\" \"《中医药法》,\" \"正确的说法\"\n- Analysis: Using professional knowledge about the \"Law of Traditional Chinese Medicine,\" individuals can cultivate and sell medicinal herbs legally, given they meet specific regulatory requirements. The law allows the processing and application of one's harvest in medicine preparation, especially in rural areas.\n- Preliminary conclusion: Options A and C are plausible because selling to companies is common and preparing medicines to treat locals is a legitimate use.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: This can be a correct option as individuals often sell their cultivated herbs to pharmaceutical companies.\n- Eliminate B: This option is likely incorrect unless specific permissions are obtained, as processing into medication requires regulatory adherence and manufacturing qualifications.\n- Eliminate C: This option is valid, as using self-farmed herbs for treatment aligns with personal licensing for village doctors under the law.\n- Eliminate D: Growing toxic medicinal herbs for personal use is heavily regulated or prohibited.\n- Remaining options: A, C\n- Preliminary conclusion: A, C \n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: A and C both directly involve the legitimate usage of Qin's self-grown medicinal herbs either through sales or direct treatment.\n- Key differences identification: B involves processing into ready-to-use formulations, which is stricter and requires specific production permissions, while D involves terrible risks with toxic herbs.\n- Option that best fits the question: Options A and C are lawful applications under cultivation rules.\n- Preliminary conclusion: A, C\n\n**Consistency Assessment:**\n- Method 1 conclusion: A, C - Confidence: Medium/High\n- Method 2 conclusion: A, C - Confidence: High\n- Method 3 conclusion: A, C - Confidence: High\n- Consistency analysis: All methods consistently conclude A and C, with logically valid deductions supporting their inclusion.\n- Final determination: Correct answer: A, C - Reason: Based on consistent conclusions across all reasoning methods, supported by sound legal regulations and practical applications within Chinese medicinal practices.\n\nCorrect answer: A, C", "question_type": "综合分析选择题", "groundtruth": "C"}
{"id": 86, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 30. 关于⽣物等效性研究的实施与样品采集的说法，正确的是（）。\nOptions: A. 通常采⽤受试制剂和参⽐制剂的单个最低规格制剂进⾏试验\nB. 从0时到最后⼀个样品采集时间t的曲线下⾯积与时间从0到⽆穷⼤的AUC之⽐通常应当达于70%\nC. 整个采样时间不少于3个末端消除半衰期\nD. 受试制剂与参⽐制剂药物含量的差值应⼩于2%\nE. ⼀般情况下，受试者试验前⾄少空腹8⼩时\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question about bioequivalence study implementation and sample collection, we will use the three reasoning methods outlined.\n\n**Reasoning Method 1: Direct Deduction**\n- The key terms include \"bioequivalence study,\" \"sample collection,\" and the specific requirements or conditions listed in the options.\n- **Analysis:**\n  - Option A: Bioequivalence studies often use the lowest dosage form, which might correspond to single dose studies.\n  - Option B: The AUC from time zero to the last sampling time should ideally cover a significant portion of the drug's total AUC, often around 80% but not necessarily 70%.\n  - Option C: Sampling time should cover at least three terminal elimination half-lives to capture enough data for accurate half-life estimation.\n  - Option D: Bioequivalence does not typically specify a <2% content difference but requires the 90% confidence interval for AUC and Cmax to fall within 80-125% of the reference.\n  - Option E: It is standard to ensure a minimum fasting period before studies to avoid food effects.\n- **Preliminary conclusion:** Options C and E are likely accurate based on common bioequivalence practices.\n\n**Reasoning Method 2: Systematic Elimination**\n- **Eliminate A:** Not necessarily incorrect, but not specifically required for bioequivalence.\n- **Eliminate B:** Incorrect percentage criterion for AUC; common criterion is around 80%.\n- **Eliminate C:** Matches standard practice for covering elimination half-lives in studies.\n- **Eliminate D:** Misunderstands bioequivalence criteria focusing more on variability.\n- **Eliminate E:** Matches standard practice.\n- **Remaining options:** C, E.\n- **Preliminary conclusion:** Options C and E are consistent with standard practices.\n\n**Reasoning Method 3: Comparative Analysis**\n- **Comparison of similar options:** Options C and E pertain to standard protocol practices; the others relate to specific measurement criteria or understandings.\n- **Key differences identification:** Option C is clear in sampling time importance; Option E aligns with fasting requirements.\n- **Option that best fits the question:** Option C clearly aligns with a crucial methodological requirement.\n- **Preliminary conclusion:** Option C has a stronger alignment with bioequivalence study methods.\n\n**Consistency Assessment:**\n- Method 1 conclusion: Options C, E - Confidence: Medium\n- Method 2 conclusion: Options C, E - Confidence: Medium\n- Method 3 conclusion: Option C - Confidence: High\n- **Consistency analysis:** Options C and E emerged consistently as correct, but Option C appeared with higher reasoning support in the third method.\n- **Final determination:** Correct answer: C - Reason: There is consistent support for Option C across all analyses, with particularly strong reasoning provided from reasoning method three, indicating it is a standard and crucial practice in bioequivalence studies.", "question_type": "最佳选择题", "groundtruth": "C"}
{"id": 87, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：患者，男，53岁，季节性过敏性⿐炎病史5年，3天前，受凉后出现流涕、⿐塞、咳嗽，咳痰，低热，头痛，⽆胸闷、⽓短等其他不适，已在医院发热门诊完成了⿐拭⼦检查，排除了甲型流感和⼄型流感，诊断为普通感冒。\n107. 为缓解该患者的感冒症状，不宜选⽤的药物是（）。\nOptions: A. 含伪⿇黄碱的复⽅抗感冒药\nB. 神经氨酸酶抑制剂\nC. ⿐⽤减充⾎剂\nD. 解热镇痛药\nE. 祛痰剂\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question and determine the final answer, let's proceed with each reasoning method independently:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- Focus on key terms in the question stem: seasonal allergic rhinitis, symptoms of common cold, exclusion of influenza.\n- Analysis:\n  - Seasonal allergies and common cold are symptomatic conditions, often treated symptomatically.\n  - Counter-indicated medications for a common cold might include those targeting influenza.\n  - Neuraminidase inhibitors are used for influenza treatment, not common cold.\n- Preliminary conclusion: B (神经氨酸酶抑制剂)\n\n**Reasoning Method 2: Systematic Elimination**  \n- Option A (伪麻黄碱): Suitable for alleviating nasal congestion.\n- Option B (神经氨酸酶抑制剂): Targets influenza, not effective for common cold.\n- Option C (鼻用减充血剂): Suitable for nasal congestion.\n- Option D (解热镇痛药): Suitable for relieving fever and pain.\n- Option E (祛痰剂): Suitable for alleviating cough with sputum.\n- Remaining options: A, C, D, E\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: All other options focus on symptomatic relief for conditions related to common cold.\n- Key differences identification: B (神经氨酸酶抑制剂) specifically targets influenza, which was ruled out.\n- Option that best fits the question: B\n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: Conclusions are consistent across all methods.\n- Final determination: B - Reason: Consistency across all reasoning methods and targeting influenza rather than common cold.\n\nCorrect answer: B", "question_type": "综合分析选择题", "groundtruth": "B"}
{"id": 88, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 多项选择题\nQuestion: 119. 属于碳青霉烯类的抗菌药物有（）。\nOptions: A. 亚胺培南\nB. 氨曲南\nC. 美罗培南\nD. 厄他培南\nE. ⽐阿培南\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine which options consist of carbapenem antibiotics, we'll apply the three reasoning methods to analyze the question.\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms: \"carbapenem antibiotics\"\n- Professional knowledge: Carbapenems are a class of antibiotics effective against a wide range of bacteria, noted for their broad-spectrum activity and resistance to beta-lactamase.\n- Analysis: Imipenem, meropenem, ertapenem, and biapenem (not aztreonam) are known carbapenems.\n- Preliminary conclusion: A, C, D, E\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate A: Not eliminated; Imipenem is a carbapenem.\n- Eliminate B: Aztreonam (B) is not a carbapenem; it is a monobactam.\n- Eliminate C: Not eliminated; Meropenem is a carbapenem.\n- Eliminate D: Not eliminated; Ertapenem is a carbapenem.\n- Eliminate E: Not eliminated; Biapenem is a carbapenem although less commonly known.\n- Remaining options: A, C, D, E\n- Preliminary conclusion: A, C, D, E\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences: Identify drug classes for each option.\n- A (Imipenem), C (Meropenem), D (Ertapenem), E (Biapenem) are all categorized similarly as carbapenems. B (Aztreonam) is distinct as a monobactam.\n- Key differences identification: Chemical structure and antibiotic class.\n- Option that best fits: A, C, D, E\n- Preliminary conclusion: A, C, D, E\n\n**Consistency Assessment:**\n- Method 1 conclusion: A, C, D, E - Confidence: High\n- Method 2 conclusion: A, C, D, E - Confidence: High\n- Method 3 conclusion: A, C, D, E - Confidence: High\n- Consistency analysis: All methods consistently identify the same options.\n- Final determination: A, C, D, E - Reason: Consistent conclusions across all reasoning methods support these options as carbapenem antibiotics.\n\nCorrect answer: A, C, D, E", "question_type": "多项选择题", "groundtruth": "ACDE"}
{"id": 89, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 52. 若⽆禁忌证，治疗2型糖尿病⾸选的⼜服降糖药物（）。\nOptions: A. 沙格列汀\nB. 达格列净\nC. 吡格列酮\nD. ⼆甲双胍\nE. 瑞格列奈\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- Key terms in the question are \"treatment,\" \"type 2 diabetes,\" \"first choice,\" and \"oral hypoglycemic drug.\"\n- Direct reasoning process: Metformin (二甲双胍) is widely recognized as the first-line oral hypoglycemic agent for the treatment of type 2 diabetes in patients without contraindications, due to its efficacy, safety profile, and cardiovascular benefits.\n- Preliminary conclusion: D. 二甲双胍\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A (沙格列汀): While saxagliptin is an oral hypoglycemic agent, metformin is preferred as the first-line treatment.\n- Eliminate B (达格列净): Dapagliflozin is primarily used when metformin alone does not achieve desired glucose control. It's not usually the first choice.\n- Eliminate C (吡格列酮): Pioglitazone is not the first-line due to potential side effects and is used after metformin or alongside it.\n- Eliminate E (瑞格列奈): Repaglinide is usually not the first-line option for type 2 diabetes.\n- Remaining options: D. 二甲双胍\n- Preliminary conclusion: D. 二甲双胍\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: All options listed are oral hypoglycemic agents.\n- Key differences identification: Metformin is distinguished as the first-line treatment option due to its established efficacy and long history of use.\n- Option that best fits the question: D. 二甲双胍\n- Preliminary conclusion: D. 二甲双胍\n\n**Consistency Assessment:**\n- Method 1 conclusion: D. Confidence: High\n- Method 2 conclusion: D. Confidence: High\n- Method 3 conclusion: D. Confidence: High\n- Consistency analysis: All reasoning methods consistently indicate D. 二甲双胍 as the correct answer.\n- Final determination: D. 二甲双胍 - Reason: Metformin is universally recognized as the first-line treatment for type 2 diabetes due to its effectiveness and safety profile.\n\nCorrect answer: D", "question_type": "配伍选择题", "groundtruth": "D"}
{"id": 90, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 综合分析选择题\nQuestion: 题干：患者，男，69岁，BMI 27.8kg/m ，既往有⾻性关节炎病史。近期爬⼭后，再次出现膝关节疼痛，患者热敷后疼痛未缓解，前来咨询如何选⽤“⽌痛药”。\n103. 如服⽤所选⽌痛药，需关注的不良反应是（）。\nOptions: A. 便秘\nB. 肾损害\nC. ⼜⼲\nD. 共济失调\nE. 剥脱性⽪炎\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct adverse reaction to be concerned about when choosing an analgesic for a patient with osteoarthritis, we will employ the three reasoning methods as outlined:\n\n**Reasoning Method 1: Direct Deduction**\n- Key terms: \"止痛药,\" \"不良反应,\" \"患者病史.\"\n- Direct reasoning process: The common analgesics often used in conditions like osteoarthritis are NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which are known for their risk of causing renal impairment, especially in patients with pre-existing conditions or older age.\n- Preliminary conclusion: B. 肾损害\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: While constipation can be a side effect of opioids, NSAIDs are more likely given the patient's condition (osteoarthritis).\n- Eliminate C: Mouth dryness (口干) is not typically associated with NSAIDs or relevant here.\n- Eliminate D: Ataxia (共济失调) is not associated with NSAIDs.\n- Eliminate E: Exfoliative dermatitis (剥脱性皮炎) is a rare side effect.\n- Remaining options: B\n- Preliminary conclusion: B. 肾损害\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Renal damage (肾损害) versus gastrointestinal involvement (便秘/剥脱性皮炎). Renal damage is a classic concern with NSAIDs.\n- Key differences identification: While constipation might be due to opioids, dehydration or specific adverse reactions are more relevant with NSAIDs like renal damage.\n- Option that best fits the question: B. 肾损害\n- Preliminary conclusion: B. 肾损害\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently point to renal damage as the primary concern for NSAIDs often used for osteoarthritis pain.\n- Final determination: B. 肾损害 - Reason: Consistency across all reasoning methods and alignment with known pharmacological evidence.\n\nCorrect answer: B.", "question_type": "综合分析选择题", "groundtruth": "B"}
{"id": 91, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 88. 属于胰岛素增敏剂，具有噻唑烷⼆酮结构，通于治疗2型糖尿病的药物（）。\nOptions: A. 阿格列汀\nB. 罗格列酮\nC. 达格列净\nD. 格列吡嗪\nE. 那格列奈\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n\n- Directly derive conclusions based on question information and professional knowledge.\n- Focus on key terms: \"胰岛素增敏剂\" (insulin sensitizer), \"噻唑烷二酮结构\" (thiazolidinedione structure), \"2型糖尿病\" (type 2 diabetes).\n- Analysis: The drug class associated with \"胰岛素增敏剂\" and \"噻唑烷二酮结构\" is thiazolidinediones, which are known to treat type 2 diabetes by increasing insulin sensitivity.\n- Preliminary conclusion: B. 罗格列酮 (Rosiglitazone), as it is a thiazolidinedione used for type 2 diabetes.\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate A (阿格列汀): It is a DPP-4 inhibitor, not an insulin sensitizer or thiazolidinedione.\n- Eliminate C (达格列净): It is an SGLT2 inhibitor, not a thiazolidinedione.\n- Eliminate D (格列吡嗪): It is a sulfonylurea, not an insulin sensitizer or a thiazolidinedione.\n- Eliminate E (那格列奈): It is a meglitinide, not a thiazolidinedione.\n- Remaining options: B. 罗格列酮\n- Preliminary conclusion: B. 罗格列酮\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare options based on drug classes and mechanisms.\n- Rosiglitazone and pioglitazone are the well-known thiazolidinediones in this group.\n- Key differences identification: Only B. 罗格列酮 among the options has the thiazolidinedione structure and insulin sensitizing action.\n- Option that best fits the question: B. 罗格列酮\n- Preliminary conclusion: B. 罗格列酮\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: B. 罗格列酮 - Confidence: High\n- Method 2 conclusion: B. 罗格列酮 - Confidence: High\n- Method 3 conclusion: B. 罗格列酮 - Confidence: High\n- Consistency analysis: All methods lead to the same conclusion without contradictions.\n- Final determination: B. 罗格列酮 - Reason: Consistent across all reasoning methods.\n\nCorrect answer: B", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 92, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 56. 根据《药品经营质量管理规范》及其有关附录⽂件，属于温湿度⾃动监测系统特有的验证项⽬是（）。\nOptions: A. 测点终端安装数量及位置确认\nB. 测点终端参数与数据联动传输确认\nC. 运输最长时限验证\nD. 极端温度保温性能验证\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer to the question based on the three reasoning methods, let's analyze each method independently:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge.\n- The question pertains to the \"automatic temperature and humidity monitoring system,\" which suggests the focus is on aspects unique to such systems.\n- Key terms: automatic monitoring system, validation projects.\n- Analysis: Automatic systems typically involve validation of the number/locations of sensors and data transmission capabilities. Options C and D seem more related to logistics or transport validation rather than the core system.\n- Preliminary conclusion: Options A and B are relevant as they pertain directly to monitoring system setup and function.\n\n**Reasoning Method 2: Systematic Elimination**\n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate C: More related to logistics rather than monitoring systems.\n- Eliminate D: Related to transport, not specific to automatic monitoring systems for storage.\n- Remaining options: A, B.\n- Preliminary conclusion: A and B make sense for validation in an automatic monitoring system.\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options.\n- Options A and B pertain to the system's setup and operation, which are critical for validation.\n- Options C and D are more about transport logistics.\n- The extreme temperature validation (D) is typically not part of automatic monitoring system validation.\n- Key differences: Options A and B focus on system specifics; C and D focus on transport/temperature factors.\n- Option that best fits the question: A or B.\n- Preliminary conclusion: A and B both seem fitting.\n\n**Consistency Assessment:**\n- Method 1 conclusion: A, B - Confidence: High\n- Method 2 conclusion: A, B - Confidence: High\n- Method 3 conclusion: A, B - Confidence: High\n- Consistency analysis: All methods consistently identify A and B as the relevant options.\n- Final determination: A or B - Reason: Based on consistent outcomes from all reasoning methods.\n\nTherefore, the correct answer, focusing on the validation items specific to an automatic temperature and humidity monitoring system according to the context, is likely: Correct answer: A, B.", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 93, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 54. 长期应⽤⼴谱抗⽣素造成⼆重感染的不良反应属于（）。\nOptions: A. 特异质反应\nB. 停药反应\nC. 后遗效应\nD. 毒性反应\nE. 继发反应\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To analyze the question, let's apply the three distinct reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- The question refers to \"长期应⽤⼴谱抗⽣素造成⼆重感染的不良反应\" which translates to \"adverse reactions of secondary infection caused by long-term use of broad-spectrum antibiotics.\"\n- Key term: Secondary infection due to antibiotic use.\n- Professional knowledge: Long-term use of broad-spectrum antibiotics can disrupt normal microbial flora, leading to an overgrowth of resistant organisms, which is known as a secondary infection.\n- Preliminary conclusion: E. 继发反应 (Secondary Reaction)\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: 特异质反应 (Idiosyncratic reaction) - This is a rare and unpredictable response, unrelated to the predictable mechanism of secondary infection.\n- Eliminate B: 停药反应 (Withdrawal reaction) - This refers to symptoms that occur upon stopping a drug, not applicable here.\n- Eliminate C: 后遗效应 (Sequelae) - This refers to an effect that remains after the acute phase of an illness, not directly relevant here.\n- Eliminate D: 毒性反应 (Toxic reaction) - While antibiotics can have toxic effects, secondary infection is not due to direct toxicity of the drug.\n- Eliminate E: 继发反应 (Secondary Reaction) - Correctly describes an infection resulting from disturbance of normal flora.\n- Remaining options: E\n- Preliminary conclusion: E. 继发反应\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similar options: A, B, C, D generally refer to different types of reactions that do not precisely fit the given scenario of secondary infection.\n- Key differences identification: E specifically describes a reaction due to the emergence of new problems following an initial treatment, fitting the context of antibiotic usage.\n- Option that best fits the question: E\n- Preliminary conclusion: E. 继发反应\n\n**Consistency Assessment:**\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All three reasoning methods consistently point to option E as the correct choice. The reasoning is aligned with professional understanding of secondary infections resulting from antibiotic use.\n- Final determination: E. 继发反应 - Reason: Consistent conclusion across all methods indicating high confidence.\n\nCorrect answer: E", "question_type": "配伍选择题", "groundtruth": "E"}
{"id": 94, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 74. 属于酪氨酸激酶抑制剂的抗肿瘤药物是（）。\nOptions: A. 来曲唑\nB. 环磷酰胺\nC. 厄洛替尼\nD. 长春新碱\nE. 多柔⽐星\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge: The question asks for an antitumor drug that is a tyrosine kinase inhibitor. These inhibitors are a specific class of drugs used in cancer treatment that block the action of enzymes involved in the signaling pathways that lead to cell growth and proliferation.\n- Focus on key terms in the question stem: \"酪氨酸激酶抑制剂\" (tyrosine kinase inhibitor), \"抗肿瘤药物\" (antitumor drug).\n- Analysis: Among the drugs listed, erlotinib (厄洛替尼) is known as a tyrosine kinase inhibitor. It is specifically used for treating certain types of cancer like non-small cell lung cancer by targeting the epidermal growth factor receptor (EGFR) tyrosine kinase.\n- Preliminary conclusion: C. 厄洛替尼\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: 来曲唑 is an aromatase inhibitor used in breast cancer treatment, not a tyrosine kinase inhibitor.\n- Eliminate B: 环磷酰胺 is an alkylating agent used in cancer chemotherapy. It does not work by inhibiting tyrosine kinase.\n- Eliminate C: As previously noted, 厄洛替尼 is a tyrosine kinase inhibitor.\n- Eliminate D: 长春新碱 is a microtubule inhibitor. It disrupts cell division, not through tyrosine kinase inhibition.\n- Eliminate E: 多柔比星 is an anthracycline antibiotic that intercalates DNA. It is not a tyrosine kinase inhibitor.\n- Remaining options: C\n- Preliminary conclusion: C. 厄洛替尼\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options: Erloitinib is different from the others as it specifically targets tyrosine kinases, whereas the other drugs either inhibit enzymes, disrupt microtubules, or interact with DNA.\n- Key differences identification: Only erlotinib matches the mechanism of action specified in the question.\n- Option that best fits the question: C. 厄洛替尼\n- Preliminary conclusion: C. 厄洛替尼\n\n**Consistency Assessment:**\n- Method 1 conclusion: C. 厄洛替尼 - Confidence: High\n- Method 2 conclusion: C. 厄洛替尼 - Confidence: High\n- Method 3 conclusion: C. 厄洛替尼 - Confidence: High\n- Consistency analysis: All reasoning methods consistently support C. 厄洛替尼 as the correct answer. There is agreement across the deduction, elimination, and comparison approaches.\n- Final determination: C. 厄洛替尼 - Reason: All methods consistently point to erlotinib as the correct choice based on its role as a tyrosine kinase inhibitor.\n\nCorrect answer: C. 厄洛替尼", "question_type": "配伍选择题", "groundtruth": "C"}
{"id": 95, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 89. 患者，⼥，65岁。诊断为社区获得性肺炎，伴肾功能不全，肌酐清除率25mL/min，宜选⽤的⽆需根据肾功能调整剂量的抗菌药物是（）。\nOptions: A. 头孢曲松\nB. 头孢唑林\nC. 头孢噻肟\nD. 头孢他啶\nE. 头孢吡肟\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for this question based on the principle of consistency, we will analyze the options using three reasoning methods.\n\n**Reasoning Method 1: Direct Deduction**\n\n- Key terms in the question stem include \"community-acquired pneumonia,\" \"renal insufficiency,\" and \"antimicrobial agents that do not require dose adjustment based on renal function.\"\n- Professional knowledge indicates that certain cephalosporins do not require renal dose adjustments.\n- Analysis: Among the cephalosporins listed, ceftriaxone (头孢曲松) is known for not requiring dose adjustments in patients with renal insufficiency because it is largely excreted via the liver.\n- Preliminary conclusion: A. 头孢曲松\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate B (头孢唑林): Requires dose adjustment in renal impairment.\n- Eliminate C (头孢噻肟): Requires dose adjustment in renal impairment.\n- Eliminate D (头孢他啶): Requires dose adjustment in renal impairment.\n- Eliminate E (头孢吡肟): Requires dose adjustment in renal impairment.\n- Remaining options: A. 头孢曲松\n- Preliminary conclusion: A. 头孢曲松\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Comparison of similar options: All options are cephalosporins, but their excretion routes differ significantly, affecting renal dosage requirements.\n- Key differences identification: Ceftriaxone is unique as it is excreted via the liver and does not require dosage adjustments in cases of renal impairment, while others are primarily renally excreted.\n- Option that best fits the question: A. 头孢曲松\n- Preliminary conclusion: A. 头孢曲松\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All methods consistently point to the same conclusion without contradictions.\n- Final determination: A. 头孢曲松 - Reason: Consistent conclusion across all methods and supported by strong evidence.\n\nCorrect answer: A", "question_type": "配伍选择题", "groundtruth": "A"}
{"id": 96, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 50. ⽤于验光配镜屈光度检查前散瞳的药物是（）。\nOptions: A. 聚⼄⼆醇滴眼液\nB. 硫酸阿托品眼⽤凝胶\nC. 雷珠单抗注射液\nD. ⽑果芸⾹碱滴眼液\nE. 丙美卡因滴眼液\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct option for a drug used for cycloplegia (paralysis of the ciliary muscle of the eye), which is essential for accurate refractive error measurements before prescribing glasses, let's analyze the options using the three reasoning methods you outlined.\n\n### Reasoning Method 1: Direct Deduction\n\n1. **Key terms**: Cycloplegia, refractive error measurement, mydriatic agent.\n2. **Analysis**: Cycloplegic agents are usually anticholinergic drugs, which cause dilation of the pupil and paralysis of the ciliary muscle. Commonly used drugs include atropine, cyclopentolate, and tropicamide.\n3. **Preliminary conclusion**: The option that fits this is B. 硫酸阿托品眼用凝胶 (Atropine sulfate ophthalmic gel), as atropine is well-known for causing cycloplegia.\n\n### Reasoning Method 2: Systematic Elimination\n\n- **Eliminate A**: 聚乙二醇滴眼液 (Polyethylene glycol eye drops) - This is a lubricant and does not cause cycloplegia.\n- **Eliminate C**: 雷珠单抗注射液 (Ranibizumab injection) - This is an anti-VEGF treatment for retinal diseases, not related to cycloplegia.\n- **Eliminate D**: 毛果芸香碱滴眼液 (Pilocarpine eye drops) - This is a miotic agent, which causes pupil constriction, opposite of what is needed for refraction.\n- **Eliminate E**: 丙美卡因滴眼液 (Proparacaine eye drops) - This is a local anesthetic and does not cause cycloplegia.\n- **Remaining option**: B. 硫酸阿托品眼用凝胶\n- **Preliminary conclusion**: B\n\n### Reasoning Method 3: Comparative Analysis\n\n- **Comparison of similar options**: None of the other options (A, C, D, E) are anticholinergic agents or cause pupil dilation.\n- **Key differences identification**: Only atropine (硫酸阿托品) is known for its cycloplegic effect.\n- **Option that best fits the question**: B\n- **Preliminary conclusion**: B\n\n### Consistency Assessment\n\n- **Method 1 conclusion**: B - Confidence: High\n- **Method 2 conclusion**: B - Confidence: High\n- **Method 3 conclusion**: B - Confidence: High\n- **Consistency analysis**: All methods consistently indicate option B as the correct choice, with high confidence.\n- **Final determination**: B - Reason: Consistent findings across all reasoning methods strongly support Atropine as the cycloplegic agent.\n\nCorrect answer: B", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 97, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 最佳选择题\nQuestion: 14. 根据下列部门的主要职责、内设机构和⼈员编制规定，负责提出国家基本药物价格政策建议的部门是（）。\nOptions: A. 国家医疗保障局\nB. 国家卫⽣健康委员会\nC. 国家发展和改⾰委员会\nD. 国家市场监督管理总局\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for which department is responsible for proposing national essential medicine price policy suggestions, let's analyze using the three reasoning methods:\n\n**Reasoning Method 1: Direct Deduction**\n- The key term in the question is \"国家基本药物价格政策建议\" (national essential medicine price policy suggestions).\n- The 国家医疗保障局 (National Healthcare Security Administration) is primarily responsible for healthcare insurance, which often includes setting and managing drug prices.\n- The preliminary conclusion from direct deduction is: A (国家医疗保障局).\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate B (国家卫生健康委员会): Primarily focused on health policy and services, not pricing.\n- Eliminate C (国家发展和改革委员会): Often involved in economic planning and reforms, but not directly in drug pricing policy.\n- Eliminate D (国家市场监督管理总局): Primarily responsible for market supervision and regulation, not specifically drug pricing policy.\n- Remaining option: A (国家医疗保障局).\n- Preliminary conclusion: A (国家医疗保障局).\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: None of the other options specifically focus on price setting or drug policy in the way the National Healthcare Security Administration does.\n- Key differences identification: A focuses on healthcare and pricing policies, including drug and essential medicine pricing.\n- Option that best fits the question: A (国家医疗保障局).\n- Preliminary conclusion: A (国家医疗保障局).\n\n**Consistency Assessment:**\n- Method 1 conclusion: A - Confidence: High\n- Method 2 conclusion: A - Confidence: High\n- Method 3 conclusion: A - Confidence: High\n- Consistency analysis: All methods consistently point to A as the correct option.\n- Final determination: A - Reason: Consistent conclusions across all reasoning methods indicate strong evidence.\n\nCorrect answer: A", "question_type": "最佳选择题", "groundtruth": "B"}
{"id": 98, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 72. 多数脂溶性⼩分⼦类药物的吸收机制是（）。\nOptions: A. 膜孔滤过\nB. 简单扩散\nC. 膜动转运\nD. 易化扩散\nE. 主动转运\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "**Reasoning Method 1: Direct Deduction**\n- Key terms in the question: \"多数脂溶性小分子类药物\" (most lipid-soluble small molecule drugs) and \"吸收机制\" (absorption mechanism).\n- Analysis: Lipid-soluble small molecules typically cross cell membranes without the need for energy or carriers, as they can diffuse directly through the lipid bilayer. This process is known as passive or simple diffusion.\n- Preliminary conclusion: B (简单扩散)\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate A: \"膜孔滤过\" (membrane pore filtration) is typically for small water-soluble molecules, not lipid-soluble ones.\n- Eliminate C: \"膜动转运\" (pinocytosis and endocytosis) is more relevant for large molecules or particles, not small molecules.\n- Eliminate D: \"易化扩散\" (facilitated diffusion) requires specific carrier proteins, and while it can occur for small molecules, lipid-soluble molecules usually rely on simple diffusion.\n- Eliminate E: \"主动转运\" (active transport) involves energy and often carrier proteins, which is not necessary for lipid-soluble molecules.\n- Remaining options: B\n- Preliminary conclusion: B\n\n**Reasoning Method 3: Comparative Analysis**\n- Comparison of similar options: Among the mechanisms (B (简单扩散), D (易化扩散)), both can involve the movement of molecules down a concentration gradient, but simple diffusion does not require a carrier protein, making it more suitable for lipid-soluble molecules.\n- Key differences identification: Simple diffusion allows molecules to pass directly through the lipid bilayer without additional energy or carriers, which is ideal for lipid-soluble small molecules.\n- Option that best fits the question: B\n- Preliminary conclusion: B\n\n**Consistency Assessment:**\n- Method 1 conclusion: B - Confidence: High\n- Method 2 conclusion: B - Confidence: High\n- Method 3 conclusion: B - Confidence: High\n- Consistency analysis: All methods consistently conclude B is the most appropriate mechanism for lipid-soluble small molecules.\n- Final determination: B - Reason: Consistent conclusions across all reasoning methods, supported by established pharmaceutical knowledge regarding passive diffusion.\n\nCorrect answer: B", "question_type": "配伍选择题", "groundtruth": "B"}
{"id": 99, "query": "As a Chinese pharmaceutical expert, please use the following three distinct reasoning methods to independently analyze the question, then determine the final answer based on the principle of consistency:\n\n**Reasoning Method 1: Direct Deduction**\n- Directly derive conclusions based on question information and professional knowledge\n- Focus on key terms in the question stem\n- Analysis: [Direct reasoning process]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 2: Systematic Elimination**  \n- Eliminate incorrect options one by one to narrow down choices\n- Eliminate A: [Reason for elimination]\n- Eliminate B: [Reason for elimination]\n- Eliminate C: [Reason for elimination]\n- Eliminate D: [Reason for elimination]\n- Eliminate E: [Reason for elimination]\n- Remaining options: [Options]\n- Preliminary conclusion: [Options]\n\n**Reasoning Method 3: Comparative Analysis**\n- Compare similarities and differences among all options\n- Comparison of similar options: [Comparative analysis]\n- Key differences identification: [Difference analysis]\n- Option that best fits the question: [Options]\n- Preliminary conclusion: [Options]\n\n**Consistency Assessment:**\n- Method 1 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 2 conclusion: [Options] - Confidence: High/Medium/Low\n- Method 3 conclusion: [Options] - Confidence: High/Medium/Low\n- Consistency analysis: [Whether conclusions are consistent across methods; if not, analyze reasons]\n- Final determination: [Options] - Reason: [Based on consistency or strongest evidence]\n\nQuestion Type: 配伍选择题\nQuestion: 48. 患者，男，54岁，因痛风服⽤⾮布司他，为增强降尿酸效果，可同时使⽤的药物是（）。\nOptions: A. 阿托伐他汀\nB. 甲巯咪唑\nC. 丙硫氧嘧啶\nD. 氢氯噻嗪\nE. 碳酸氢钠\n\nPlease output: Correct answer: [option letters]\n", "model_answer": "To determine the correct answer for the question, we'll apply the reasoning methods outlined.\n\n**Reasoning Method 1: Direct Deduction**\n\n- Directly derive conclusions based on question information and professional knowledge.\n- Key terms: \"痛风\" (gout), \"⾮布司他\" (febuxostat), \"增强降尿酸效果\" (enhance uric acid reduction).\n- Analysis: Febuxostat is a xanthine oxidase inhibitor used to treat gout by reducing uric acid production. To enhance uric acid reduction, a medication that alkalizes urine or aids in uric acid excretion would be pertinent.\n- Preliminary conclusion: E. 碳酸氢钠, as it can alkalize urine and help in the excretion of uric acid.\n\n**Reasoning Method 2: Systematic Elimination**\n\n- Eliminate incorrect options one by one to narrow down choices.\n- Eliminate A: 阿托伐他汀 is a statin for cholesterol, unrelated to uric acid reduction.\n- Eliminate B: 甲巯咪唑 is used for hyperthyroidism; does not impact uric acid.\n- Eliminate C: 丙硫氧嘧啶 is also for hyperthyroidism; not relevant to uric acid handling.\n- Eliminate D: 氢氯噻嗪 is a diuretic which can potentially increase uric acid levels.\n- Eliminate E: 碳酸氢钠, actually helps in alkalizing urine, aiding uric acid excretion.\n- Remaining options: E\n- Preliminary conclusion: E. 碳酸氢钠\n\n**Reasoning Method 3: Comparative Analysis**\n\n- Compare similarities and differences among all options.\n- Comparison of similar options: A, B, C, relate to different therapeutic areas not involved in uric acid management.\n- Key differences identification: D can worsen uric acid levels, E helps in excretion via urine alkalization.\n- Option that best fits the question: E.\n- Preliminary conclusion: E. 碳酸氢钠\n\n**Consistency Assessment:**\n\n- Method 1 conclusion: E - Confidence: High\n- Method 2 conclusion: E - Confidence: High\n- Method 3 conclusion: E - Confidence: High\n- Consistency analysis: All methods consistently indicate that option E is the correct answer to enhance the uric acid reduction effect of febuxostat.\n- Final determination: E. 碳酸氢钠 - Reason: Based on consistent conclusions across all reasoning methods.\n\n**Correct answer: E**", "question_type": "配伍选择题", "groundtruth": "E"}
